BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2017;112:212-39. [PMID: 28071659 DOI: 10.1038/ajg.2016.563] [Cited by in Crossref: 744] [Cited by in F6Publishing: 743] [Article Influence: 124.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian XL, Suo BJ, Zhang H, Lu HP, Li CL, Zhang YX, Ren XL, Yao XY, Zhou LY, Song ZQ. Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial. Helicobacter 2023;28:e12935. [PMID: 36374159 DOI: 10.1111/hel.12935] [Reference Citation Analysis]
2 Lee JW, Kim N, Choi SI, Jang JY, Song CH, Nam RH, Lee DH. Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea. Helicobacter 2023;28:e12939. [PMID: 36478622 DOI: 10.1111/hel.12939] [Reference Citation Analysis]
3 Katelaris P, Hunt R, Bazzoli F, Cohen H, Fock KM, Gemilyan M, Malfertheiner P, Mégraud F, Piscoya A, Quach D, Vakil N, Vaz Coelho LG, LeMair A, Melberg J. Helicobacter pylori World Gastroenterology Organization Global Guideline. J Clin Gastroenterol 2023;57:111-26. [PMID: 36598803 DOI: 10.1097/MCG.0000000000001719] [Reference Citation Analysis]
4 Miendje Deyi VY, Ntounda R, Louis H, Kahegeshe NL, Nkuize M, Burette A, Kotilea K, Gossum MV, Delhaye M, Bontems P. Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021. Diagn Microbiol Infect Dis 2023;105:115855. [PMID: 36462449 DOI: 10.1016/j.diagmicrobio.2022.115855] [Reference Citation Analysis]
5 Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M, Yadlapati R. Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019. Sci Rep 2023;13:1375. [PMID: 36697470 DOI: 10.1038/s41598-023-28200-3] [Reference Citation Analysis]
6 Yunusa I, Love BL. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States. Am J Gastroenterol 2023. [PMID: 36693030 DOI: 10.14309/ajg.0000000000002146] [Reference Citation Analysis]
7 Xu G, Ma S, Dong L, Mendez-sanchez N, Li H, Qi X. Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology 2023;2023:1-13. [DOI: 10.1155/2023/5521239] [Reference Citation Analysis]
8 Liu L, Nahata MC. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection. Ann Pharmacother 2023;:10600280221149708. [PMID: 36688309 DOI: 10.1177/10600280221149708] [Reference Citation Analysis]
9 Poliantsev AA, Frolov DV, Linchenko AM, Karpenko SN, Kosivtsov OA, Chernovolenko AA, Kaplunova EV. Prevention of gastrointestinal bleeding in patients operated on the arteries of the lower extremities for critical ischemia. jour 2023. [DOI: 10.31146/1682-8658-ecg-207-11-160-170] [Reference Citation Analysis]
10 Elbehiry A, Marzouk E, Aldubaib M, Abalkhail A, Anagreyyah S, Anajirih N, Almuzaini AM, Rawway M, Alfadhel A, Draz A, Abu-okail A. Helicobacter pylori Infection: Current Status and Future Prospects on Diagnostic, Therapeutic and Control Challenges. Antibiotics 2023;12:191. [DOI: 10.3390/antibiotics12020191] [Reference Citation Analysis]
11 Liuzzo G, Patrono C. Helicobacter pylori eradication as a gastroprotective strategy in elderly aspirin-treated subjects: established facts and unanswered questions. Eur Heart J 2023:ehac808. [PMID: 36638779 DOI: 10.1093/eurheartj/ehac808] [Reference Citation Analysis]
12 Song Z, Suo B, Tian X, Ren X, Xue Y, Niu Z, Zhou L. Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial. Dig Liver Dis 2023:S1590-8658(22)00867-2. [PMID: 36646526 DOI: 10.1016/j.dld.2022.12.019] [Reference Citation Analysis]
13 Liu W, Kong W, Hui W, Wang C, Jiang Q, Shi H, Gao F. Characteristics of different types of Helicobacter pylori: New evidence from non-amplified white light endoscopy. Front Microbiol 2023;13. [DOI: 10.3389/fmicb.2022.999564] [Reference Citation Analysis]
14 Zhang W, Gui Q, Chen J, Yu D, Su W, Zhu C, Liang X, Lu H. Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study. Helicobacter 2023;:e12946. [PMID: 36633162 DOI: 10.1111/hel.12946] [Reference Citation Analysis]
15 Abukhalil AD, Ali O, Saad A, Falana H, Al-Shami N, Naseef HA, Rabba A. Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study. Int J Gen Med 2023;16:141-50. [PMID: 36659914 DOI: 10.2147/IJGM.S396202] [Reference Citation Analysis]
16 Chiu Y, Lee F, Kuo C, Lin Y, Liang K, Tseng L, Chen Y, Chang C. Seven‐day vonoprazan‐based triple therapy as first‐line Helicobacter pylori treatment in comparison with extended sequential therapy. JGH Open 2023. [DOI: 10.1002/jgh3.12858] [Reference Citation Analysis]
17 Zhou BG, Mei YZ, Zhang M, Jiang X, Li YY, Ding YB. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therap Adv Gastroenterol 2023;16:17562848221147756. [PMID: 36644129 DOI: 10.1177/17562848221147756] [Reference Citation Analysis]
18 Braendli T, Schindler V, Braun DL, Murray FR, Hente JM, Pohl D. Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland. Swiss Med Wkly 2023;153:40024. [PMID: 36652712 DOI: 10.57187/smw.2023.40024] [Reference Citation Analysis]
19 Cummings LC, Hojat LS, Nguyen DC, Stempak LM, Rhoads DD, Sadri N. Tailored Treatment Based on Helicobacter pylori Genetic Markers of Resistance Is Associated With Higher Eradication Success. Am J Gastroenterol 2023. [PMID: 36574274 DOI: 10.14309/ajg.0000000000002085] [Reference Citation Analysis]
20 Lee ME, Katz PO. Gastroesophageal reflux disease and the role of Helicobacter pylori. Esophageal Disease and the Role of the Microbiome 2023. [DOI: 10.1016/b978-0-323-95070-1.00007-2] [Reference Citation Analysis]
21 Hua S, Lye EC. Impact of gastric and bowel surgery on gastrointestinal drug delivery. Drug Deliv Transl Res 2023;13:37-53. [PMID: 35585472 DOI: 10.1007/s13346-022-01179-6] [Reference Citation Analysis]
22 Kim I, Maeng L, Kim JS, Kim B, Cheung DY, Kim JI, Park S. Quantitative Multiplex Real-Time Polymerase Chain Reaction Assay for the Detection of Helicobacter pylori and Clarithromycin Resistance.. [DOI: 10.21203/rs.3.rs-2375894/v1] [Reference Citation Analysis]
23 Marginean CM, Cioboata R, Olteanu M, Vasile CM, Popescu M, Popescu AIS, Bondari S, Pirscoveanu D, Marginean IC, Iacob GA, Popescu MD, Stanciu M, Mitrut P. The Importance of Accurate Early Diagnosis and Eradication in Helicobacter pylori Infection: Pictorial Summary Review in Children and Adults. Antibiotics (Basel) 2022;12. [PMID: 36671261 DOI: 10.3390/antibiotics12010060] [Reference Citation Analysis]
24 Çağlar R. Helicobacter pylori Eradikasyonunda Kullanılan Kombine Tedavilerin Etkinliklerinin Karşılaştırılması. SABD 2022. [DOI: 10.33631/sabd.1210607] [Reference Citation Analysis]
25 Atanda H, Balogun TA, Alshehri MM, Olivos-Ramirez G, Vilca-Quispe J, Chenet-Zuta M, Cárdenas-Cárdenas R, Delgado Wong H, Ropón-Palacios G, Umar HI. In silico study revealed the inhibitory activity of selected phytomolecules of C. rotundus against VacA implicated in gastric ulcer. J Biomol Struct Dyn 2022;:1-12. [PMID: 36571437 DOI: 10.1080/07391102.2022.2160814] [Reference Citation Analysis]
26 Zhao Z, Zou PY, Su NY, Guo Y, Wang XW, Zhao JT, Mei H, Shi Q, Wang B, Chen DF, Lan CH. High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial. Therap Adv Gastroenterol 2022;15:17562848221145566. [PMID: 36600682 DOI: 10.1177/17562848221145566] [Reference Citation Analysis]
27 Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD, Li LC. Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 2022. [PMID: 36567647 DOI: 10.1002/ddr.22025] [Reference Citation Analysis]
28 Gatta L, Nyssen OP, Fiorini G, Saracino IM, Pavoni M, Romano M, Gravina AG, Granata L, Pellicano R, Gasbarrini A, Di Leo A, Losurdo G, Franceschi F, Nardone G, Rocco A, Dore MP, Farinati F, Ghisa M, Bellini M, Holton J, Puig I, Vaira D, Borghi C, Mégraud F, O'Morain C, Gisbert JP. Effectiveness of first and second-line empirical treatment in Italy: Results of the European registry on Helicobacter pylori management. United European Gastroenterol J 2022. [PMID: 36565017 DOI: 10.1002/ueg2.12348] [Reference Citation Analysis]
29 Mestrovic A, Perkovic N, Tonkic A, Sundov Z, Kumric M, Bozic J. Personalized Approach in Eradication of Helicobacter pylori Infection. Antibiotics (Basel) 2022;12. [PMID: 36671208 DOI: 10.3390/antibiotics12010007] [Reference Citation Analysis]
30 Zhou M, Zeng Y, Xi Y, Luo S, Qi J, Zhao G, Sun Y, Guo Y, Cheng F. School-based Hygiene Intervention to Prevent HelicObacter Pylori infection among childrEn (SHIP HOPE): protocol for a cluster-randomised controlled trial. BMJ Open 2022;12:e064207. [PMID: 36600426 DOI: 10.1136/bmjopen-2022-064207] [Reference Citation Analysis]
31 Ding Y, Li Y, Liu J, Wang J, Wan M, Lin M, Lin B, Zhang W, Kong Q, Wang S, Mu Y, Duan M, Han Z, Zuo X, Li Y. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med 2022. [DOI: 10.1007/s10238-022-00953-7] [Reference Citation Analysis]
32 Li H, Sun H. Metal Complexes as Resistance Breakers or Metalloantibiotics for Combating Antimicrobial Resistance. Encyclopedia of Inorganic and Bioinorganic Chemistry 2022. [DOI: 10.1002/9781119951438.eibc2827] [Reference Citation Analysis]
33 Dănilă C, Cardos IA, Pop-Crisan A, Marc F, Hoza A, Chirla R, Pascalău A, Magheru C, Cavalu S. Correlations between Endoscopic and Histopathological Assessment of Helicobacter pylori-Induced Gastric Pathology-A Cross-Sectional Retrospective Study. Life (Basel) 2022;12. [PMID: 36556461 DOI: 10.3390/life12122096] [Reference Citation Analysis]
34 Akbari Rad M, Goshayeshi L, Moodi Ghalibaf AA, Mehrad Majd H, Soleimani G, Kolahi Ahari R. Helicobacter pylori Standard Triple Therapy Outcomes in Iranian Population: A Retrospective Population-based Study in Mashhad, Northeast of Iran. Jundishapur J Microbiol 2022;15. [DOI: 10.5812/jjm-127842] [Reference Citation Analysis]
35 Blondeau JM. Immunomodulatory Effects of Macrolides Considering Evidence from Human and Veterinary Medicine. Microorganisms 2022;10. [PMID: 36557690 DOI: 10.3390/microorganisms10122438] [Reference Citation Analysis]
36 Yang T, Liu B, Zhou J, Shen Y, Song X, Tang X, Benghezal M, Marshall BJ, Tang H, Li H. The Inappropriateness of Using Rifampicin E-Test to Predict Rifabutin Resistance in Helicobacter pylori. J Infect Dis 2022;226:S479-85. [PMID: 36478247 DOI: 10.1093/infdis/jiac417] [Reference Citation Analysis]
37 Zhou J, Shen Y, Song X, Zhou L, Tang H, Li H. Evaluation of a Molecular Mosprie Assay for Detection of Helicobacter pylori and Resistance to Clarithromycin and Levofloxacin. J Infect Dis 2022;226:S503-9. [PMID: 36478246 DOI: 10.1093/infdis/jiac402] [Reference Citation Analysis]
38 Chitas R, Nunes C, Reis S, Parreira P, Martins MCL. How Charge, Size and Protein Corona Modulate the Specific Activity of Nanostructured Lipid Carriers (NLC) against Helicobacter pylori. Pharmaceutics 2022;14. [PMID: 36559239 DOI: 10.3390/pharmaceutics14122745] [Reference Citation Analysis]
39 Tang X, Shen Y, Song X, Benghezal M, Marshall BJ, Tang H, Li H. Reassessment of the Broth Microdilution Method for Susceptibility Testing of Helicobacter pylori. J Infect Dis 2022;226:S486-92. [PMID: 36478248 DOI: 10.1093/infdis/jiac389] [Reference Citation Analysis]
40 Roberts LT, Issa PP, Sinnathamby ES, Granier M, Mayeux H, Eubanks TN, Malone K, Ahmadzadeh S, Cornett EM, Shekoohi S, Kaye AD. Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice. Life (Basel) 2022;12. [PMID: 36556402 DOI: 10.3390/life12122038] [Reference Citation Analysis]
41 Burgos-Santamaría D, Nyssen OP, Gasbarrini A, Vaira D, Pérez-Aisa Á, Rodrigo L, Pellicano R, Keco-Huerga A, Pabón-Carrasco M, Castro-Fernandez M, Boltin D, Barrio J, Phull P, Kupcinskas J, Jonaitis L, Ortiz-Polo I, Tepes B, Lucendo AJ, Huguet JM, Areia M, Jurecic NB, Denkovski M, Bujanda L, Ramos-San Román J, Cuadrado-Lavín A, Gomez-Camarero J, Jiménez Moreno MA, Lanas A, Martinez-Dominguez SJ, Alfaro E, Marcos-Pinto R, Milivojevic V, Rokkas T, Leja M, Smith S, Tonkić A, Buzás GM, Doulberis M, Venerito M, Lerang F, Bordin DS, Lamy V, Capelle LG, Marlicz W, Dobru D, Gridnyev O, Puig I, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Empirical rescue treatment of Helicobacter pylori infection in third and subsequent lines: 8-year experience in 2144 patients from the European Registry on H. pylori management (Hp-EuReg). Gut 2022:gutjnl-2022-328232. [PMID: 36591610 DOI: 10.1136/gutjnl-2022-328232] [Reference Citation Analysis]
42 Wernly S, Semmler G, Völkerer A, Flamm M, Aigner E, Niederseer D, Wernly B, Datz C. Helicobacter pylori and cardiovascular risk: Only a dead Helicobacter is a good Helicobacter? Helicobacter 2022;27:e12928. [PMID: 36046921 DOI: 10.1111/hel.12928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI; Taiwan Acid-related Disease & Microbiota Consortium (TARD-M). REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter 2022;27:e12931. [PMID: 36161426 DOI: 10.1111/hel.12931] [Reference Citation Analysis]
44 Azrad M, Vazana D, On A, Paritski M, Rohana H, Roshrosh H, Agay-Shay K, Peretz A. Antibiotic resistance patterns of Helicobacter pylori in North Israel - A six-year study. Helicobacter 2022;27:e12932. [PMID: 36110057 DOI: 10.1111/hel.12932] [Reference Citation Analysis]
45 Vita NA, Anderson SM, LaFleur MD, Lee RE. Targeting Helicobacter pylori for antibacterial drug discovery with novel therapeutics. Curr Opin Microbiol 2022;70:102203. [PMID: 36156373 DOI: 10.1016/j.mib.2022.102203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Liang B, Yuan Y, Peng XJ, Liu XL, Hu XK, Xing DM. Current and future perspectives for Helicobacter pylori treatment and management: From antibiotics to probiotics. Front Cell Infect Microbiol 2022;12:1042070. [PMID: 36506013 DOI: 10.3389/fcimb.2022.1042070] [Reference Citation Analysis]
47 Yu C, Qiu J, Xiong M, Ou C, Zeng M, Song H. Trends in Helicobacter pylori-related gastric ulcer research from 2012 to 2022: A bibliometric and visual analysis. Front Med (Lausanne) 2022;9:1027534. [PMID: 36507534 DOI: 10.3389/fmed.2022.1027534] [Reference Citation Analysis]
48 Argueta EA, Ho JJC, Elfanagely Y, D'Agata E, Moss SF. Clinical Implication of Drug Resistance for H. pylori Management. Antibiotics (Basel) 2022;11. [PMID: 36551341 DOI: 10.3390/antibiotics11121684] [Reference Citation Analysis]
49 Aumpan N, Mahachai V, Vilaichone RK. Management of Helicobacter pylori infection. JGH Open 2023;7:3-15. [PMID: 36660052 DOI: 10.1002/jgh3.12843] [Reference Citation Analysis]
50 Helicobacter pylori Primary and Secondary Antimicrobial Resistance through 22 Years of Culture Experience (2000-2021).. [DOI: 10.21203/rs.3.rs-2196259/v2] [Reference Citation Analysis]
51 Lee MW, Kim GH. Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency. Gut and Liver 2022;16:807-808. [DOI: 10.5009/gnl220414] [Reference Citation Analysis]
52 Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, Smith N, Leifke E, Chey WD. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol 2022. [PMID: 36191284 DOI: 10.14309/ajg.0000000000002045] [Reference Citation Analysis]
53 Che TH, Nguyen TC, Ngo DTT, Nguyen HT, Vo KT, Ngo XM, Truong DQ, Bontems P, Robert A, Nguyen PNV. High Prevalence of Helicobacter pylori Infection Among School-Aged Children in Ho Chi Minh City, VietNam. Int J Public Health 2022;67. [DOI: 10.3389/ijph.2022.1605354] [Reference Citation Analysis]
54 Fekadu S, Engiso H, Seyfe S, Iizasa H, Godebo A, Deyno S, Yoshiyama H. Effectiveness of eradication therapy for Helicobacter pylori infection in Africa: A systematic review and meta-analysis.. [DOI: 10.21203/rs.3.rs-2078777/v1] [Reference Citation Analysis]
55 K. J, N. V, R. N, C. K, R. S. EXPERIMENTAL DESIGN APPROACH TO FABRICATE AND OPTIMIZE FLOATING TABLETS OF LEVOFLOXACIN FOR HELICOBACTER PYLORI INFECTION. Int J App Pharm 2022. [DOI: 10.22159/ijap.2022v14i6.45809] [Reference Citation Analysis]
56 Koseki M, Sheu M, Tsai K, Ho C, Liu H, Lin H, Lin C, Huang C. Comparison of the incidence of immune thrombocytopenia between adult patients infected with Helicobacter pylori with and without eradication therapy: A retrospective cohort study in Taiwan.. [DOI: 10.21203/rs.3.rs-2196609/v1] [Reference Citation Analysis]
57 Wang X, Chen X, Liu W, Liang W, Liu M. Rationale and Design of LAPIS: A Multicenter Prospective Cohort Study to Investigate the Efficacy and Safety of Low-Dose Aspirin in Elderly Chinese Patients. IJGM 2022;Volume 15:8333-8341. [DOI: 10.2147/ijgm.s391259] [Reference Citation Analysis]
58 Hawkey C, Avery A, Coupland CAC, Crooks C, Dumbleton J, Hobbs FDR, Kendrick D, Moore M, Morris C, Rubin G, Smith M, Stevenson D, Mant DC, Ford AC, Macdonald TM, Bradburn M, Klauza CA, Shone A, Logan RF, Deeks JJ, Mccoll KE, Goddard AF, Stevens R, Sami S, Haughney J, Cupples ME, Morar M, O'brien W. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. The Lancet 2022;400:1597-1606. [DOI: 10.1016/s0140-6736(22)01843-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Ahmad W. The Zingiber Officinale Roscoe Combat Helicobacter Pylori Infection in Human Gastrointestinal Tract Diagnosis and Treatment. PJHS 2022. [DOI: 10.54393/pjhs.v3i05.192] [Reference Citation Analysis]
60 de Arbulo MG, Tamayo E, Bujanda L, Mendibil L, Mendiola J, Cilla G, Montes M. Helicobacter pylori Primary and Secondary Antimicrobial Resistance through 22 Years of Culture Experience (2000-2021).. [DOI: 10.21203/rs.3.rs-2196259/v1] [Reference Citation Analysis]
61 Bisht N, P. Garg A. Helicobacter pylori Gastric Infection: Pathogenesis and Clinical Management. Helicobacter pylori Infection - An Up to Date on the Pathogenic Mechanisms, Diagnosis and Clinical Management [Working Title] 2022. [DOI: 10.5772/intechopen.106783] [Reference Citation Analysis]
62 Yang H, Guan L, Hu B, Moreira L. Detection and Treatment of Helicobacter pylori: Problems and Advances. Gastroenterology Research and Practice 2022;2022:1-10. [DOI: 10.1155/2022/4710964] [Reference Citation Analysis]
63 Sousa C, Ferreira R, Santos SB, Azevedo NF, Melo LDR. Advances on diagnosis of Helicobacter pylori infections. Crit Rev Microbiol 2022;:1-22. [PMID: 36264672 DOI: 10.1080/1040841X.2022.2125287] [Reference Citation Analysis]
64 Yu G, Zhang T, Xu H, Bi Y, Feng X, Wang J, Li T, Zhang C, Sun Y. Investigating the Active Substance and Mechanism of San-Jiu-Wei-Tai Granules via UPLC-QE-Orbitrap-MS and Network Pharmacology. Evid Based Complement Alternat Med 2022;2022:1487903. [PMID: 36299773 DOI: 10.1155/2022/1487903] [Reference Citation Analysis]
65 Swarnakar R, Yadav SL. “Helicobacter pylori treatment guideline: An Indian perspective”: Letter to the editor. World J Clin Cases 2022; 10(29): 10817-10819 [DOI: 10.12998/wjcc.v10.i29.10817] [Reference Citation Analysis]
66 Mesquita A, Rocha-Castro C, Guimarães D, Costa J, Soutinho J, Taveira-Gomes T. Multicentric Study to Assess Helicobacter pylori Incidence, Patient Reported Adverse Events, Compliance and Effectiveness, in Real-World Setting. Int J Environ Res Public Health 2022;19. [PMID: 36232149 DOI: 10.3390/ijerph191912847] [Reference Citation Analysis]
67 Huard K, Haddad K, Saada Y, Nguyen J, Banon D, Matteau A, Mansour S, Potter BJ. Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). Sci Rep 2022;12:16591. [PMID: 36198683 DOI: 10.1038/s41598-022-17034-0] [Reference Citation Analysis]
68 Chen XX, Chen YX, Bi HX, Zhao X, Zhang LF, Liu JY, Shi YQ. Efficacy and safety of triple therapy containing berberine hydrochloride, amoxicillin, and rabeprazole in the eradication of Helicobacter pylori. J Dig Dis 2022;23:568-76. [PMID: 36415112 DOI: 10.1111/1751-2980.13146] [Reference Citation Analysis]
69 Kong Q, Li Y, Li R, Li Z, Zheng X, Wang Z, Song K, Zhang X, Liu J, Han Z, Duan M, Ding Y, Zhang W, Lin M, Wang J, Wan M, Lin B, Wang S, Zuo X, Li Y. Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study. Helicobacter 2022;27:e12912. [PMID: 35816511 DOI: 10.1111/hel.12912] [Reference Citation Analysis]
70 Munir M, LeMaitre B, Lobo Z, Psevdos G. A 15-year review of Helicobacter pylori screening and treatment among United States Veterans. Helicobacter 2022;27:e12919. [PMID: 35899999 DOI: 10.1111/hel.12919] [Reference Citation Analysis]
71 Han YY, Long H, Lin Y, He Q, Chen WG, Ding XW, Zhou L, An P, Wang F, Zhang ZY, Hu YL, Li PY. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection: A large-scale prospective, multicenter, open-label, randomized controlled study. Helicobacter 2022;27:e12922. [PMID: 35939559 DOI: 10.1111/hel.12922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Wang JW, Hsu PI, Lin MH, Kao J, Tsay FW, Wu IT, Shie CB, Wu DC. The efficacy of culture-guided versus empirical therapy with high-dose proton pump inhibitor as third-line treatment of Helicobacter pylori infection: A real-world clinical experience. J Gastroenterol Hepatol 2022;37:1928-34. [PMID: 35816187 DOI: 10.1111/jgh.15942] [Reference Citation Analysis]
73 Huang RJ, Epplein M, Hamashima C, Choi IJ, Lee E, Deapen D, Woo Y, Tran T, Shah SC, Inadomi JM, Greenwald DA, Hwang JH. An Approach to the Primary and Secondary Prevention of Gastric Cancer in the United States. Clin Gastroenterol Hepatol 2022;20:2218-2228.e2. [PMID: 34624563 DOI: 10.1016/j.cgh.2021.09.039] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
74 Zhao Q, Wang W, Zhou S, Su J, Sun H, Zhai J, Hu Y. Jinghua Weikang capsule for helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Front Pharmacol 2022;13:959184. [DOI: 10.3389/fphar.2022.959184] [Reference Citation Analysis]
75 Goni E, Tammer I, Schütte K, Thon C, Jechorek D, Mahajan UM, Vasapolli R, Macke L, Aulinger B, Selgrad M, Link A, Malfertheiner P, Schulz C. The influence of gastric atrophy on Helicobacter pylori antibiotics resistance in therapy-naïve patients. Front Microbiol 2022;13:938676. [DOI: 10.3389/fmicb.2022.938676] [Reference Citation Analysis]
76 Zeng J, Xie C, Zhang L, Liu X, Chan MTV, Wu WKK, Chen H. Host Cell Antimicrobial Responses against Helicobacter pylori Infection: From Biological Aspects to Therapeutic Strategies. Int J Mol Sci 2022;23:10941. [PMID: 36142852 DOI: 10.3390/ijms231810941] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
77 Wang Y, Xiang Y, Liao O, Wu Y, Li Y, Du Q, Ye J. Short-term outcomes and intermediate-term follow-up of Helicobacter pylori infection treatment for naïve patients: a retrospective observational study. BMJ Open 2022;12:e062096. [PMID: 36115671 DOI: 10.1136/bmjopen-2022-062096] [Reference Citation Analysis]
78 Rahman SH, Chaudhry AW, Raoof S, Khan N, Khan AH. Helicobacter pylori-Negative Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Presenting as Massive Gastrointestinal Bleed. Cureus 2022. [DOI: 10.7759/cureus.29125] [Reference Citation Analysis]
79 Ma Q, Li H, Liao J, Cai Z, Zhang B. Tailored therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Front Pharmacol 2022;13:908202. [DOI: 10.3389/fphar.2022.908202] [Reference Citation Analysis]
80 Mărginean CD, Mărginean CO, Meliț LE. Helicobacter pylori-Related Extraintestinal Manifestations—Myth or Reality. Children 2022;9:1352. [DOI: 10.3390/children9091352] [Reference Citation Analysis]
81 Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology 2022;163:608-19. [PMID: 35679950 DOI: 10.1053/j.gastro.2022.05.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
82 Fallone CA. The Current Role of Vonoprazan in Helicobacter pylori Treatment. Gastroenterology 2022;163:572-4. [PMID: 35780869 DOI: 10.1053/j.gastro.2022.06.076] [Reference Citation Analysis]
83 Gisbert JP, Hunt RH. Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs. Aliment Pharmacol Ther 2022;56:1074-5. [PMID: 35995738 DOI: 10.1111/apt.17142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Norwood DA, Montalvan EE, Dominguez RL, Morgan DR. Gastric Cancer: Emerging Trends in Prevention, Diagnosis, and Treatment. Gastroenterol Clin North Am 2022;51:501-18. [PMID: 36153107 DOI: 10.1016/j.gtc.2022.05.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Shah SC, Bonnet K, Schulte R, Peek RM Jr, Schlundt D, Roumie CL. Helicobacter pylori Management Is Associated with Predominantly Negative Patient Experiences: Results from a Focused Qualitative Analysis. Dig Dis Sci 2022;67:4387-94. [PMID: 35034240 DOI: 10.1007/s10620-021-07320-8] [Reference Citation Analysis]
86 Zhang P, Li Z, Chen P, Zhang A, Zeng Y, Zhang X, Huang Q, Liu D, Qi S, Mao C. Regular proton pump inhibitor use and incident dementia: population-based cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-022-02478-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Jung C, Rezar R, Wischmann P, Masyuk M, Datz C, Bruno RR, Kelm M, Wernly B. The role of anemia on admission in acute coronary syndrome - An umbrella review of systematic reviews and meta-analyses. Int J Cardiol 2022:S0167-5273(22)01262-1. [PMID: 36055474 DOI: 10.1016/j.ijcard.2022.08.052] [Reference Citation Analysis]
88 Shatila M, Thomas AS. Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection. JCM 2022;11:5086. [DOI: 10.3390/jcm11175086] [Reference Citation Analysis]
89 Resina E, Donday MG, Martínez-domínguez SJ, Laserna-mendieta EJ, Lanas Á, Lucendo AJ, Sánchez-luengo M, Alcaide N, Fernández-salazar L, De La Peña-negro L, Bujanda L, Arbulo MGD, Alcedo J, Pérez-aísa Á, Rodríguez R, Hermida S, Brenes Y, Nyssen OP, Gisbert JP. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study. JCM 2022;11:5077. [DOI: 10.3390/jcm11175077] [Reference Citation Analysis]
90 Tempera PJ, Michael M, Tageldin O, Hasak S. Gastric Cancer Due to Chronic H. pylori Infection: What We Know and Where We Are Going. Diseases 2022;10:57. [DOI: 10.3390/diseases10030057] [Reference Citation Analysis]
91 Lai JN, Liao YJ, Lin CL, Chang CS, Peng YC. Impact of Helicobacter pylori eradication timing on the risk of thromboembolism events in patients with peptic ulcer disease: a population-based cohort study. BMJ Open 2022;12:e060361. [PMID: 36002209 DOI: 10.1136/bmjopen-2021-060361] [Reference Citation Analysis]
92 Wu Y, Geng J, Cheng X, Yang Y, Yu Y, Wang L, Dong Q, Chi Z, Liu C. Cosmetic-Derived Mannosylerythritol Lipid-B-Phospholipid Nanoliposome: An Acid-Stabilized Carrier for Efficient Gastromucosal Delivery of Amoxicillin for In Vivo Treatment of Helicobacter pylori. ACS Omega 2022;7:29086-99. [PMID: 36033659 DOI: 10.1021/acsomega.2c02953] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Hou X, Wang J, Du Q, Tian D, Hu N, Liu D, Zhou F, Xie L, Gu L, Kudou K, Zhang S. Efficacy and safety of vonoprazan-based quadruple therapy for the eradication of Helicobacter pylori in patients with peptic ulcers: a pooled analysis of two randomized, double-blind, double-dummy, phase 3 trials.. [DOI: 10.21203/rs.3.rs-1837897/v1] [Reference Citation Analysis]
94 Kim SJ, Jee SR, Park MI, Jung K, Kim GH, Lee MW, Lee J, Jang JS, Koh M; Busan and Gyeongnam Society of Helicobacter and Upper Gastrointestinal Research. A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations. Medicine (Baltimore) 2022;101:e30069. [PMID: 35984159 DOI: 10.1097/MD.0000000000030069] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Zhou J, Liu C, Liu B, Wang Y, Benghezal M, Marshall BJ, Tang H, Li H. Association of serum pepsinogens and gastrin-17 with Helicobacter pylori infection assessed by urea breath test. Front Cell Infect Microbiol 2022;12:980399. [DOI: 10.3389/fcimb.2022.980399] [Reference Citation Analysis]
96 Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, Gasbarrini A, Hunt RH, Leja M, O'Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022:gutjnl-2022-327745. [PMID: 35944925 DOI: 10.1136/gutjnl-2022-327745] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 28.0] [Reference Citation Analysis]
97 He J, Liu Y, Ouyang Q, Li R, Li J, Chen W, Hu W, He L, Bao Q, Li P, Hu C. Helicobacter pylori and unignorable extragastric diseases: Mechanism and implications. Front Microbiol 2022;13:972777. [DOI: 10.3389/fmicb.2022.972777] [Reference Citation Analysis]
98 Kuo C, Ke J, Kuo T, Lin C, Hsieh S, Chiu Y, Wu H, Huang M, Bui N, Chiu C, Chiu C, Lai C. Multiple amino acid substitutions in penicillin-binding protein-1A confer amoxicillin resistance in refractory Helicobacter pylori infection. Journal of Microbiology, Immunology and Infection 2022. [DOI: 10.1016/j.jmii.2022.07.006] [Reference Citation Analysis]
99 Ho JJC, Navarro M, Sawyer K, Elfanagely Y, Moss SF. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022;117:1221-30. [PMID: 35509128 DOI: 10.14309/ajg.0000000000001828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
100 Ang D. Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply. Aliment Pharmacol Ther 2022;56:754-5. [PMID: 35879904 DOI: 10.1111/apt.17133] [Reference Citation Analysis]
101 Souissi S, Makni C, Belhadj Ammar L, Bousnina O, Kallel L. Correlation between the intensity of Helicobacter pylori colonization and severity of gastritis: Results of a prospective study. Helicobacter 2022;27:e12910. [PMID: 35696278 DOI: 10.1111/hel.12910] [Reference Citation Analysis]
102 Ang D, Koo SH, Chan YH, Tan TY, Soon GH, Tan CK, Lin KW, Krishnasamy-Balasubramanian JK, Wong YJ, Kumar R, R R, Tan Y, Ong PJ, Tan YJ, Li JW, Kwek AB, Ang TL. Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication. Aliment Pharmacol Ther 2022;56:436-49. [PMID: 35665947 DOI: 10.1111/apt.17070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
103 Inokuchi K, Mori H, Matsuzaki J, Hirata K, Harada Y, Saito Y, Suzuki H, Kanai T, Masaoka T. Efficacy and safety of low-dose rifabutin-based 7-day triple therapy as a third- or later-line Helicobacter pylori eradication regimen. Helicobacter 2022;27:e12900. [PMID: 35644041 DOI: 10.1111/hel.12900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Neves NCV, de Mello MP, Smith SM, Boylan F, Caliari MV, Castilho RO. Chemical Composition and In Vitro Anti-Helicobacter pylori Activity of Campomanesia lineatifolia Ruiz & Pavón (Myrtaceae) Essential Oil. Plants 2022;11:1945. [DOI: 10.3390/plants11151945] [Reference Citation Analysis]
105 Dharan M, Wozny D. Helicobacter pylori infection and small intestinal bacterial overgrowth–more than what meets the eye. World J Clin Cases 2022; 10(21): 7209-7214 [DOI: 10.12998/wjcc.v10.i21.7209] [Reference Citation Analysis]
106 Wang Y, Tang J, Zhou S, Liang TT, Wang FF, Ning H. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review - Are They Potential Eradication Regimens? Infect Drug Resist 2022;15:3733-49. [PMID: 35859911 DOI: 10.2147/IDR.S371131] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
107 Öztürk A. MİDEDE H. PYLORİ ERADİKASYON ORANLARI ORAL H. PYLORİNİN DİŞETİ (PERİODONTAL) TEDAVİSİ İLE ELİMİNASYONU İLE ARTIRILABİLİR Mİ? LİTERATUR TARAMASI. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi 2022. [DOI: 10.17567/ataunidfd.956984] [Reference Citation Analysis]
108 Kim SE, Hwang JH. Management of Helicobacter pylori Infection: A Comparison between Korea and the United States. Gut Liver 2022;16:503-14. [PMID: 35843686 DOI: 10.5009/gnl210224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Huang Y, Chen J, Ding Z, Liang X, Lu H. Susceptibility testing alone will not reliably achieve high Helicobacter pylori cure rates: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1212-21. [PMID: 35434851 DOI: 10.1111/jgh.15864] [Reference Citation Analysis]
110 Hung KW, Maratt JK, Cho WK, Shah BJ, Anjou CI, Leiman DA. AGA Institute Quality Measure Development for the Management of Gastric Intestinal Metaplasia With Helicobacter pylori. Gastroenterology 2022;163:3-7. [PMID: 35337856 DOI: 10.1053/j.gastro.2022.03.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Sisto F, Carradori S, D’alessandro S, Santo N, Lattuada N, Haynes RK, Taramelli D, Grande R. In Vitro Activity of the Arylaminoartemisinin GC012 against Helicobacter pylori and Its Effects on Biofilm. Pathogens 2022;11:740. [DOI: 10.3390/pathogens11070740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Turshudzhyan A, Samuel S, Tawfik A, Tadros M. Rebuilding trust in proton pump inhibitor therapy. World J Gastroenterol 2022; 28(24): 2667-2679 [DOI: 10.3748/wjg.v28.i24.2667] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
113 Smakotina SA, Kolmogorova TO. Empathy, psychological characteristics, and compliance in patients with chronic gastritis. Fundamentalʹnaâ i kliničeskaâ medicina 2022;7:84-93. [DOI: 10.23946/2500-0764-2022-7-2-84-93] [Reference Citation Analysis]
114 Potapova MV, Broyaka NA, Skvortsov KY, Konobeeva EV. Helicobacter pylori roles in haematology disease pathogenesis. Sibirskij nauchnyj medicinskij zhurnal 2022;42:18-35. [DOI: 10.18699/ssmj20220302] [Reference Citation Analysis]
115 Grosso R, de-Paz M. Scope and Limitations of Current Antibiotic Therapies against Helicobacter pylori: Reviewing Amoxicillin Gastroretentive Formulations. Pharmaceutics 2022;14:1340. [DOI: 10.3390/pharmaceutics14071340] [Reference Citation Analysis]
116 Galaz J, Romero R, Arenas-hernandez M, Farias-jofre M, Motomura K, Liu Z, Kawahara N, Demery-poulos C, Liu TN, Padron J, Panaitescu B, Gomez-lopez N. Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal–fetal inflammation in mice. BMC Pregnancy Childbirth 2022;22. [DOI: 10.1186/s12884-022-04764-2] [Reference Citation Analysis]
117 Alarfaj SJ, Abdallah Mostafa S, Abdelsalam RA, Negm WA, El-masry TA, Hussein IA, El Nakib AM. Helicobacter pylori Infection in Cirrhotic Patients With Portal Hypertensive Gastropathy: A New Enigma? Front Med 2022;9:902255. [DOI: 10.3389/fmed.2022.902255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Yamamichi N, Shimamoto T, Takahashi Y, Takahashi M, Takeuchi C, Wada R, Fujishiro M. Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. PLoS ONE 2022;17:e0270252. [DOI: 10.1371/journal.pone.0270252] [Reference Citation Analysis]
119 Goldberg L, Amrick TJ. Successful Eradication of Helicobacter pylori with 5-Day Concomitant Treatment. GastroHep 2022;2022:1-4. [DOI: 10.1155/2022/1211329] [Reference Citation Analysis]
120 Nyssen OP, Espada M, Gisbert JP. Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Microbiol 2022;13:913436. [DOI: 10.3389/fmicb.2022.913436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Zou Y, Chen X, Sun Y, Li P, Xu M, Fang P, Zhang S, Yuan G, Deng X, Hu H. Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria. J Control Release 2022;348:370-85. [PMID: 35662575 DOI: 10.1016/j.jconrel.2022.05.044] [Reference Citation Analysis]
122 Wasielica-berger J, Gugnacki P, Mlynarczyk M, Rogalski P, Swidnicka-siergiejko A, Antonowicz S, Krzyzak M, Maslach D, Dabrowski A, Daniluk J. Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland. IJERPH 2022;19:6921. [DOI: 10.3390/ijerph19116921] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
123 Song Z, Chen Y, Lu H, Zeng Z, Wang W, Liu X, Zhang G, Du Q, Xia X, Li C, Jiang S, Wu T, Li P, He S, Zhu Y, Zhang G, Xu J, Li Y, Huo L, Lan C, Miao Y, Jiang H, Chen P, Shi L, Tuo B, Zhang D, Jiang K, Wang J, Yao P, Huang X, Yang S, Wang X, Zhou L. Diagnosis and treatment of Helicobacter pylori infection by physicians in China: A nationwide cross-sectional study. Helicobacter 2022;27:e12889. [PMID: 35363917 DOI: 10.1111/hel.12889] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
124 Scaccaglia M, Rega M, Bacci C, Giovanardi D, Pinelli S, Pelosi G, Bisceglie F. Bismuth complex of quinoline thiosemicarbazone restores carbapenem sensitivity in NDM-1-positive Klebsiella pneumoniae. Journal of Inorganic Biochemistry 2022. [DOI: 10.1016/j.jinorgbio.2022.111887] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
125 Saif N, Jensen N, Farrar E, Blackstone S, Hauck FR. Prevalence of Helicobacter pylori infection among resettled refugees presenting to a family medicine clinic in the United States. Helicobacter 2022;27:e12894. [PMID: 35484785 DOI: 10.1111/hel.12894] [Reference Citation Analysis]
126 Jiang F, Guo CG, Cheung KS, Li B, Law SYK, Leung WK. Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study. Helicobacter 2022;27:e12893. [PMID: 35411663 DOI: 10.1111/hel.12893] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Congedi J, Williams C, Baldock KL. Epidemiology of Helicobacter pylori in Australia: a scoping review. PeerJ 2022;10:e13430. [PMID: 35669956 DOI: 10.7717/peerj.13430] [Reference Citation Analysis]
128 Motta-raymundo A, Rosmaninho P, Santos DF, Ferreira RD, Silva SP, Ferreira C, Sousa AE, Silva SL. Contribution of Helicobacter pylori to the Inflammatory Complications of Common Variable Immunodeficiency. Front Immunol 2022;13:834137. [DOI: 10.3389/fimmu.2022.834137] [Reference Citation Analysis]
129 Sheu N, Huang S, Wu D, Kao JY, Lin K. Effects of Helicobacter pylori treatment on the incidences of autoimmune diseases and inflammatory bowel disease in patients with diabetes mellitus. PLoS ONE 2022;17:e0265323. [DOI: 10.1371/journal.pone.0265323] [Reference Citation Analysis]
130 Lu Q, Zhang Z, Xu Y, Chen Y, Li C. Sanguinarine, a major alkaloid from Zanthoxylum nitidum (Roxb.) DC., inhibits urease of Helicobacter pylori and jack bean: Susceptibility and mechanism. J Ethnopharmacol 2022;:115388. [PMID: 35577159 DOI: 10.1016/j.jep.2022.115388] [Reference Citation Analysis]
131 Poliantsev AA, Frolov DV, Linchenko AM, Karpenko SN, Kosivtsov OA, Chernovolenko AA, Kaplunova EV. Prevention of erosive and ulcerative gastroduodenal bleeding in patients after endovascular surgery on the arteries of the lower extremities for critical ischemia. VESTNIK KHIRURGII IMENI I I GREKOVA 2022;181:24-32. [DOI: 10.24884/0042-4625-2022-181-2-24-32] [Reference Citation Analysis]
132 Kirsch SH, Haeckl FPJ, Müller R. Beyond the approved: target sites and inhibitors of bacterial RNA polymerase from bacteria and fungi. Nat Prod Rep 2022. [PMID: 35507039 DOI: 10.1039/d1np00067e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
133 Lin BS, Li YY, Qiao C, Liu J, Wang J, Wan M, Lin MJ, Zhang WL, Ding YM, Kong QZ, Duan M, Zuo XL, Li YQ. Implementation of WeChat-based patient-doctor interaction in the management of Helicobacter pylori infection: A propensity score matching analysis. J Dig Dis 2022;23:280-7. [PMID: 35821639 DOI: 10.1111/1751-2980.13114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Leontiadis GI, Longstreth GF. Evolutionary Medicine Perspectives: Helicobacter pylori, Lactose Intolerance, and 3 Hypotheses for Functional and Inflammatory Gastrointestinal and Hepatobiliary Disorders. Am J Gastroenterol 2022;117:721-8. [PMID: 35169106 DOI: 10.14309/ajg.0000000000001681] [Reference Citation Analysis]
135 Voss SJ, McGuinness DH, Weir W, Sutton DGM. A study comparing the healthy and diseased equine glandular gastric microbiota sampled with sheathed transendoscopic cytology brushes. J Equine Vet Sci 2022;:104002. [PMID: 35490972 DOI: 10.1016/j.jevs.2022.104002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Knoop RF, Gaertner PC, Petzold G, Amanzada A, Ellenrieder V, Neesse A, Bremer SCB, Kunsch S, Mascellino MT. Systematic Retesting for Helicobacter pylori: The Potential Overestimation of Suppressive Conditions. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/5380001] [Reference Citation Analysis]
137 Sheptulin AA, Rabotyagova YS. Нow to increase the effectiveness of eradication therapy of <i>Helicobacter pylori</i> infection? jour 2022;100:47-50. [DOI: 10.30629/0023-2149-2022-100-1-47-50] [Reference Citation Analysis]
138 Choe Y, Kim JS, Choi HH, Kim DB, Park JM, Oh JH, Kim TH, Cheung DY, Chung WC, Kim BW, Kim SS. The Influence of Past Metronidazole Exposure on the Outcome of Helicobacter pylori Eradication. Front Microbiol 2022;13:857569. [PMID: 35401472 DOI: 10.3389/fmicb.2022.857569] [Reference Citation Analysis]
139 Ansari S, Yamaoka Y. Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance. Clin Microbiol Rev 2022;:e0025821. [PMID: 35404105 DOI: 10.1128/cmr.00258-21] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Assefa B, Tadesse A, Abay Z, Abebe A, Tesfaye T, Tadesse M, Molla A. Peptic ulcer disease among dyspeptic patients at endoscopy unit, University of Gondar hospital, Northwest Ethiopia. BMC Gastroenterol 2022;22:164. [PMID: 35382748 DOI: 10.1186/s12876-022-02245-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Chang YW, Shin GY, Kim JW, Moon JC, Chang EJ, Oh CH, Jang JY. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Dig Dis Sci 2022;67:1222-30. [PMID: 33755825 DOI: 10.1007/s10620-021-06938-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
142 Wang L, Yao H, Tong T, Lau K, Leung SY, Ho JWK, Leung WK. Dynamic changes in antibiotic resistance genes and gut microbiota after Helicobacter pylori eradication therapies. Helicobacter 2022;27:e12871. [PMID: 34969161 DOI: 10.1111/hel.12871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
143 Vanden Bulcke A, Waked B, Haems L, Lambrecht G, Hervent AS, Alliet G, Baert F, Vervaeke S. Antimicrobial resistance of Helicobacter pylori in West Flanders - Belgium: an observational cross-sectional study. Acta Clin Belg 2022;77:360-7. [PMID: 33502281 DOI: 10.1080/17843286.2021.1872307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Liu Y, Wang S, Yang F, Chi W, Ding L, Liu T, Zhu F, Ji D, Zhou J, Fang Y, Zhang J, Xiang P, Zhang Y, Zhao H. Antimicrobial resistance patterns and genetic elements associated with the antibiotic resistance of Helicobacter pylori strains from Shanghai. Gut Pathog 2022;14:14. [PMID: 35354484 DOI: 10.1186/s13099-022-00488-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
145 Guo Z, Tian S, Wang W, Zhang Y, Li J, Lin R. Correlation Analysis Among Genotype Resistance, Phenotype Resistance, and Eradication Effect After Resistance-Guided Quadruple Therapies in Refractory Helicobacter pylori Infections. Front Microbiol 2022;13:861626. [PMID: 35330762 DOI: 10.3389/fmicb.2022.861626] [Reference Citation Analysis]
146 Nyssen OP, Vaira D, Saracino IM, Fiorini G, Caldas M, Bujanda L, Pellicano R, Keco-Huerga A, Pabón-Carrasco M, Oblitas Susanibar E, Di Leo A, Losurdo G, Pérez-Aísa Á, Gasbarrini A, Boltin D, Smith S, Phull P, Rokkas T, Lamarque D, Cano-Català A, Puig I, Mégraud F, O'Morain C, Gisbert JP. Experience with Rifabutin-Containing Therapy in 500 Patients from the European Registry on Helicobacter pylori Management (Hp-EuReg). J Clin Med 2022;11:1658. [PMID: 35329984 DOI: 10.3390/jcm11061658] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
147 Shah SC, Shah S, Halvorson AE, Hung A, Greevy RA Jr, Roumie CL. Helicobacter pylori eradication therapy is not associated with increased risk of cardiovascular mortality, based on a national cohort study. Gastro Hep Adv 2022;1:25-8. [PMID: 35253008 DOI: 10.1016/j.gastha.2021.10.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
148 Shakir SM, Otiso J, Keller G, Heule HV, Osborn LJ, Cole N, Schuetz AN, Richter SS, Couturier MR, Lainhart W. Multicenter Evaluation of a Gradient Diffusion Method for Antimicrobial Susceptibility Testing of Helicobacter pylori. Microbiol Spectr. [DOI: 10.1128/spectrum.02111-21] [Reference Citation Analysis]
149 Yang C, Li S, Huang T, Lin H, Jiang Z, He Y, Yuan J, An H. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials. J Clin Pharm Ther 2022. [PMID: 35247003 DOI: 10.1111/jcpt.13637] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
150 Warner AJ, Hathaway-schrader JD, Lubker R, Davies C, Novince CM. Tetracyclines and bone: Unclear actions with potentially lasting effects. Bone 2022. [DOI: 10.1016/j.bone.2022.116377] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
151 Klang E, Soffer S, Barash Y, Shachar E, Lahat A. Changes in Helicobacter pylori Treatment from Discovery to Nowadays: A High-Level Analysis of PubMed Publications. CEG 2022;Volume 15:51-8. [DOI: 10.2147/ceg.s342048] [Reference Citation Analysis]
152 Azad KN, Realegeno SE, Kagan RM, Schwab DA, Batterman HJ, Marlowe EM. An Easily Digestible Review of Helicobacter pylori Diagnostics. Clinical Microbiology Newsletter 2022;44:51-61. [DOI: 10.1016/j.clinmicnews.2022.03.001] [Reference Citation Analysis]
153 Han L, Shu X, Wang J. Helicobacter pylori-Mediated Oxidative Stress and Gastric Diseases: A Review. Front Microbiol 2022;13:811258. [PMID: 35211104 DOI: 10.3389/fmicb.2022.811258] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
154 Cardos AI, Maghiar A, Zaha DC, Pop O, Fritea L, Miere (Groza) F, Cavalu S. Evolution of Diagnostic Methods for Helicobacter pylori Infections: From Traditional Tests to High Technology, Advanced Sensitivity and Discrimination Tools. Diagnostics 2022;12:508. [DOI: 10.3390/diagnostics12020508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
155 Ho C, Liu T, Lin Y, Chen Y, Chen M, Wang H, Liou T. Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection. Microorganisms 2022;10:415. [DOI: 10.3390/microorganisms10020415] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
156 Rossi D, Bertoni F, Zucca E. Marginal-Zone Lymphomas. N Engl J Med 2022;386:568-81. [PMID: 35139275 DOI: 10.1056/NEJMra2102568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
157 Zagari RM, Romano M, Frazzoni L, Marasco G, Dajti E, Arcidiacono PG, Armuzzi A, Biagi F, Cannizzaro R, Cavestro GM, Ciacci C, Monica F, Peralta S, Radaelli F, Bazzoli F. Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. Helicobacter 2022;27:e12862. [PMID: 34766392 DOI: 10.1111/hel.12862] [Reference Citation Analysis]
158 Nyssen OP, Vaira D, Tepes B, Kupcinskas L, Bordin D, Pérez-Aisa Á, Gasbarrini A, Castro-Fernández M, Bujanda L, Garre A, Lucendo A, Vologzhanina L, Jurecic NB, Rodrigo-Sáez L, Huguet JM, Voynovan I, Perez-Lasala J, Romero PM, Vujasinovic M, Abdulkhakov R, Barrio J, Fernandez-Salazar L, Mégraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). J Clin Gastroenterol 2022;56:e98-e108. [PMID: 33405435 DOI: 10.1097/MCG.0000000000001482] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 17.0] [Reference Citation Analysis]
159 Viazis N, Argyriou K, Kotzampassi K, Christodoulou DK, Apostolopoulos P, Georgopoulos SD, Liatsos C, Giouleme O, Koustenis K, Veretanos C, Stogiannou D, Moutzoukis M, Poutakidis C, Mylonas II, Tseti I, Mantzaris GJ. A Four-Probiotics Regimen Combined with A Standard Helicobacter pylori-Eradication Treatment Reduces Side Effects and Increases Eradication Rates. Nutrients 2022;14:632. [PMID: 35276991 DOI: 10.3390/nu14030632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
160 Suzuki S, 後藤田 卓. Potential of Vonoprazan Dual Therapy and Current IssuesRelated Helicobacter Pylori Treatment. Nichidai Igaku Zasshi 2022;81:53-57. [DOI: 10.4264/numa.81.1_53] [Reference Citation Analysis]
161 Yu J, Yang P, Qin X, Li C, Lv Y, Wang X. Impact of smoking on the eradication of Helicobacter pylori. Helicobacter 2022;27:e12860. [PMID: 34708484 DOI: 10.1111/hel.12860] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
162 Brennan DE, O'Morain C, McNamara D, Smith SM. Combined antrum and corpus biopsy protocol improves Helicobacter pylori culture success. World J Gastrointest Pathophysiol 2022; 13(1): 34-40 [DOI: 10.4291/wjgp.v13.i1.34] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 Wang K, Lou D, Dai W, Fu R, Ma Z. Comparison of sequential therapy with concomitant therapy in first-line treatment of Helicobacter pylori: an updated meta-analysis. J Med Microbiol 2022;71. [PMID: 35041577 DOI: 10.1099/jmm.0.001490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Levitan BN, Skvortsov VV, Samokhvalova PD. Modern approaches in treatment of helicobacteriosis in patients with peptic ulcer. Medicinskij alfavit 2022. [DOI: 10.33667/2078-5631-2021-40-7-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
165 Fiori-Duarte AT, de Oliveira Guarnieri JP, de Oliveira Borlot JRP, Lancellotti M, Rodrigues RP, Kitagawa RR, Kawano DF. In silico design and in vitro assessment of anti-Helicobacter pylori compounds as potential small-molecule arginase inhibitors. Mol Divers 2022. [PMID: 34997872 DOI: 10.1007/s11030-021-10371-8] [Reference Citation Analysis]
166 Kim J, Gong EJ, Seo M, Seo HI, Park JK, Lee SJ, Han KH, Jeong WJ, Kim YD, Cheon GJ. Efficacy of Twice a Day Bismuth Quadruple Therapy for Second-Line Treatment of Helicobacter pylori Infection. JPM 2022;12:56. [DOI: 10.3390/jpm12010056] [Reference Citation Analysis]
167 Sharndama HC, Mba IE. Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms. Braz J Microbiol 2022. [PMID: 34988937 DOI: 10.1007/s42770-021-00675-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
168 Malfertheiner P, Moss SF, Daniele P, Pelletier C, Jacob R, Tremblay G, Hubscher E, Leifke E, Chey WD. Potassium-Competitive Acid Blocker and Proton Pump Inhibitor–Based Regimens for First-Line Helicobacter pylori Eradication: A Network Meta-Analysis. Gastro Hep Advances 2022;1:824-834. [DOI: 10.1016/j.gastha.2022.06.009] [Reference Citation Analysis]
169 Dabbebi H, Elloumi H, Kechiche C, Hammemi E, Cheikh I, Jmaa A. Effect of Helicobacter pylori eradication therapy on the response of MALT-Gastric lymphoma. Tunis Med 2022;100:37-43. [PMID: 35822330] [Reference Citation Analysis]
170 Das N, Ragavan ML, Mandal SK. Probiotics in the prevention and treatment of infections with Helicobacter pylori, Enterohemorrhagic Escherichia coli, and Rotavirus. Probiotics in the Prevention and Management of Human Diseases 2022. [DOI: 10.1016/b978-0-12-823733-5.00001-5] [Reference Citation Analysis]
171 Afzal A, Bal AM. Metronidazole. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00187-0] [Reference Citation Analysis]
172 Lormohammadi L, Nikkhahi F, Bolori S, Karami AA, Hajian S, Rad N, Peymani A, Samimi R. High level of resistance to metronidazole and clarithromycin among Helicobacter pylori clinical isolates in Qazvin province, Iran. Gene Reports 2022. [DOI: 10.1016/j.genrep.2022.101494] [Reference Citation Analysis]
173 Brown H, Cantrell S, Tang H, Epplein M, Garman KS. Racial Differences in Helicobacter pylori Prevalence in the US: A Systematic Review. Gastro Hep Advances 2022;1:857-868. [DOI: 10.1016/j.gastha.2022.06.001] [Reference Citation Analysis]
174 Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch Microbiol 2022;204:692. [PMID: 36344628 DOI: 10.1007/s00203-022-03314-w] [Reference Citation Analysis]
175 Orenstein R. Select Gastrointestinal and Hepatobiliary Infections. A Rational Approach to Clinical Infectious Diseases 2022. [DOI: 10.1016/b978-0-323-69578-7.00010-7] [Reference Citation Analysis]
176 Kathi PR, Babaria R, Banerjee B. Impact of helicobacter pylori on human physiology and digestive disorders. Nutrition and Functional Foods in Boosting Digestion, Metabolism and Immune Health 2022. [DOI: 10.1016/b978-0-12-821232-5.00021-5] [Reference Citation Analysis]
177 Hughes GJ. Gastrointestinal Endoscopy - Upper. A Medication Guide to Internal Medicine Tests and Procedures 2022. [DOI: 10.1016/b978-0-323-79007-9.00032-5] [Reference Citation Analysis]
178 Visaggi P, de Bortoli N, Barberio B, Savarino V, Oleas R, Rosi EM, Marchi S, Ribolsi M, Savarino E. Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. J Clin Gastroenterol 2022;56:23-35. [PMID: 34739406 DOI: 10.1097/MCG.0000000000001629] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
179 Gaur S, Bal AM. Tetracyclines. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00185-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]
181 Howden CW, Spechler SJ, Vaezi MF, Fendrick AM, Atkinson C, Pelletier C, Jacob R, Brunton S. Study of Acid-related Disorders: Real-world Physician and Patient Perspectives on Burden of Helicobacter pylori Infection. Gastro Hep Advances 2022;1:231-240. [DOI: 10.1016/j.gastha.2021.12.005] [Reference Citation Analysis]
182 Fonseca DR, Moura A, Leiro V, Silva-Carvalho R, Estevinho BN, Seabra CL, Henriques PC, Lucena M, Teixeira C, Gomes P, Parreira P, Martins MCL. Grafting MSI-78A onto chitosan microspheres enhances its antimicrobial activity. Acta Biomater 2022;137:186-98. [PMID: 34634508 DOI: 10.1016/j.actbio.2021.09.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
183 Howden CW, Sheldon KL, Almenoff JS, Chey WD. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Dig Dis Sci 2022;67:4382-6. [PMID: 34862940 DOI: 10.1007/s10620-021-07323-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
184 Jha SK, Kumar R, Kumar A, Purkayastha S, Keshri R, Kumar S, Singh AV. Addition of Nitazoxanide to Standard Clarithromycin Based Triple Therapy for 2 Weeks Effectively Eradicates Treatment-Naive Helicobacter Pylori Infection. A Single Centre prospective, open-label study. Middle East J Dig Dis 2022;14:77-84. [PMID: 36619726 DOI: 10.34172/mejdd.2022.259] [Reference Citation Analysis]
185 Lagwinski NP, Petras RE. Gastrointestinal System. Gattuso's Differential Diagnosis in Surgical Pathology 2022. [DOI: 10.1016/b978-0-323-66165-2.00006-5] [Reference Citation Analysis]
186 Bal AM. Macrolide Antibiotics. Comprehensive Pharmacology 2022. [DOI: 10.1016/b978-0-12-820472-6.00167-5] [Reference Citation Analysis]
187 Mai Q, Su G, Qin L, Gong S, Liang M, Gan Y, Huang X, Su X, Su B, Wei X, Yang M. Exploration and Study of Jianpi Qushi Powder Combined with Standard Anti HP Quadruple Therapy in the Treatment of HP Infectious Gastritis of Spleen Deficiency and Dampness Stagnation Type. NS 2022;14:56-61. [DOI: 10.4236/ns.2022.142006] [Reference Citation Analysis]
188 George CM. Chapter 25: Gastrointestinal Diseases. The APhA Complete Review for Pharmacy, 13th Edition 2022. [DOI: 10.21019/9781582123615.ch25] [Reference Citation Analysis]
189 Yang JC, Kao JY. Treatment considerations in Helicobacter pylori management. Aliment Pharmacol Ther 2022;55 Suppl 1:S22-8. [PMID: 34989432 DOI: 10.1111/apt.16652] [Reference Citation Analysis]
190 Shih C, Shie C, Hsu P. Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances. Therap Adv Gastroenterol 2022;15:175628482211381. [DOI: 10.1177/17562848221138168] [Reference Citation Analysis]
191 . Viszeralchirurgie. FAP Allgemein- und Viszeralchirurgie 2022. [DOI: 10.1016/b978-3-437-23244-2.00005-7] [Reference Citation Analysis]
192 Kim Y, Choi IJ. Current Evidence for a Paradigm Shift in Gastric Cancer Prevention From Endoscopic Screening to Helicobacter pylori Eradication in Korea. J Gastric Cancer 2022;22:e22. [DOI: 10.5230/jgc.2022.22.e22] [Reference Citation Analysis]
193 Alsohaibani F, Peedikayil M, Alshahrani A, Somily A, Alsulaiman R, Azzam N, Almadi M. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi J Gastroenterol 2022;0:0. [DOI: 10.4103/sjg.sjg_288_22] [Reference Citation Analysis]
194 Bayraktar M, Dabak R. Screening of Helicobacter pylori in patients with dyspeptic complaints with the urea breath test and its usability in family medicine. Turkish Journal of Family Medicine and Primary Care 2021. [DOI: 10.21763/tjfmpc.865772] [Reference Citation Analysis]
195 Qin Y, Lao YH, Wang H, Zhang J, Yi K, Chen Z, Han J, Song W, Tao Y, Li M. Combatting Helicobacter pylori with oral nanomedicines. J Mater Chem B 2021;9:9826-38. [PMID: 34854456 DOI: 10.1039/d1tb02038b] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Zhao Y, Li Y, Luan Z, Ma C, Yang L, Zhang W, Shi C. Establishment of a TaqMan-MGB probe multiplex real-time PCR system for one-step levofloxacin and clarithromycin resistant Helicobacter pylori detection. J Microbiol Methods 2021;192:106393. [PMID: 34919971 DOI: 10.1016/j.mimet.2021.106393] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
197 Bordin DS. Errors in the diagnosis and treatment of <i>Helicobacter pylori</i> infection: in anticipation of new conciliation documents. jour 2021. [DOI: 10.31146/1682-8658-ecg-193-9-5-14] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
198 Hofmann R, Bäck M. Gastro-Cardiology: A Novel Perspective for the Gastrocardiac Syndrome. Front Cardiovasc Med 2021;8:764478. [PMID: 34869678 DOI: 10.3389/fcvm.2021.764478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
199 Yao X, Xiao S, Zhou L. Integrative proteomic and metabolomic analyses reveal the mechanism by which bismuth enables Helicobacter pylori eradication. Helicobacter 2021;26:e12846. [PMID: 34414638 DOI: 10.1111/hel.12846] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
200 Bunchorntavakul C, Buranathawornsom A. Randomized clinical trial: 7-day vonoprazan-based versus 14-day omeprazole-based triple therapy for Helicobacter pylori. J Gastroenterol Hepatol 2021;36:3308-13. [PMID: 34622504 DOI: 10.1111/jgh.15700] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
201 Kao JY, Almenoff JS, Portenier DD, Sheldon KL. Helicobacter pylori eradication by low‐dose rifabutin triple therapy (RHB‐105) is unaffected by high body mass index. GastroHep 2021;3:426-434. [DOI: 10.1002/ygh2.494] [Reference Citation Analysis]
202 Collatuzzo G, Fiorini G, Vaira B, Violante FS, Farioli A, Boffetta P. The role of the occupational physician in controlling gastric cancer attributable to Helicobacter pylori infection: A review. Preventive Medicine Reports 2021;24:101527. [DOI: 10.1016/j.pmedr.2021.101527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
203 Dutta AK, Phull PS. Treatment of Helicobacter pylori infection in the presence of penicillin allergy. World J Gastroenterol 2021; 27(44): 7661-7668 [PMID: 34908805 DOI: 10.3748/wjg.v27.i44.7661] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
204 Dao LV, Dao HV, Nguyen HT, Vu VT, Tran ATN, Dat VQ, Hoang LB, Nguyen HTV, Nguyen TD. Helicobacter pylori infection and eradication outcomes among Vietnamese patients in the same households: Findings from a non-randomized study. PLoS One 2021;16:e0260454. [PMID: 34818349 DOI: 10.1371/journal.pone.0260454] [Reference Citation Analysis]
205 Fernandez-perez S, Velazco G, Lenik JM, Achuo-egbe Y, Harley J. Helicobacter pylori Resistance to Triple Therapy in a Multicultural Population in New York City. Cureus 2021. [DOI: 10.7759/cureus.19883] [Reference Citation Analysis]
206 Kuang S, Xu J, Chen M, Zhang Y, Shi F, Lu X. The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27944. [PMID: 34964772 DOI: 10.1097/MD.0000000000027944] [Reference Citation Analysis]
207 Luu MN, Quach DT, Hiyama T. Screening and surveillance for gastric cancer: Does family history play an important role in shaping our strategy? Asia Pac J Clin Oncol 2021. [PMID: 34811928 DOI: 10.1111/ajco.13704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
208 Bordin DS, Krolevets TS, Livzan MA. Are physicians ready to comply with the guidelines for diagnosis and management of Helicobacter pylori-associated diseases: the survey results 2020–2021. Alʹm klin med 2021;49:455-468. [DOI: 10.18786/2072-0505-2021-49-051] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
209 Liu Y, Shuai P, Liu YP, Li DY. Association between Helicobacter pylori infection and food-specific immunoglobulin G in Southwest China. World J Clin Cases 2021; 9(32): 9815-9824 [PMID: 34877320 DOI: 10.12998/wjcc.v9.i32.9815] [Reference Citation Analysis]
210 Wu SE, Chen WL. Detrimental relevance of Helicobacter pylori infection with sarcopenia. Gut Pathog 2021;13:67. [PMID: 34782007 DOI: 10.1186/s13099-021-00464-y] [Reference Citation Analysis]
211 Boubrik F, Belmouden A, Kadmiri NE. Potential Non-invasive Biomarkers of Helicobacter pylori-Associated Gastric Cancer. J Gastrointest Cancer 2021. [PMID: 34767179 DOI: 10.1007/s12029-021-00734-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
212 Wylie MR, Windham IH, Blum FC, Wu H, Merrell DS. In vitro antibacterial activity of nimbolide against Helicobacter pylori. J Ethnopharmacol 2021;:114828. [PMID: 34763046 DOI: 10.1016/j.jep.2021.114828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
213 Haq MMU, Furqan M, Zia A, Khalil A, Kalwar HA. The efficacy of levofloxacin‐based sequential regimen to eradicate Helicobacter pylori infection. GastroHep 2021;3:384-387. [DOI: 10.1002/ygh2.482] [Reference Citation Analysis]
214 Griffith DM, Li H, Werrett MV, Andrews PC, Sun H. Medicinal chemistry and biomedical applications of bismuth-based compounds and nanoparticles. Chem Soc Rev 2021;50:12037-69. [PMID: 34533144 DOI: 10.1039/d0cs00031k] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 14.5] [Reference Citation Analysis]
215 Boonyabaramee P, Pittayanon R, Sunpavat A, Lerttanatum N, Faknak N, Wisedopas N. The Helicobacter pylori detection rate by using combination of rapid urease test at antrum and body vs histopathology in population who stop proton pump inhibitor less than 2 weeks. GastroHep 2021;3:339-343. [DOI: 10.1002/ygh2.496] [Reference Citation Analysis]
216 Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology 2021;161:1443-59. [PMID: 34358488 DOI: 10.1053/j.gastro.2021.07.043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
217 Binmaeil H, Hanafiah A, Mohamed Rose I, Raja Ali RA. Development and Validation of Multiplex Quantitative PCR Assay for Detection of Helicobacter pylori and Mutations Conferring Resistance to Clarithromycin and Levofloxacin in Gastric Biopsy. Infect Drug Resist 2021;14:4129-45. [PMID: 34675558 DOI: 10.2147/IDR.S325056] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
218 Keikha M, Karbalaei M. Probiotics as the live microscopic fighters against Helicobacter pylori gastric infections. BMC Gastroenterol 2021;21:388. [PMID: 34670526 DOI: 10.1186/s12876-021-01977-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
219 Huang Q, Jia X, Chu Y, Zhang X, Ye H. Helicobacter pylori Infection in Geriatric Patients: Current Situation and Treatment Regimens. Front Med (Lausanne) 2021;8:713908. [PMID: 34660627 DOI: 10.3389/fmed.2021.713908] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
220 Suzuki S, Kusano C, Horii T, Ichijima R, Ikehara H. The Ideal Helicobacter pylori Treatment for the Present and the Future. Digestion 2022;103:62-8. [PMID: 34662879 DOI: 10.1159/000519413] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
221 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. Management of Helicobacter pylori infection in the pediatric age. An Pediatr (Engl Ed) 2021;95:383.e1-9. [PMID: 34642127 DOI: 10.1016/j.anpede.2021.05.004] [Reference Citation Analysis]
222 Mao LQ, Zhou YL, Wang SS, Chen L, Hu Y, Yu LM, Xu JM, Lyu B. Impact of Helicobacter pylori eradication on the gastric microbiome. Gut Pathog 2021;13:60. [PMID: 34645495 DOI: 10.1186/s13099-021-00460-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
223 Xirouchakis E, Georgopoulos SD. Evaluating treatments with rifabutin and amoxicillin for eradication of Helicobacter pylori infection in adults: a systematic review. Expert Opin Pharmacother 2021;:1-10. [PMID: 34595999 DOI: 10.1080/14656566.2021.1982894] [Reference Citation Analysis]
224 Gingold-Belfer R, Niv Y, Schmilovitz-Weiss H, Levi Z, Boltin D. Susceptibility-guided versus empirical treatment for Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:2649-58. [PMID: 34114673 DOI: 10.1111/jgh.15575] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
225 Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC; Taiwan Acid-related Disease, Microbiota (TARD-M) Consortium. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter 2021;26:e12840. [PMID: 34390083 DOI: 10.1111/hel.12840] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
226 Tsimpiris A, Grigoriadis A, Tsolianos I, Moschos I, Goulis DG, Kouklakis G. Periodontitis and Helicobacter pylori Infection: Eradication and Periodontal Therapy Combination. Eur J Dent 2021. [PMID: 34598295 DOI: 10.1055/s-0041-1731928] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
227 Ouyang Y, Zhang W, Huang Y, Wang Y, Shao Q, Wu X, Lu N, Xie C. Effect of Helicobacter pylori eradication on hyperplastic gastric polyps: A systematic review and meta-analysis. Helicobacter 2021;26:e12838. [PMID: 34333811 DOI: 10.1111/hel.12838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
228 Gunaratne AW, Hamblin H, Clancy A, Magat AJMC, Dawson MVM, Tu J, Borody TJ. Combinations of antibiotics and vonoprazan for the treatment of Helicobacter pylori infections-Exploratory study. Helicobacter 2021;26:e12830. [PMID: 34247436 DOI: 10.1111/hel.12830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
229 Lee JW, Kim N, Nam RH, Jang JY, Choi Y, Lee DH. Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance. Helicobacter 2021;26:e12844. [PMID: 34382277 DOI: 10.1111/hel.12844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
230 Sousa C, Ferreira R, Azevedo NF, Oleastro M, Azeredo J, Figueiredo C, Melo LDR. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol 2021;:1-21. [PMID: 34569892 DOI: 10.1080/1040841X.2021.1975643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
231 Salillas S, Galano-Frutos JJ, Mahía A, Maity R, Conde-Giménez M, Anoz-Carbonell E, Berlamont H, Velazquez-Campoy A, Touati E, Mamat U, Schaible UE, Gálvez JA, Díaz-de-Villegas MD, Haesebrouck F, Aínsa JA, Sancho J. Selective Targeting of Human and Animal Pathogens of the Helicobacter Genus by Flavodoxin Inhibitors: Efficacy, Synergy, Resistance and Mechanistic Studies. Int J Mol Sci 2021;22:10137. [PMID: 34576300 DOI: 10.3390/ijms221810137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Gomez-Ramirez U, Valencia-Mayoral P, Mendoza-Elizalde S, Murillo-Eliosa JR, Solórzano Santos F, Contreras-Rodríguez A, Zúñiga G, Aguilar-Rodea P, Jiménez-Rojas VL, Vigueras Galindo JC, Salazar-García M, Velázquez-Guadarrama N. Role of Helicobacter pylori and Other Environmental Factors in the Development of Gastric Dysbiosis. Pathogens 2021;10:1203. [PMID: 34578235 DOI: 10.3390/pathogens10091203] [Reference Citation Analysis]
233 Tucker AN, Carlson TJ, Sarkar A. Challenges in Drug Discovery for Intracellular Bacteria. Pathogens 2021;10:1172. [PMID: 34578204 DOI: 10.3390/pathogens10091172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
234 Jo HG, Kim YS. Helicobacter pylori Eradication Therapy-associated Diarrhea. Korean J Helicobacter Up Gastrointest Res 2021;21:203-14. [DOI: 10.7704/kjhugr.2021.0037] [Reference Citation Analysis]
235 Zeng R, Cheng Y, Luo D, Wang J, Yang J, Jiang L, Zhuo Z, Guo K, Wu H, Leung FW, Sha W, Chen H. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer 2021;156:190-201. [PMID: 34481369 DOI: 10.1016/j.ejca.2021.07.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
236 Cha B, Bang BW, Shin JB, Ko EJ, Ko W, Kwon KS, Shin YW, Suh YJ, Kim H. Bismuth containing quadruple therapy versus tailored therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area. Scand J Gastroenterol 2021;56:1017-22. [PMID: 34369255 DOI: 10.1080/00365521.2021.1948606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
237 Bahadori A, Gökmen TG, Köksal F, Tumgor G, Agin M, Sadighi A, Ziaee M, Rahbarnia L. High prevalence of clarithromycin resistant Helicobacter pylori in Turkish children with gastric disorders. Gene Reports 2021;24:101275. [DOI: 10.1016/j.genrep.2021.101275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
238 Hackett RJ, Preston SL. H.pylori, part II : management in an era of antibiotic resistance. Trends Urology & Men Health 2021;12:18-24. [DOI: 10.1002/tre.818] [Reference Citation Analysis]
239 Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications. Nat Rev Gastroenterol Hepatol 2021;18:613-29. [PMID: 34002081 DOI: 10.1038/s41575-021-00449-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 32.0] [Reference Citation Analysis]
240 Frater JL. Trends in iron deficiency anemia research 2001-2020: A bibliometric analysis. World J Meta-Anal 2021; 9(4): 389-404 [DOI: 10.13105/wjma.v9.i4.389] [Reference Citation Analysis]
241 Milner E, Stevens B, An M, Lam V, Ainsworth M, Dihle P, Stearns J, Dombrowski A, Rego D, Segars K. Utilizing Probiotics for the Prevention and Treatment of Gastrointestinal Diseases. Front Microbiol 2021;12:689958. [PMID: 34434175 DOI: 10.3389/fmicb.2021.689958] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
242 Couto ME, Oliveira I, Domingues N, Viterbo L, Martins Â, Moreira I, Espírito Santo A, Chacim S, Moreira C, Pereira D, Henrique R, Mariz J. Gastric MALT Lymphoma: A 8-Year Experience. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01483-0] [Reference Citation Analysis]
243 Mousavi T, Nikfar S, Abdollahi M. The pharmacotherapeutic management of duodenal and gastric ulcers. Expert Opin Pharmacother 2021;:1-27. [PMID: 34435515 DOI: 10.1080/14656566.2021.1959914] [Reference Citation Analysis]
244 Sarajlic P, Simonsson M, Jernberg T, Bäck M, Hofmann R. Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study. Eur Heart J Cardiovasc Pharmacother 2021:pvab059. [PMID: 34423350 DOI: 10.1093/ehjcvp/pvab059] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
245 Kornoukhova LA, Emanuel VL, Denisov NL, Nikonov EL. Helicobacter pylori infection: place of serological and cultural diagnostics in clinical guidelines. Klin Lab Diagn 2021;66:496-501. [PMID: 34388321 DOI: 10.51620/0869-2084-2021-66-8-496-501] [Reference Citation Analysis]
246 Liu J, Ji CR, Li YY, Qiao C, Hu JN, Wan M, Lin MJ, Lin BS, Wang J, Zha J, Li LX, Zuo XL. Two Different 1-Week Quadruple Therapies Given Back-to-Back Consecutive Therapy for Difficult-to-Treat Helicobacter pylori Infection: A Pilot Study. Clin Transl Gastroenterol 2021;12:e00391. [PMID: 34397042 DOI: 10.14309/ctg.0000000000000391] [Reference Citation Analysis]
247 Nazzal L, Francois F, Henderson N, Liu M, Li H, Koh H, Wang C, Gao Z, Perez GP, Asplin JR, Goldfarb DS, Blaser MJ. Effect of antibiotic treatment on Oxalobacter formigenes colonization of the gut microbiome and urinary oxalate excretion. Sci Rep 2021;11:16428. [PMID: 34385560 DOI: 10.1038/s41598-021-95992-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
248 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
249 Kankeu Fonkoua LA, Yoon HH. Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data. Onco Targets Ther 2021;14:4361-81. [PMID: 34385820 DOI: 10.2147/OTT.S216047] [Reference Citation Analysis]
250 Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol 2020;7:e000472. [PMID: 32883715 DOI: 10.1136/bmjgast-2020-000472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
251 Shin K, Cho MJ, Oh JH, Lim CH. Second-Line Bismuth-Containing Quadruple Therapy for Helicobacterpylori Infection: A 12-Year Study of Annual Eradication Rates. J Clin Med 2021;10:3273. [PMID: 34362057 DOI: 10.3390/jcm10153273] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
252 Li B, Su Y, Xiang N, Qin B, Li G, Wan T, Liu X, Wang D, Jiang C, Wen L, Feng QS. Comparative serum microRNA array analysis of the spleen-stomach dampness-heat syndrome in different diseases: Chronic hepatitis B and chronic gastritis. Anat Rec (Hoboken) 2021;304:2620-31. [PMID: 34288535 DOI: 10.1002/ar.24690] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
254 Korotkaya Y, Shores D. Helicobacter pylori in Pediatric Patients. Pediatr Rev 2020;41:585-92. [PMID: 33139411 DOI: 10.1542/pir.2019-0048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
255 Bricker-Ford R. Novel "High-dose Quad" Salvage Therapy Approach for Helicobacter pylori Infection: A Case Report. J Pharm Pract 2021;:8971900211033143. [PMID: 34269127 DOI: 10.1177/08971900211033143] [Reference Citation Analysis]
256 Kim SY, Park JM, Lim CH, Lee HA, Shin GY, Choe Y, Cho YK, Choi MG. Types of 23S Ribosomal RNA Point Mutations and Therapeutic Outcomes for Helicobacter pylori. Gut Liver 2021;15:528-36. [PMID: 33376228 DOI: 10.5009/gnl20225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
257 Goodman C, Lyon KN, Scotto A, Smith C, Sebrell TA, Gentry AB, Bala G, Stoner GD, Bimczok D. A High-Throughput Metabolic Microarray Assay Reveals Antibacterial Effects of Black and Red Raspberries and Blackberries against Helicobacter pylori Infection. Antibiotics (Basel) 2021;10:845. [PMID: 34356766 DOI: 10.3390/antibiotics10070845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
258 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
259 Lynch KL, Falk GW. Helicobacter pylori and GERD. The Esophagus 2021. [DOI: 10.1002/9781119599692.ch24] [Reference Citation Analysis]
260 Buzás GM. Helicobacter pylori and non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol 2020;66:267-79. [PMID: 32724031 DOI: 10.23736/S1121-421X.20.02671-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
261 Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol 2020;11:e00194. [PMID: 33094958 DOI: 10.14309/ctg.0000000000000194] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
262 Alhalabi M, Alassi MW, Alaa Eddin K, Cheha K. Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infect Dis 2021;21:642. [PMID: 34218802 DOI: 10.1186/s12879-021-06356-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
263 Thein W, Po WW, Choi WS, Sohn UD. Autophagy and Digestive Disorders: Advances in Understanding and Therapeutic Approaches. Biomol Ther (Seoul) 2021;29:353-64. [PMID: 34127572 DOI: 10.4062/biomolther.2021.086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
264 Shah SC, Peek RM Jr. Chemoprevention Against Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:519-42. [PMID: 34053637 DOI: 10.1016/j.giec.2021.03.006] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
265 Deguchi H, Yamazaki H, Kamitani T, Yamamoto Y, Fukuhara S. Impact of Vonoprazan Triple-Drug Blister Packs on H. pylori Eradication Rates in Japan: Interrupted Time Series Analysis. Adv Ther 2021;38:3937-47. [PMID: 34091865 DOI: 10.1007/s12325-021-01784-w] [Reference Citation Analysis]
266 Kim J, Wang TC. Helicobacter pylori and Gastric Cancer. Gastrointest Endosc Clin N Am 2021;31:451-65. [PMID: 34053633 DOI: 10.1016/j.giec.2021.03.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
267 Fathy El Sayed A, Magd Eldin Mohammad Sadek A, Ahmed Ragab Abdelhamid W. Comparison between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Trial. Middle East J Dig Dis 2021;13:223-9. [PMID: 36606218 DOI: 10.34172/mejdd.2021.229] [Reference Citation Analysis]
268 Liu C, Wang Y, Shi J, Zhang C, Nie J, Li S, Zheng T. The status and progress of first-line treatment against Helicobacter pylori infection: a review. Therap Adv Gastroenterol 2021;14:1756284821989177. [PMID: 34262609 DOI: 10.1177/1756284821989177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
269 Sayuk GS, Gyawali CP. Functional Dyspepsia: Diagnostic and Therapeutic Approaches. Drugs 2020;80:1319-36. [PMID: 32691294 DOI: 10.1007/s40265-020-01362-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
270 Galicia Poblet G, Alarcón Cavero T, Alonso Pérez N, Borrell Martínez B, Botija Arcos G, Cilleruelo Pascual ML, González Martín LM, Hernández Hernández A, Martínez Escribano B, Ortola Castells X, Rizo Pascual J, Urruzuno Tellería P, Vegas Álvarez AM. [Management of Helicobacter pylori infection in the pediatric age]. An Pediatr (Barc) 2021:S1695-4033(21)00202-2. [PMID: 34183279 DOI: 10.1016/j.anpedi.2021.05.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
271 Cortés P, Nelson AD, Bi Y, Stancampiano FF, Murray LP, Pujalte GGA, Gomez V, Harris DM. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive Review. J Prim Care Community Health 2021;12:21501327211014087. [PMID: 33949229 DOI: 10.1177/21501327211014087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
272 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. [Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer]. Korean J Gastroenterol 2020;75:264-91. [PMID: 32448858 DOI: 10.4166/kjg.2020.75.5.264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
273 Martin-Nuñez GM, Cornejo-Pareja I, Clemente-Postigo M, Tinahones FJ. Gut Microbiota: The Missing Link Between Helicobacter pylori Infection and Metabolic Disorders? Front Endocrinol (Lausanne) 2021;12:639856. [PMID: 34220702 DOI: 10.3389/fendo.2021.639856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
274 Tenório MCDS, Graciliano NG, Moura FA, Oliveira ACM, Goulart MOF. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants (Basel) 2021;10:967. [PMID: 34208683 DOI: 10.3390/antiox10060967] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 16.5] [Reference Citation Analysis]
275 Choe AR, Shim KN, Park Y, Song EM, Tae CH, Jung SA. Cost-Effectiveness, Efficacy, and Safety Analysis of Tailored Therapy in Patients with Helicobacter pylori Infection. J Clin Med 2021;10:2619. [PMID: 34198677 DOI: 10.3390/jcm10122619] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
276 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med 2021;36:807-38. [PMID: 34092054 DOI: 10.3904/kjim.2020.701] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
277 Huh KY, Chung H, Kim YK, Lee S, Bhatia S, Takanami Y, Nakaya R, Yu KS. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. Br J Clin Pharmacol 2021. [PMID: 34080718 DOI: 10.1111/bcp.14934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
278 Feng M, Harijan RK, Harris LD, Tyler PC, Fröhlich RFG, Brown M, Schramm VL. Aminofutalosine Deaminase in the Menaquinone Pathway of Helicobacter pylori. Biochemistry 2021;60:1933-46. [PMID: 34077175 DOI: 10.1021/acs.biochem.1c00215] [Reference Citation Analysis]
279 Xu H, Wang W, Ma X, Feng R, Su Y, Cheng L, Yang Y, Zhang D. Comparative efficacy and safety of high-dose dual therapy, bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection: a network meta-analysis. Eur J Gastroenterol Hepatol 2021;33:775-86. [PMID: 32639419 DOI: 10.1097/MEG.0000000000001835] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
280 Kim YJ, Chung WC, Kim DB. Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter 2021;26:e12792. [PMID: 33650225 DOI: 10.1111/hel.12792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
281 Nyssen OP, Perez-Aisa A, Tepes B, Castro-Fernandez M, Kupcinskas J, Jonaitis L, Bujanda L, Lucendo A, Jurecic NB, Perez-Lasala J, Shvets O, Fadeenko G, Huguet JM, Kikec Z, Bordin D, Voynovan I, Leja M, Machado JC, Areia M, Fernandez-Salazar L, Rodrigo L, Alekseenko S, Barrio J, Ortuño J, Perona M, Vologzhanina L, Romero PM, Zaytsev O, Rokkas T, Georgopoulos S, Pellicano R, Buzas GM, Modolell I, Gomez Rodriguez BJ, Simsek I, Simsek C, Lafuente MR, Ilchishina T, Camarero JG, Dominguez-Cajal M, Ntouli V, Dekhnich NN, Phull P, Nuñez O, Lerang F, Venerito M, Heluwaert F, Tonkic A, Caldas M, Puig I, Megraud F, O'Morain C, Gisbert JP; Hp-EuReg Investigators. Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). Am J Gastroenterol 2021;116:1220-9. [PMID: 33840725 DOI: 10.14309/ajg.0000000000001246] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
282 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M, Korean College of Helicobacter and Upper Gastrointesinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Med 2021;96:160-189. [DOI: 10.3904/kjm.2021.96.3.160] [Reference Citation Analysis]
283 Rodriguez N, Kennedy AG, Tompkins BJ, VanOpdorp J, Heffley J, Ganguly E. Quality improvement opportunities exist for Helicobacter pylori treatment and confirmatory testing. Clin Res Hepatol Gastroenterol 2021;45:101720. [PMID: 34087425 DOI: 10.1016/j.clinre.2021.101720] [Reference Citation Analysis]
284 Cho J, Prashar A, Jones NL, Moss SF. Helicobacter pylori Infection. Gastroenterol Clin North Am 2021;50:261-82. [PMID: 34024441 DOI: 10.1016/j.gtc.2021.02.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
285 Gingold-Belfer R, Niv Y, Levi Z, Boltin D. Rifabutin triple therapy for first-line and rescue treatment of Helicobacter pylori infection: A systematic review and meta-analysis. J Gastroenterol Hepatol 2021;36:1392-402. [PMID: 33037845 DOI: 10.1111/jgh.15294] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
286 Heffley JD, Zubarik R. A standardized protocol improves testing rates for Helicobacter Pylori among inpatients with peptic ulcer disease. Helicobacter 2021;26:e12800. [PMID: 33720493 DOI: 10.1111/hel.12800] [Reference Citation Analysis]
287 Nkuize M, Vanderpas J, Buset M, Gomez-Galdon M, Delforge M, Miendje-Deyi VY, Muls V, De Wit S. Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study. Microbiologyopen 2021;10:e1184. [PMID: 34180600 DOI: 10.1002/mbo3.1184] [Reference Citation Analysis]
288 Jeong YS, Kim MS, Lee N, Lee A, Chae YJ, Chung SJ, Lee KR. Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans. Pharmaceutics 2021;13:813. [PMID: 34072547 DOI: 10.3390/pharmaceutics13060813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Bhat S, Nunes D. Pharmacist-Managed Helicobacter pylori Treatment Service Within a Gastroenterology Clinic: Workflow and Real-World Experiences. Ann Pharmacother 2021;:10600280211021501. [PMID: 34049441 DOI: 10.1177/10600280211021501] [Reference Citation Analysis]
290 Lee JW, Kim SJ, Choi CW, Kim HJ, Kang DH, Kim HW, Park SB, Nam HS, Ryu DG. Seven-day triple therapy is sufficient to eradicate infection caused by Helicobacter pylori without 23S rRNA point mutation. Medicine (Baltimore) 2021;100:e26133. [PMID: 34032763 DOI: 10.1097/MD.0000000000026133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
291 Mugengana AK, Vita NA, Brown Gandt A, Moran K, Agyapong G, Sharma LK, Griffith EC, Liu J, Yang L, Gavrish E, Hevener KE, LaFleur MD, Lee RE. The Discovery and Development of Thienopyrimidines as Inhibitors of Helicobacter pylori That Act through Inhibition of the Respiratory Complex I. ACS Infect Dis 2021;7:1044-58. [PMID: 33471519 DOI: 10.1021/acsinfecdis.0c00300] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
292 Cui R, Song Z, Suo B, Tian X, Xue Y, Meng L, Niu Z, Jin Z, Zhang H, Zhou L. Correlation Analysis Among Genotype Resistance, Phenotype Resistance and Eradication Effect of Helicobacter pylori. Infect Drug Resist 2021;14:1747-56. [PMID: 34012273 DOI: 10.2147/IDR.S305996] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
293 Nelson A, Bi Y, Harris D. Helicobacter Pylori: a comprehensive review for primary care providers. Rom J Intern Med 2021;59:112-8. [PMID: 33565305 DOI: 10.2478/rjim-2020-0043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
294 Matos R, Amorim I, Magalhães A, Haesebrouck F, Gärtner F, Reis CA. Adhesion of Helicobacter Species to the Human Gastric Mucosa: A Deep Look Into Glycans Role. Front Mol Biosci 2021;8:656439. [PMID: 34026832 DOI: 10.3389/fmolb.2021.656439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
295 Hafeez M, Qureshi ZA, Khattak AL, Saeed F, Asghar A, Azam K, Khan MA. Helicobacter Pylori Eradication Therapy: Still a Challenge. Cureus 2021;13:e14872. [PMID: 34113506 DOI: 10.7759/cureus.14872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
296 Hackett RJ, Preston SL. H.pylori infection, part I: clinical burden and diagnosis. Trends Urology & Men Health 2021;12:13-19. [DOI: 10.1002/tre.801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Argueta EA, Alsamman MA, Moss SF, D'Agata EMC. Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology 2021;160:2181-2183.e1. [PMID: 33577874 DOI: 10.1053/j.gastro.2021.02.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
298 Migone De Amicis M, Rimondi A, Elli L, Motta I. Acquired Refractory Iron Deficiency Anemia. Mediterr J Hematol Infect Dis 2021;13:e2021028. [PMID: 34007416 DOI: 10.4084/MJHID.2021.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
299 Woo HJ, Yang JY, Lee P, Kim JB, Kim SH. Zerumbone Inhibits Helicobacter pylori Urease Activity. Molecules 2021;26:2663. [PMID: 34062878 DOI: 10.3390/molecules26092663] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
300 Ekin N, Ebik B, Bacaksiz F. Helikobakter Pylori Birinci Basamak Tedavisi Alan Hastalarda Üç Farklı Tedavi Rejiminin Etkinliğinin Değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi 2021. [DOI: 10.35440/hutfd.822754] [Reference Citation Analysis]
301 Marrero Rolon R, Cunningham SA, Mandrekar JN, Polo ET, Patel R. Clinical Evaluation of a Real-Time PCR Assay for Simultaneous Detection of Helicobacter pylori and Genotypic Markers of Clarithromycin Resistance Directly from Stool. J Clin Microbiol 2021;59:e03040-20. [PMID: 33536295 DOI: 10.1128/JCM.03040-20] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
302 Sanchez-Garrido J, Slater SL, Clements A, Shenoy AR, Frankel G. Vying for the control of inflammasomes: The cytosolic frontier of enteric bacterial pathogen-host interactions. Cell Microbiol 2020;22:e13184. [PMID: 32185892 DOI: 10.1111/cmi.13184] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
303 Kocsmár É, Buzás GM, Szirtes I, Kocsmár I, Kramer Z, Szijártó A, Fadgyas-Freyler P, Szénás K, Rugge M, Fassan M, Kiss A, Schaff Z, Röst G, Lotz G. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun 2021;12:2255. [PMID: 33859206 DOI: 10.1038/s41467-021-22557-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
304 Ozturk T, Sengul D, Sengul I. Helicobacter pylori and association between its positivity and anatomotopographic settlement in the stomach with the host age range. Ann Afr Med 2021;20:1-8. [PMID: 33727504 DOI: 10.4103/aam.aam_69_19] [Reference Citation Analysis]
305 Spósito L, Fortunato GC, de Camargo BAF, Ramos MADS, Souza MPC, Meneguin AB, Bauab TM, Chorilli M. Exploiting drug delivery systems for oral route in the peptic ulcer disease treatment. J Drug Target 2021;:1-19. [PMID: 33729081 DOI: 10.1080/1061186X.2021.1904249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Spiteri JA, Zahra G, Schembri J, Pisani A, Borg E, Spiteri N, Bianco EZ, Caruana P, Gauci J, Muscat M, Barbara C, Ellul P. Identification of antibiotic resistance patterns in Helicobacter pylori strains isolated from gastric biopsies using real-time PCR and genotypic analysis. Ann Gastroenterol 2021;34:501-9. [PMID: 34276188 DOI: 10.20524/aog.2021.0624] [Reference Citation Analysis]
307 Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology 2021;160:1831-41. [PMID: 33524402 DOI: 10.1053/j.gastro.2020.11.059] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 23.5] [Reference Citation Analysis]
308 Lacout C, Savey L, Bourguiba R, Giurgea I, Amselem S, Hoyeau N, Galland J, Amiot X, Grateau G, Ducharme-Bénard S, Georgin-Lavialle S. "Helicobacter pylori in familial mediterranean fever: A series of 120 patients from literature and from france". Helicobacter 2021;26:e12789. [PMID: 33586832 DOI: 10.1111/hel.12789] [Reference Citation Analysis]
309 Eto H, Suzuki S, Kusano C, Ikehara H, Ichijima R, Ito H, Kawabe K, Kawamura M, Yoda Y, Nakahara M, Gotoda T. Impact of body size on first-line Helicobacter pylori eradication success using vonoprazan and amoxicillin dual therapy. Helicobacter 2021;26:e12788. [PMID: 33580612 DOI: 10.1111/hel.12788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
310 Diseases of the Stomach. Non-Neoplastic Disorders of the Gastrointestinal Tract 2021. [DOI: 10.55418/9781933477930-03] [Reference Citation Analysis]
311 Pak K, Junga Z, Mertz A, Singla M. The Patterns and Associated Cost of Serologic Testing for Helicobacter pylori in the U.S. Military Health System. Mil Med 2020;185:e1417-9. [PMID: 32633752 DOI: 10.1093/milmed/usaa141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
312 Jia J, Zhang C, Liu Y, Huang Y, Bai Y, Hang X, Zeng L, Zhu D, Bi H. Armeniaspirol A: a novel anti-Helicobacter pylori agent. Microb Biotechnol 2021. [PMID: 33780131 DOI: 10.1111/1751-7915.13807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
313 Fitzgerald R, Smith SM. An Overview of Helicobacter pylori Infection. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 1-14. [DOI: 10.1007/978-1-0716-1302-3_1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
314 Brennan D, O’morain C, Mcnamara D, Smith SM. Molecular Detection of Antibiotic-Resistant Helicobacter pylori. In: Smith SM, editor. Helicobacter Pylori. New York: Springer US; 2021. pp. 29-36. [DOI: 10.1007/978-1-0716-1302-3_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
315 Hung KT, Yang SC, Wu CK, Wang HM, Yao CC, Liang CM, Tai WC, Wu KL, Kuo YH, Lee CH, Chuah SK. Eradication Rates for Esomeprazole and Lansoprazole-Based 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Anti-Helicobacter pylori Treatment in Real World Clinical Practice. Infect Drug Resist 2021;14:1239-46. [PMID: 33790594 DOI: 10.2147/IDR.S304711] [Reference Citation Analysis]
316 Su DJ, Chang MH, Yang JC, Ni YH, Hsu HY, Wu JF. Fourteen-day sequential therapy is superior to 7-day triple therapy as first-line regimen for Helicobacter pylori infected children. J Formos Med Assoc 2021:S0929-6646(21)00106-6. [PMID: 33745813 DOI: 10.1016/j.jfma.2021.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
317 Lala VG, Bobat B, Haagensen M, Kathan P, Mahomed A. Metronidazole-induced encephalopathy. SA J Radiol 2021;25:2016. [PMID: 33824746 DOI: 10.4102/sajr.v25i1.2016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
318 Jung HK, Kang SJ, Lee YC, Yang HJ, Park SY, Shin CM, Kim SE, Lim HC, Kim JH, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M;  Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168-195. [PMID: 33468712 DOI: 10.5009/gnl20288] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 12.0] [Reference Citation Analysis]
319 Kong S, Chen H, Huang K, Jin D, Zhang G, Ye F. Antibiotic susceptibility guided reuse of levofloxacin-based therapy in a penicillin-allergic patient for Helicobacter pylori infection: A case report. Medicine (Baltimore) 2021;100:e24915. [PMID: 33725850 DOI: 10.1097/MD.0000000000024915] [Reference Citation Analysis]
320 Kang SJ, Jung H, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:35-47. [DOI: 10.7704/kjhugr.2020.0056] [Reference Citation Analysis]
321 Spurnic AR, Bukumiric Z, Jevtovic D, Brmbolic B, Pekmezovic T, Salemovic D, Pesic Pavlovic I, Milosevic I, Ranin J, Korac M. Helicobacter pylori infection rates in dyspeptic Serbian HIV-infected patients compared to HIV-negative controls. PLoS One 2021;16:e0248041. [PMID: 33690620 DOI: 10.1371/journal.pone.0248041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
322 Yang H, Jung H, Kang SJ, Lee YC, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointesinal Research. Salvage Regimens after Failure of Previous Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:59-71. [DOI: 10.7704/kjhugr.2020.0053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
323 Kim SE, Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M, Korean College of Helicobacter and Upper Gastrointesinal Research. A 10- or 14-day Bismuth-containing Quadruple Therapy as a First-line Helicobacter pylori Eradication Therapy: A Systematic Review and Meta-analysis. Korean J Helicobacter Up Gastrointest Res 2021;21:48-58. [DOI: 10.7704/kjhugr.2020.0052] [Reference Citation Analysis]
324 Kim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol 2021;21:95. [PMID: 33653284 DOI: 10.1186/s12876-021-01680-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
325 Scarpignato C, Hunt RH. Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers. Curr Treat Options Gastro 2021;19:94-132. [DOI: 10.1007/s11938-020-00330-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
326 Piazuelo MB, Bravo LE, Mera RM, Camargo MC, Bravo JC, Delgado AG, Washington MK, Rosero A, Garcia LS, Realpe JL, Cifuentes SP, Morgan DR, Peek RM Jr, Correa P, Wilson KT. The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions. Gastroenterology 2021;160:1106-1117.e3. [PMID: 33220252 DOI: 10.1053/j.gastro.2020.11.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 12.5] [Reference Citation Analysis]
327 Watanabe J, Hamasaki M, Kotani K. The Effect of Helicobacter pylori Eradication on Lipid Levels: A Meta-Analysis. J Clin Med 2021;10:904. [PMID: 33668848 DOI: 10.3390/jcm10050904] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
328 Kang S, Kim Y, Ahn JY, Jung HY, Kim N, Na HK, Lee JH, Jung KW, Kim DH, Choi KD, Song HJ, Lee GH. Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for Helicobacter pylori Eradication in the Clinical Setting. Antibiotics (Basel) 2021;10:214. [PMID: 33669969 DOI: 10.3390/antibiotics10020214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
329 Liu W, Tian J, Hui W, Kong W, Feng Y, Si J, Gao F. A retrospective study assessing the acceleration effect of type I Helicobacter pylori infection on the progress of atrophic gastritis. Sci Rep 2021;11:4143. [PMID: 33603125 DOI: 10.1038/s41598-021-83647-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
330 Luo P, Huang Y, Hang X, Tong Q, Zeng L, Jia J, Zhang G, Bi H. Dihydrotanshinone I Is Effective against Drug-Resistant Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2021;65:e01921-20. [PMID: 33318002 DOI: 10.1128/AAC.01921-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
331 Andreev DN, Kucheryavyy YA, Maev IV. Efficacy of butyric acid inclusion in eradication regimens for <i>Helicobacter pylori </i>infection: a meta-analysis of controlled trials. Terapevticheskii arkhiv 2021;93:158-163. [DOI: 10.26442/00403660.2021.02.200608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
332 Huang LW, Li L. Siliankang combined with esomeprazole sodium for treatment of Helicobacter pylori-associated gastritis: Efficacy and influence on NF-κB signaling pathway. Shijie Huaren Xiaohua Zazhi 2021; 29(3): 131-137 [DOI: 10.11569/wcjd.v29.i3.131] [Reference Citation Analysis]
333 Oliveira SB. Helicobacter Pylori infection within a colonic interposition. Journal of Pediatric Surgery Case Reports 2021;65:101722. [DOI: 10.1016/j.epsc.2020.101722] [Reference Citation Analysis]
334 Hofreuter D, Behrendt J, Franz A, Meyer J, Jansen A, Bluemel B, Eisele B, Koken M, Glocker EO. Antimicrobial resistance of Helicobacter pylori in an eastern German region. Helicobacter 2021;26:e12765. [PMID: 33067911 DOI: 10.1111/hel.12765] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
335 Costable NJ, Greenwald DA. Upper Gastrointestinal Bleeding. Clin Geriatr Med 2021;37:155-72. [PMID: 33213769 DOI: 10.1016/j.cger.2020.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
336 Kumar S, Metz DC, Kaplan DE, Goldberg DS. Low Rates of Retesting for Eradication of Helicobacter pylori Infection After Treatment in the Veterans Health Administration. Clin Gastroenterol Hepatol 2021;19:305-313.e1. [PMID: 32272245 DOI: 10.1016/j.cgh.2020.03.059] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
337 Singh H, Chung H, Awan I, Mone A, Cooper R, Patel S, Grigoryan Z, Ishida Y, Papachristou C, Judge T, DeSipio J, Phadtare S. Designing strategies for eradication of Helicobacter pylori based on prevalence patterns of infection and antibiotic resistance in a low-income, medically underserved community in the United States. Helicobacter 2021;26:e12769. [PMID: 33167084 DOI: 10.1111/hel.12769] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
338 Sharara AI. Confirmatory Testing for Eradication of Helicobacter pylori: Challenges and Opportunities. Clin Gastroenterol Hepatol 2021;19:232-4. [PMID: 32492481 DOI: 10.1016/j.cgh.2020.05.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
339 Li J, Deng J, Wang Z, Li H, Wan C. Antibiotic Resistance of Helicobacter pylori Strains Isolated From Pediatric Patients in Southwest China. Front Microbiol 2020;11:621791. [PMID: 33574804 DOI: 10.3389/fmicb.2020.621791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
340 Villegas I, Rosillo MÁ, Alarcón-de-la-Lastra C, Vázquez-Román V, Llorente M, Sánchez S, Gil AG, Alcalde P, González E, Rosell E, Nieto C, Fernandez-Campos F. Amoxicillin and Clarithromycin Mucoadhesive Delivery System for Helicobacter pylori Infection in a Mouse Model: Characterization, Pharmacokinetics, and Efficacy. Pharmaceutics 2021;13:153. [PMID: 33498958 DOI: 10.3390/pharmaceutics13020153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
341 Zheng H, Xie Q, Zhan M, Jin C, Li Q. Cost‑effectiveness Analysis of Helicobacter pylori Eradication Therapy in First-Degree Relatives of Patients with Gastric Cancer. Patient Prefer Adherence 2021;15:77-85. [PMID: 33519193 DOI: 10.2147/PPA.S286860] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
342 Li B, Cheung KS, Wong IY, Leung WK, Law S. Nonaspirin nonsteroidal anti-inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory-wide study. Cancer 2021;127:1805-15. [PMID: 33471380 DOI: 10.1002/cncr.33412] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
343 Bakheit AH, Al-Kahtani HM, Albraiki S. Rabeprazole: A comprehensive profile. Profiles Drug Subst Excip Relat Methodol 2021;46:137-83. [PMID: 33461697 DOI: 10.1016/bs.podrm.2020.07.003] [Reference Citation Analysis]
344 Shafrir A, Shauly-Aharonov M, Katz LH, Paltiel O, Pickman Y, Ackerman Z. The Association between Serum Vitamin D Levels and Helicobacter pylori Presence and Eradication. Nutrients 2021;13:278. [PMID: 33478000 DOI: 10.3390/nu13010278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
345 Rohr M, Aljabban J, Rudeski-Rohr T, Lessans S, Nakkina SP, Hadley D, Zhu X, Altomare DA. Meta-Analysis Reveals the Prognostic Relevance of Nuclear and Membrane-Associated Bile Acid Receptors in Gastric Cancer. Clin Transl Gastroenterol 2021;12:e00295. [PMID: 33492921 DOI: 10.14309/ctg.0000000000000295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
346 Ghim JL, Chin MC, Jung J, Lee J, Kim S, Kim B, Song GS, Choi YK, Shin JG. Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. J Clin Pharmacol 2021;61:913-22. [PMID: 33341955 DOI: 10.1002/jcph.1805] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
347 Rojas García P, van der Pol S, van Asselt ADI, Postma M, Rodríguez-Ibeas R, Juárez-Castelló CA, González M, Antoñanzas F. Efficiency of Diagnostic Testing for Helicobacter pylori Infections-A Systematic Review. Antibiotics (Basel) 2021;10:55. [PMID: 33430005 DOI: 10.3390/antibiotics10010055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
348 Damanhuri NS, Kumolosasi E, Omar MS, Razak AFA, Mansor AH. The influence of P-glycoprotein expression in the standard treatment of Helicobacter pylori infection in Sprague Dawley rats. Daru 2021;29:13-22. [PMID: 33405191 DOI: 10.1007/s40199-020-00377-2] [Reference Citation Analysis]
349 Gong RJ, Xu CX, Li H, Liu XM. Polymerase chain reaction-based tests for detecting Helicobacter pylori clarithromycin resistance in stool samples: A meta-analysis. World J Clin Cases 2021; 9(1): 133-147 [PMID: 33511178 DOI: 10.12998/wjcc.v9.i1.133] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
350 Huanbutta K, Sriamornsak P, Kittanaphon T, Suwanpitak K, Klinkesorn N, Sangnim T. Development of a zero-order kinetics drug release floating tablet with anti–flip-up design fabricated by 3D-printing technique. J Pharm Investig 2021;51:213-22. [DOI: 10.1007/s40005-020-00507-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
351 Taşkın D, Yılmaz BN, Taşkın T, Omurtag GZ. The Influence of Different Extraction Methods/Solvents on Composition, Biological Activities and ADMET Predictions of Phenolics in Tribulus terrestris. Braz arch biol technol 2021;64. [DOI: 10.1590/1678-4324-2021210249] [Reference Citation Analysis]
352 Graham DY, El-Serag HB. European Registry on Helicobacter pylori management shows that gastroenterology has largely failed in its efforts to guide practitioners. Gut 2021;70:1-2. [PMID: 32958543 DOI: 10.1136/gutjnl-2020-322385] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
353 Wang Q, Li G. Bi( iii ) MOFs: syntheses, structures and applications. Inorg Chem Front 2021;8:572-89. [DOI: 10.1039/d0qi01055c] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
354 Watanabe T. Synthesis and Structure−Activity Relationship Study of Intervenolin, an Antitumor and Anti-Helicobacter pylori Quinolone Natural Product. HETEROCYCLES 2021;102:1894. [DOI: 10.3987/rev-21-957] [Reference Citation Analysis]
355 Piper MS, Hall KE. Gastroenterology. Geriatrics for Specialists 2021. [DOI: 10.1007/978-3-030-76271-1_21] [Reference Citation Analysis]
356 Gao T, Hou M, Zhang B, Pan X, Liu C, Sun C, Jia M, Lin S, Xiong K, Ma A. Effects of cranberry beverages on oxidative stress and gut microbiota in subjects with Helicobacter pylori infection: a randomized, double-blind, placebo-controlled trial. Food Funct 2021;12:6878-88. [PMID: 34126630 DOI: 10.1039/d1fo00467k] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
357 Wärme J, Sundqvist M, Mars K, Aladellie L, Pawelzik SC, Erlinge D, Jernberg T, James S, Hofmann R, Bäck M. Helicobacter pylori screening in clinical routine during hospitalization for acute myocardial infarction. Am Heart J 2021;231:105-9. [PMID: 33144087 DOI: 10.1016/j.ahj.2020.10.072] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
358 Carlson TJ, Gonzales-Luna AJ, Garey KW. Recent developments in antimicrobial therapy for gastrointestinal infections. Curr Opin Gastroenterol 2021;37:30-6. [PMID: 33229860 DOI: 10.1097/MOG.0000000000000696] [Reference Citation Analysis]
359 Mirković A, Savić N. Medical treatment and prevention of Helicobacter pylori infection. Sestrinska vizija 2021;5:10-13. [DOI: 10.5937/sestrviz2109010m] [Reference Citation Analysis]
360 Howden CW, Graham DY. Recent Developments Pertaining to H. pylori Infection. Am J Gastroenterol 2021;116:1-3. [PMID: 33378314 DOI: 10.14309/ajg.0000000000001031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
361 Rrapi E, Narayan S, Siskin G, Stain SC, Tadros M, Tafen M. Bipolar and Monopolar Cautery, Clips, Bands, Spray, Injections, Embolization, and Minimally Invasive Surgery. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-71468-0_10] [Reference Citation Analysis]
362 Pakala T. Specific Gastrointestinal Microbial Infections. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-72592-1_7] [Reference Citation Analysis]
363 Kay M, Bhesania N, Wyllie R. Esophagogastroduodenoscopy and Related Techniques. Pediatric Gastrointestinal and Liver Disease 2021. [DOI: 10.1016/b978-0-323-67293-1.00060-8] [Reference Citation Analysis]
364 Naut ER, Singh G. Non-Invasive Office Screening Methods. Clinical Gastroenterology 2021. [DOI: 10.1007/978-3-030-71468-0_2] [Reference Citation Analysis]
365 Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials. J Clin Gastroenterol 2021;55:856-64. [PMID: 33074949 DOI: 10.1097/MCG.0000000000001448] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
366 Bachman M, Lamps LW. Infections of the Gastrointestinal Tract. Practical Gastrointestinal Pathology 2021. [DOI: 10.1007/978-3-030-51268-2_10] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
367 Moreira Pinto S, Isenberg D. GI hepatic and nonhepatic diseases. Lahita's Systemic Lupus Erythematosus 2021. [DOI: 10.1016/b978-0-12-820583-9.00041-5] [Reference Citation Analysis]
368 Costable NJ, Greenwald DA. Upper Gastrointestinal Bleeding. Geriatric Gastroenterology 2021. [DOI: 10.1007/978-3-030-30192-7_47] [Reference Citation Analysis]
369 Mestrovic A, Perkovic N, Bozic J, Pavicic Ivelja M, Vukovic J, Kardum G, Puljiz Z, Tonkic A. Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection. PLoS One 2020;15:e0244500. [PMID: 33378403 DOI: 10.1371/journal.pone.0244500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
370 Gisbert JP. Rifabutin for the Treatment of Helicobacter Pylori Infection: A Review. Pathogens 2020;10:15. [PMID: 33379336 DOI: 10.3390/pathogens10010015] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
371 Liyen Cartelle A, Uy PP, Koehler TE, Yap JEL. Persistent Helicobacter pylori Infection: An Insight to the Limitations of Current Clinical Practice. Cureus 2020;12:e12309. [PMID: 33520508 DOI: 10.7759/cureus.12309] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
372 Domanovich-Asor T, Motro Y, Khalfin B, Craddock HA, Peretz A, Moran-Gilad J. Genomic Analysis of Antimicrobial Resistance Genotype-to-Phenotype Agreement in Helicobacter pylori. Microorganisms 2020;9:E2. [PMID: 33374988 DOI: 10.3390/microorganisms9010002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
373 Yu X, Feng D, Wang G, Dong Z, Zhou Q, Zhang Y. Correlation Analysis of Helicobacter pylori Infection and Digestive Tract Symptoms in Children and Related Factors of Infection. Iran J Public Health 2020;49:1912-20. [PMID: 33346225 DOI: 10.18502/ijph.v49i10.4694] [Reference Citation Analysis]
374 Kolesnikova IY, Ivakhnenko IV, Ponomareva AV, Krayushkin SI. Modern aspects of eradication therapy. Spravočnik vrača obŝej praktiki (Journal of Family Medicine) 2020. [DOI: 10.33920/med-10-2012-05] [Reference Citation Analysis]
375 Andreev DN, Maev IV. [Rebamipide: evidence base for use in gastroenterology]. Ter Arkh 2020;92:97-104. [PMID: 33720581 DOI: 10.26442/00403660.2020.12.200455] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
376 Nelson ND, Tondon R, Fortuna D, Westerhoff M, Swanson PE, Furth E. Helicobacter pylori Antigen But Not the Organism Is Occasionally Present Within Germinal Centers: Implications for Patient Management and Biology. Am J Surg Pathol 2020;44:1528-34. [PMID: 32657781 DOI: 10.1097/PAS.0000000000001542] [Reference Citation Analysis]
377 Jung H, Kang SJ, Lee YC, Yang H, Park S, Shin CM, Kim SE, Lim HC, Kim J, Nam SY, Shin WG, Park JM, Choi IJ, Kim JG, Choi M; Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-based Guidelines for the Treatment of Helicobacter pylori Infection in Korea: 2020 Revised Edition. Korean J Helicobacter Up Gastrointest Res 2020;20:261-87. [DOI: 10.7704/kjhugr.2020.0045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
378 Park JK. Can Hybrid Therapy Be an Alternative to the First-line Regimen for Helicobacter pylori Infection? Korean J Helicobacter Up Gastrointest Res 2020;20:257-260. [DOI: 10.7704/kjhugr.2020.0051] [Reference Citation Analysis]
379 Liang CM, Tai WC, Hsu PI, Wu DC, Kuo CH, Tsay FW, Lee CL, Chen KY, Chuah SK. Trend of changes in antibiotic resistance in Helicobacter pylori from 2013 to 2019: a multicentre report from Taiwan. Therap Adv Gastroenterol 2020;13:1756284820976990. [PMID: 33354229 DOI: 10.1177/1756284820976990] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
380 Du N, Scherer C, Porto A. Assessment of Community Pediatric Providers’ Approach to Children With Helicobacter pylori. JPGN Reports 2021;2:e033. [DOI: 10.1097/pg9.0000000000000033] [Reference Citation Analysis]
381 Ekeuku SO, Thong BKS, Quraisiah A, Annuar F, Hanafiah A, Nur Azlina MF, Chin KY. The Skeletal Effects of Short-Term Triple Therapy in a Rat Model of Gastric Ulcer Induced by Helicobacter pylori Infection. Drug Des Devel Ther 2020;14:5359-66. [PMID: 33324037 DOI: 10.2147/DDDT.S287239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
382 Chang S, Shih Y, Lee W, Kuo M, Tsay F, Kuo L, Huang W, Shie C. 14‐day reverse hybrid therapy vs 7‐day concomitant therapy in the first‐line treatment of Helicobacter pylori infection. Adv in Digestive Medicine 2022;9:38-43. [DOI: 10.1002/aid2.13243] [Reference Citation Analysis]
383 Abrignani MG, Gatta L, Gabrielli D, Milazzo G, De Francesco V, De Luca L, Francese M, Imazio M, Riccio E, Rossini R, Scotto di Uccio F, Soncini M, Zullo A, Colivicchi F, Di Lenarda A, Gulizia MM, Monica F. Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). Eur J Intern Med 2021;85:1-13. [PMID: 33279389 DOI: 10.1016/j.ejim.2020.11.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
384 Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut 2020;69:2093-112. [PMID: 33004546 DOI: 10.1136/gutjnl-2020-322368] [Cited by in Crossref: 111] [Cited by in F6Publishing: 96] [Article Influence: 37.0] [Reference Citation Analysis]
385 Wilhelm S, Kale-pradhan P. Chapter 20: Prebiotics and Probiotics. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 20th Edition 2020. [DOI: 10.21019/9781582123172.ch20] [Reference Citation Analysis]
386 Zhou JJ, Shi X, Zheng SP, Tang D, Cai T, Yao Y, Wang F. Efficacy of bismuth-based quadruple therapy for eradication of Helicobacter pylori infection based on previous antibiotic exposure: A large-scale prospective, single-center clinical trial in China. Helicobacter 2020;25:e12755. [PMID: 32914914 DOI: 10.1111/hel.12755] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
387 Luo L, Ji Y, Yu L, Huang Y, Liang X, Graham DY, Lu H. 14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment. Dig Dis Sci 2020;65:3639-46. [PMID: 32020360 DOI: 10.1007/s10620-020-06115-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
388 Janairo JIB. A principal component regression model for predicting phytochemical binding to the H. pylori CagA protein. Netw Model Anal Health Inform Bioinforma 2020;9:45. [DOI: 10.1007/s13721-020-00252-9] [Reference Citation Analysis]
389 Chisty A. Update on Indigestion. Med Clin North Am 2021;105:19-30. [PMID: 33246519 DOI: 10.1016/j.mcna.2020.08.012] [Reference Citation Analysis]
390 Hathroubi S, Hu S, Ottemann KM. Genetic requirements and transcriptomics of Helicobacter pylori biofilm formation on abiotic and biotic surfaces. NPJ Biofilms Microbiomes 2020;6:56. [PMID: 33247117 DOI: 10.1038/s41522-020-00167-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
391 Guo B, Cao NW, Zhou HY, Chu XJ, Li BZ. Efficacy and safety of bismuth-containing quadruple treatment and concomitant treatment for first-line Helicobacter pylori eradication: A systematic review and meta-analysis. Microb Pathog 2021;152:104661. [PMID: 33249167 DOI: 10.1016/j.micpath.2020.104661] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
392 Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
393 Joo MK. Helicobacter pylori Eradication in Drug-related Peptic Ulcer. Korean J Gastroenterol 2020;76:227-231. [DOI: 10.4166/kjg.2020.141] [Reference Citation Analysis]
394 Trenque T. Bismuth and pharmacovigilance. Therapie 2021;76:383-4. [PMID: 33218671 DOI: 10.1016/j.therap.2020.11.001] [Reference Citation Analysis]
395 Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother 2021;22:729-41. [PMID: 33131337 DOI: 10.1080/14656566.2020.1845649] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
396 Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? Therap Adv Gastroenterol. 2020;13:1756284820968736. [PMID: 33240392 DOI: 10.1177/1756284820968736] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
397 Kanno T, Moayyedi P. Who Needs Gastroprotection in 2020? Curr Treat Options Gastroenterol 2020;:1-17. [PMID: 33199955 DOI: 10.1007/s11938-020-00316-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
398 Kim YI, Kim YA, Lee JW, Kim HJ, Kim SH, Kim SG, Kim JI, Kim JJ, Choi IJ. Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension. Gut Liver. 2020;14:47-56. [PMID: 30974928 DOI: 10.5009/gnl18510] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
399 Gisbert JP. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020;25:E5084. [PMID: 33147814 DOI: 10.3390/molecules25215084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
400 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Antonelli G, Cavallo R, Borghi C, Vaira D. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection. European Journal of Internal Medicine 2020;81:50-3. [DOI: 10.1016/j.ejim.2020.06.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
401 Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. The Lancet 2020;396:1689-702. [DOI: 10.1016/s0140-6736(20)30469-4] [Cited by in Crossref: 106] [Cited by in F6Publishing: 118] [Article Influence: 35.3] [Reference Citation Analysis]
402 Huang T, Yang S, Tai W, Liang C, Kuo C, Yao C, Wu C, Kuo Y, Chou Y, Lee C, Wu K, Chuah S. The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance. Biomedical Journal 2020. [DOI: 10.1016/j.bj.2020.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
403 Isaza-gómez E, Ángel-gonzález MS, Ocampo-muñoz M, Díaz-quintero CA, Molina-céspedes IC, Velásquez-martínez MA, Posada-moreno P, Salazar-ochoa S. Controversias en cirugía: Erradicación del Helicobacter pylori ¿Terapia a todos o según indicaciones usuales? Rev Colomb Cir 2020;35:665-674. [DOI: 10.30944/20117582.563] [Reference Citation Analysis]
404 Açar S. Helikobakter Pylori Eradikasyonunda Modifiye Hibrit Tedavi Etkinliği. Zeynep Kamil Tıp Bülteni 2020. [DOI: 10.16948/zktipb.773921] [Reference Citation Analysis]
405 Roszczenko-Jasińska P, Wojtyś MI, Jagusztyn-Krynicka EK. Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol 2020;104:9891-905. [PMID: 33052519 DOI: 10.1007/s00253-020-10945-w] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 9.0] [Reference Citation Analysis]
406 Park CH, Yang DH, Kim JW, Kim JH, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical practice guideline for endoscopic resection of early gastrointestinal cancer. Intest Res 2021;19:127-57. [PMID: 33045799 DOI: 10.5217/ir.2020.00020] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
407 Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel) 2020;9:E685. [PMID: 33050205 DOI: 10.3390/antibiotics9100685] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
408 Lee SW, Moon SJ, Kim SH, Jung SH, Song KH, Kim SM, Sung JK, Lee DS. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori. Medicine (Baltimore) 2020;99:e22137. [PMID: 32957336 DOI: 10.1097/MD.0000000000022137] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
409 Graham DY. Transitioning of Helicobacter pylori Therapy from Trial and Error to Antimicrobial Stewardship. Antibiotics (Basel) 2020;9:E671. [PMID: 33023041 DOI: 10.3390/antibiotics9100671] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
410 Mohan BP, Khan SR, Kassab LL, Ponnada S, Mohy-Ud-Din N, Chandan S, Dulai PS, Kochhar GS. Convolutional neural networks in the computer-aided diagnosis of Helicobacter pylori infection and non-causal comparison to physician endoscopists: a systematic review with meta-analysis.Ann Gastroenterol. 2021;34:20-25. [PMID: 33414617 DOI: 10.20524/aog.2020.0542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
411 Hsu PI, Tsay FW, Kao JY, Peng NJ, Tsai KW, Tsai TJ, Kuo CH, Kao SS, Wang HM, Chen YH, Shie CB, Wu DC; Taiwan Acid-related Disease & Microbiota (TARD-M) Consortium. Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2020;35:1731-7. [PMID: 32167605 DOI: 10.1111/jgh.15034] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
412 Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, Zhang X, Cheng H. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: A retrospective, real-life study. Helicobacter 2020;25:e12717. [PMID: 32548932 DOI: 10.1111/hel.12717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
413 Hirata Y, Yamada A, Niikura R, Shichijo S, Hayakawa Y, Koike K. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study. Helicobacter 2020;25:e12719. [PMID: 32602161 DOI: 10.1111/hel.12719] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
414 Farhoud NS, Ibrahim OM, Ezzat SE. Efficacy and Cost-effectiveness Comparison of 10-Day, 14-Day Sequential Versus 14-Day Triple Therapies for Treating Helicobacter pylori Infection in Egyptian Patients. J Clin Gastroenterol 2020;54:806-12. [PMID: 31904681 DOI: 10.1097/MCG.0000000000001278] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
415 Hussein NR, Mirkhan SA, Ramadhan AA, Issa RS, Naqid IA, Yassin B, Hasso SS, Salih RS, Mahmood SA. Levofloxacin-Based Regimen Versus Bismuth Quadruple Regimen for Helicobacter pylori Eradication in Kurdistan Region, Iraq. Avicenna J Clin Microbiol Infect 2020;7:81-84. [DOI: 10.34172/ajcmi.2020.18] [Reference Citation Analysis]
416 Miftahussurur M, Pratama Putra B, Yamaoka Y. The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals (Basel) 2020;13:E276. [PMID: 32998241 DOI: 10.3390/ph13100276] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
417 Park JY, Shin TS, Kim JH, Yoon HJ, Kim BJ, Kim JG. The Prevalence of Multidrug Resistance of Helicobacter pylori and Its Impact on Eradication in Korea from 2017 to 2019: A Single-Center Study. Antibiotics (Basel) 2020;9:E646. [PMID: 32992624 DOI: 10.3390/antibiotics9100646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
418 Bang CS, Lee JJ, Baik GH. Artificial Intelligence for the Prediction of Helicobacter Pylori Infection in Endoscopic Images: Systematic Review and Meta-Analysis Of Diagnostic Test Accuracy. J Med Internet Res. 2020;22:e21983. [PMID: 32936088 DOI: 10.2196/21983] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 13.0] [Reference Citation Analysis]
419 Tang X, Chen X, Shen Y, Yang T, Hu R, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Primary antibiotic resistance of Helicobacter pylori among a Chinese Tibetan population. Future Microbiol 2020;15:1353-61. [PMID: 32900223 DOI: 10.2217/fmb-2020-0206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
420 Arispe Angulo KR, Farooq A, Samra H, Weldemichael W, Anderson J, Jorns JM. Data-Driven Development of an Institutional "Gross-Only" Policy for the Examination of Select Surgical Pathology Specimens. Am J Clin Pathol 2020;154:486-93. [PMID: 32561904 DOI: 10.1093/ajcp/aqaa065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
421 He M, Zheng Y, Ma A, Zhang C, Yu Y, Wang H, Chen Y, Xiang M, Tao K, Shen J. Helicobacter pylori is associated with weakened pulmonary function and reduced incidence of allergic conditions in patients with chronic cough. Exp Ther Med 2020;20:47. [PMID: 32952638 DOI: 10.3892/etm.2020.9176] [Reference Citation Analysis]
422 Maev IV, Andreev DN, Govorun VM, Ilina EN, Kucheryavyy YA, Oganesian TS, Melnikova EV, Zayratyants OV, Parfenova TV, Dzhedzheia LV, Kirillova NV, Maevskaya EA, Fomenko AK, Lobanova EG, Zaborovskii AV, Kriukov KA. [Antibiotic resistance of Helicobacter pylori in the European part of the Russian Federation: first results]. Ter Arkh 2020;92:24-8. [PMID: 33346458 DOI: 10.26442/00403660.2020.08.000761] [Reference Citation Analysis]
423 Abdulkhakov SR, Bordin DS, Abdulkhakov RA, Safina DD, Gizdatullina AR, Gimadieva LZ, Safina GM, Ziyatdinov AI, Maturina AM, Nyssen OP, Megraud F, O'Morain C, Perez-Gisbert J. [European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan]. Ter Arkh 2020;92:52-9. [PMID: 33346462 DOI: 10.26442/00403660.2020.08.000758] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
424 Zhao Y, Ren M, Wang X, Lu G, Lu X, Zhang D, He S. Telephone-Based Reeducation of Drug Administration for Helicobacterpylori Eradication: A Multicenter Randomized Controlled Study. Gastroenterol Res Pract 2020;2020:8972473. [PMID: 32802048 DOI: 10.1155/2020/8972473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
425 Zhang L, Liu J, Meng F, Guan Y, Wang Y, Zhu S, Liu Y, Xie Q, Yu J, Zhang S. Pharmacokinetics of Bismuth following Oral Administration of Wei Bi Mei in Healthy Chinese Volunteers. Evid Based Complement Alternat Med 2020;2020:2679034. [PMID: 32855646 DOI: 10.1155/2020/2679034] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Crankshaw S, Butt J, Gierisch JM, Barrett NJ, Mervin-Blake S, Oeffinger K, Patierno S, Worthy V, Godbee R, Epplein M. The Durham Initiative for Stomach Health (DISH): a pilot community-based Helicobacter pylori education and screening study. BMC Gastroenterol 2020;20:261. [PMID: 32762641 DOI: 10.1186/s12876-020-01405-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
427 Taskin T, Dogan M, Yilmaz BN, Senkardes I. Phytochemical screening and evaluation of antioxidant, enzyme inhibition, anti-proliferative and calcium oxalate anti-crystallization activities of Micromeria fruticosa spp. brachycalyx and Rhus coriaria. Biocatalysis and Agricultural Biotechnology 2020;27:101670. [DOI: 10.1016/j.bcab.2020.101670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
428 Ye Q, Shao X, Shen R, Chen D, Shen J. Changes in the human gut microbiota composition caused by Helicobacter pylori eradication therapy: A systematic review and meta-analysis. Helicobacter 2020;25:e12713. [PMID: 32515529 DOI: 10.1111/hel.12713] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
429 Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, Lu H. PPI-amoxicillin dual therapy for Helicobacter pylori infection: An update based on a systematic review and meta-analysis. Helicobacter 2020;25:e12692. [PMID: 32314468 DOI: 10.1111/hel.12692] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
430 Wu Y, Su T, Zhou X, Lu N, Li Z, Du Y. Awareness and attitudes regarding Helicobacter pylori infection in Chinese physicians and public population: A national cross-sectional survey. Helicobacter 2020;25:e12705. [PMID: 32476197 DOI: 10.1111/hel.12705] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
431 Romano M, Gravina AG, Nardone G, Federico A, Dallio M, Martorano M, Mucherino C, Romiti A, Avallone L, Granata L, Priadko K, Compare D, Tuccillo C, Romito MR, Sgambato D, Miranda A, Romano L, Loguercio C, Bazzoli F, Zagari RM. Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. Helicobacter 2020;25:e12694. [PMID: 32314519 DOI: 10.1111/hel.12694] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
432 Zhu YJ, Zhang Y, Wang TY, Zhao JT, Zhao Z, Zhu JR, Lan CH. High dose PPI-amoxicillin dual therapy for the treatment of Helicobacter pylori infection: a systematic review with meta-analysis. Therap Adv Gastroenterol 2020;13:1756284820937115. [PMID: 33110448 DOI: 10.1177/1756284820937115] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
433 Olmedo L, Azagra R, Aguyé A, Pascual M, Calvet X, Gené E. High Effectiveness of a 14-Day Concomitant Therapy for Helicobacter pylori Treatment in Primary Care. An Observational Multicenter Study. J Clin Med 2020;9:E2410. [PMID: 32731455 DOI: 10.3390/jcm9082410] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
434 Kim YS, Nam Y, Song J, Kim H. Gastroprotective and Healing Effects of Polygonum cuspidatum Root on Experimentally Induced Gastric Ulcers in Rats. Nutrients 2020;12:E2241. [PMID: 32727104 DOI: 10.3390/nu12082241] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
435 Chen Z, Chen H, Yu L, Xin H, Kong J, Bai Y, Zeng W, Zhang J, Wu Q, Fan H. Bioinformatic identification of key pathways, hub genes, and microbiota for therapeutic intervention in Helicobacter pylori infection. J Cell Physiol 2021;236:1158-83. [PMID: 32710499 DOI: 10.1002/jcp.29925] [Reference Citation Analysis]
436 Kim SY, Chung JW. Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance. Antibiotics (Basel) 2020;9:E436. [PMID: 32717826 DOI: 10.3390/antibiotics9080436] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
437 Zagari RM, Frazzoni L, Marasco G, Fuccio L, Bazzoli F. Treatment of Helicobacter pylori infection: a clinical practice update. Minerva Med 2021;112:281-7. [PMID: 32700868 DOI: 10.23736/S0026-4806.20.06810-X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
438 Gou X, Jia J, Xue Y, Ding W, Dong Z, Tian D, Chen M, Bi H, Hong K, Tang J. New pyrones and their analogs from the marine mangrove-derived Aspergillus sp. DM94 with antibacterial activity against Helicobacter pylori. Appl Microbiol Biotechnol 2020;104:7971-8. [DOI: 10.1007/s00253-020-10792-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
439 Ionova Y, Ashenhurst J, Zhan J, Nhan H, Kosinski C, Tamraz B, Chubb A. CYP2C19 Allele Frequencies in Over 2.2 Million Direct-to-Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System. Clin Transl Sci 2020;13:1298-306. [PMID: 32506666 DOI: 10.1111/cts.12830] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
440 Maurya AP, Rajkumari J, Bhattacharjee A, Pandey P. Development, spread and persistence of antibiotic resistance genes (ARGs) in the soil microbiomes through co-selection. Rev Environ Health 2020;35:371-8. [PMID: 32681784 DOI: 10.1515/reveh-2020-0035] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
441 Saleem N, Howden CW. Update on the Management of Helicobacter pylori Infection. Curr Treat Options Gastroenterol 2020;:1-12. [PMID: 32837180 DOI: 10.1007/s11938-020-00300-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
442 Azzaya D, Gantuya B, Oyuntsetseg K, Davaadorj D, Matsumoto T, Akada J, Yamaoka Y. High Antibiotic Resistance of Helicobacter pylori and Its Associated Novel Gene Mutations among the Mongolian Population. Microorganisms 2020;8:E1062. [PMID: 32708761 DOI: 10.3390/microorganisms8071062] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
443 Fiori-Duarte AT, Rodrigues RP, Kitagawa RR, Kawano DF. Insights into the Design of Inhibitors of the Urease Enzyme - A Major Target for the Treatment of Helicobacter pylori Infections. Curr Med Chem 2020;27:3967-82. [PMID: 30827224 DOI: 10.2174/0929867326666190301143549] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
444 Kuo CJ, Lin CY, Le PH, Chang PY, Lai CH, Lin WR, Chang ML, Hsu JT, Cheng HT, Tseng CN, Lin CJ, Su MY, Hsieh SY, Chiu CT. Rescue therapy with rifabutin regimen for refractory Helicobacter pylori infection with dual drug-resistant strains. BMC Gastroenterol 2020;20:218. [PMID: 32650737 DOI: 10.1186/s12876-020-01370-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
445 Li Y, Lv T, He C, Wang H, Cram DS, Zhou L, Zhang J, Jiang W. Evaluation of multiplex ARMS-PCR for detection of Helicobacter pylori mutations conferring resistance to clarithromycin and levofloxacin. Gut Pathog 2020;12:35. [PMID: 32670416 DOI: 10.1186/s13099-020-00373-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
446 Bosch DE, Krumm N, Wener MH, Yeh MM, Truong CD, Reddi DM, Liu Y, Swanson PE, Schmidt RA, Bryan A. Serology Is More Sensitive Than Urea Breath Test or Stool Antigen for the Initial Diagnosis of Helicobacter pylori Gastritis When Compared With Histopathology. Am J Clin Pathol 2020;154:255-65. [PMID: 32445464 DOI: 10.1093/ajcp/aqaa043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
447 Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2020;7:CD005583. [PMID: 32628791 DOI: 10.1002/14651858.CD005583.pub3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
448 Guevara B, Cogdill AG. Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Dig Dis Sci 2020;65:1917-31. [PMID: 32170476 DOI: 10.1007/s10620-020-06193-7] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 14.7] [Reference Citation Analysis]
449 Liou JM, Lee YC, Wu MS. Treatment of Helicobacter pylori infection and its long-term impacts on gut microbiota. J Gastroenterol Hepatol 2020;35:1107-16. [PMID: 31984532 DOI: 10.1111/jgh.14992] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
450 Saltzman JR. The challenge of nonvariceal upper GI bleeding management in patients with acute coronary syndrome receiving dual-antiplatelet therapy. Gastrointest Endosc 2020;92:75-7. [PMID: 32586567 DOI: 10.1016/j.gie.2020.03.012] [Reference Citation Analysis]
451 Apostolopoulos P, Ekmektzoglou K, Georgopoulos S, Chounta E, Theofanopoulou A, Kalantzis C, Vlachou E, Tsibouris P, Alexandrakis G. 10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country. J Clin Gastroenterol 2020;54:522-7. [PMID: 32028286 DOI: 10.1097/MCG.0000000000001328] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
452 Etçioğlu E, Aydin A. Birinci Basamakta Dispepsi Şikayeti Olan Erişkin Hastaya Klinik Yaklaşım. Sakarya Medical Journal 2020. [DOI: 10.31832/smj.747308] [Reference Citation Analysis]
453 Bang CS, Lee JJ, Baik GH. Artificial Intelligence for the Prediction of Helicobacter Pylori Infection in Endoscopic Images: Systematic Review and Meta-Analysis Of Diagnostic Test Accuracy (Preprint).. [DOI: 10.2196/preprints.21983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
454 Yang H. Helicobacter pylori Eradication Therapy to Prevent Gastric Cancer in First-degree Relatives of Gastric Cancer Patient. Korean J Gastroenterol 2020;75:366-368. [DOI: 10.4166/kjg.2020.75.6.366] [Reference Citation Analysis]
455 Matos R, De Witte C, Smet A, Berlamont H, De Bruyckere S, Amorim I, Gärtner F, Haesebrouck F. Antimicrobial Susceptibility Pattern of Helicobacter heilmannii and Helicobacter ailurogastricus Isolates. Microorganisms 2020;8:E957. [PMID: 32630563 DOI: 10.3390/microorganisms8060957] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
456 Hathroubi S, Zerebinski J, Clarke A, Ottemann KM. Helicobacter pylori Biofilm Confers Antibiotic Tolerance in Part via A Protein-Dependent Mechanism. Antibiotics (Basel) 2020;9:E355. [PMID: 32599828 DOI: 10.3390/antibiotics9060355] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
457 Jee SR. Could Helicobacter pylori Treatment Reduce the Risk of Gastric Cancer in Individuals with a Family History of the Disease? Korean J Helicobacter Up Gastrointest Res 2020;20:169-171. [DOI: 10.7704/kjhugr.2020.0016] [Reference Citation Analysis]
458 Park CH, Yang D, Kim JW, Kim J, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak M, Kim B, Lee HJ, Lee HS, Choi M, Park D, Lee JY, Byeon J, Park CG, Cho JY, Lee ST, Chun HJ. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer. Korean J Helicobacter Up Gastrointest Res 2020;20:117-45. [DOI: 10.7704/kjhugr.2020.0023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
459 Batac FI, Miller MA, Moriarty ME, Shen Z, Fox JG, Ottemann KM. Helicobacter spp. in Necropsied Southern Sea Otters (Enhydra lutris nereis) Is Associated With Gastric Ulcers and Sensitive to Multiple Antibiotics. Front Mar Sci 2020;7:413. [DOI: 10.3389/fmars.2020.00413] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
460 Yoon K, Kim N. Significance of Helicobacter pylori Eradication on Atrophic Gastritis and Intestinal Metaplasia. Korean J Helicobacter Up Gastrointest Res 2020;20:107-16. [DOI: 10.7704/kjhugr.2020.0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
461 Liou JM, Chen CC, Chang CM, Fang YJ, Bair MJ, Chen PY, Chang CY, Hsu YC, Chen MJ, Lee JY, Yang TH, Luo JC, Chen CY, Hsu WF, Chen YN, Wu JY, Lin JT, Lu TP, Chuang EY, El-Omar EM, Wu MS;  Taiwan Gastrointestinal Disease and Helicobacter Consortium. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial. Lancet Infect Dis. 2019;19:1109-1120. [PMID: 31559966 DOI: 10.1016/s1473-3099(19)30272-5] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 27.3] [Reference Citation Analysis]
462 Rattanasuwan T, Khoury AP, Ebied AM. Proton Pump Inhibitors: for What and for How Long. SN Compr Clin Med 2020;2:719-726. [DOI: 10.1007/s42399-020-00268-2] [Reference Citation Analysis]
463 Suzuki S, Gotoda T, Kusano C, Ikehara H, Ichijima R, Ohyauchi M, Ito H, Kawamura M, Ogata Y, Ohtaka M, Nakahara M, Kawabe K. Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan. Gut 2020;69:1019-26. [PMID: 31915235 DOI: 10.1136/gutjnl-2019-319954] [Cited by in Crossref: 75] [Cited by in F6Publishing: 65] [Article Influence: 25.0] [Reference Citation Analysis]
464 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología 2020;43:301-9. [DOI: 10.1016/j.gastrohep.2019.12.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
465 Yoon K, Kim N, Lee JW, Yoon H, Shin CM, Park YS, Lee DH. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea. Helicobacter 2020;25:e12685. [PMID: 32141173 DOI: 10.1111/hel.12685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
466 Alcedo J, Gracia M, García-cámara P, Palacín C, Gallego S, Jimeno-ayllon C, Frago S, Aured I, Luzón L. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy. Gastroenterología y Hepatología (English Edition) 2020;43:301-309. [DOI: 10.1016/j.gastre.2019.12.002] [Reference Citation Analysis]
467 Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylori to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist 2020;13:1567-73. [PMID: 32547126 DOI: 10.2147/IDR.S250200] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
468 Liang CM, Hsu CH, Chung CH, Chen CY, Wang LY, Hsu SD, Chang PK, Hong ZJ, Chien WC, Hu JM. Risk for Irritable Bowel Syndrome in Patients with Helicobacter Pylori Infection: A Nationwide Population-Based Study Cohort Study in Taiwan. Int J Environ Res Public Health 2020;17:E3737. [PMID: 32466223 DOI: 10.3390/ijerph17103737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
469 Dicheva DT, Karaulov SA, Andreev DN, Berezutskaya OE, Golovkina NL. Efficacy of <i>Helicobacter pylori</i> eradication therapy of infection with omeprazole and rabeprazole in overweight and obese patients. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-4-100-105] [Reference Citation Analysis]
470 Andreev DN, Maev IV, Samsonov AA. The importance of probiotics in optimizing the efficacy and safety of <i>Helicobacter pylori</i> infection eradication therapy. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-5-9-16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
471 Baccani I, Faraoni P, Marini M, Gnerucci A, Orsini B, Pecile P, Romano G, Fusi F, Rossolini GM, Antonelli A. Synergistic effect of photodynamic therapy at 400 nm and doxycycline against Helicobacter pylori. Future Microbiol 2019;14:1199-205. [PMID: 31625444 DOI: 10.2217/fmb-2019-0129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
472 Nakashima H, Kawahira H, Kawachi H, Sakaki N. Endoscopic three-categorical diagnosis of Helicobacter pylori infection using linked color imaging and deep learning: a single-center prospective study (with video). Gastric Cancer. 2020;23:1033-1040. [PMID: 32382973 DOI: 10.1007/s10120-020-01077-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
473 Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection. Gut Microbes 2020;11:1314-23. [PMID: 32362221 DOI: 10.1080/19490976.2020.1754118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
474 Choi Y, Kim N, Yun CY, Choi YJ, Yoon H, Shin CM, Park YS, Ahn SH, Joong Park D, Lee HS, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH, Lee DH, Kim HH. Effect of Helicobacter pylori eradication after subtotal gastrectomy on the survival rate of patients with gastric cancer: follow-up for up to 15 years. Gastric Cancer 2020;23:1051-63. [PMID: 32361784 DOI: 10.1007/s10120-020-01076-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
475 Kumar S, Metz DC, Kaplan DE, Goldberg DS. Treatment of Helicobacter pylori Is Not Associated With Future Clostridium difficile Infection. Am J Gastroenterol 2020;115:716-22. [PMID: 32356953 DOI: 10.14309/ajg.0000000000000626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
476 Zhang Y, Zhu YJ, Zhao Z, Zhao JT, Wang TY, Yang J, Chen DF, Lan CH. Efficacy of modified esomeprazole-amoxicillin dual therapies for Helicobacter pylori infection: an open-label, randomized trial. Eur J Gastroenterol Hepatol 2020;32:563-8. [PMID: 31851093 DOI: 10.1097/MEG.0000000000001646] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
477 Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol 2020; 26(15): 1733-1744 [PMID: 32351290 DOI: 10.3748/wjg.v26.i15.1733] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
478 Di J, Zhang J, Cao L, Huang TT, Zhang JX, Mi YN, Xiao X, Yan PP, Wu ML, Yao T, Liu DZ, Liu J, Cao YX. Hydrogen Peroxide-Mediated Oxygen Enrichment Eradicates Helicobacter pylori In Vitro and In Vivo. Antimicrob Agents Chemother 2020;64:e02192-19. [PMID: 32071054 DOI: 10.1128/AAC.02192-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
479 Alsohaibani F, Alquaiz M, Alkahtani K, Alashgar H, Peedikayil M, AlFadda A, Almadi M. Efficacy of a bismuth-based quadruple therapy regimen for Helicobacter pylori eradication in Saudi Arabia. Saudi J Gastroenterol 2020;26:84-8. [PMID: 32295933 DOI: 10.4103/sjg.SJG_626_19] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
480 Negrini R, Villanacci V, Poiesi C, Savio A. Anti-Glycan Autoantibodies Induced by Helicobacter pylori as a Potential Risk Factor for Myocardial Infarction. Front Immunol 2020;11:597. [PMID: 32322255 DOI: 10.3389/fimmu.2020.00597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
481 Myint NPST, Zaw TT, Sain K, Waiyan S, Danta M, Cooper D, Aung NM, Kyi MM, Hanson J. Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability. J Gastroenterol Hepatol 2020;35:617-23. [PMID: 31758571 DOI: 10.1111/jgh.14942] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
482 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Schmilovitz-Weiss H, Dotan I, Birkenfeld S. Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success. J Clin Gastroenterol 2020;54:333-7. [PMID: 31305279 DOI: 10.1097/MCG.0000000000001237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
483 Park CH, Yang DH, Kim JW, Kim JH, Min YW, Lee SH, Bae JH, Chung H, Choi KD, Park JC, Lee H, Kwak MS, Kim B, Lee HJ, Lee HS, Choi M, Park DA, Lee JY, Byeon JS, Park CG, Cho JY, Lee ST, Chun HJ. Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer.Clin Endosc. 2020;53:142-166. [PMID: 32252507 DOI: 10.5946/ce.2020.032] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
484 Abdel-Razik A, Mousa N, Elhelaly R, Elzehery R, Hasan AS, Abdelsalam M, Seif AS, Tawfik AM, El-Wakeel N, Eldars W. Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study. Front Med (Lausanne) 2020;7:96. [PMID: 32266280 DOI: 10.3389/fmed.2020.00096] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
485 Yang T, Hu R, Tang X, Shen Y, Tay A, Pi X, Wang G, Debowski AW, Stubbs KA, Benghezal M, Marshall BJ, Li H, Tang H. Susceptibility-guided bismuth quadruple therapies for resistant Helicobacter pylori infections. Precision Clinical Medicine 2020;3:127-35. [DOI: 10.1093/pcmedi/pbaa010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
486 Howell AB, Wang L. Potential of cranberry for suppressing Helicobacter pylori, a risk factor for gastric cancer. JBR 2020;10:11-20. [DOI: 10.3233/jbr-180375] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
487 Saracino IM, Pavoni M, Zullo A, Fiorini G, Saccomanno L, Lazzarotto T, Cavallo R, Antonelli G, Vaira D. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients. Antibiotics (Basel) 2020;9:E121. [PMID: 32183165 DOI: 10.3390/antibiotics9030121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
488 Özer Etik D, Sezer S, Suna N, Öztaş E, Kılıç ZMY. Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication? Turk J Gastroenterol 2019;30:667-72. [PMID: 31258136 DOI: 10.5152/tjg.2019.18793] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
489 Cárdenas PA, Garcés D, Prado-Vivar B, Flores N, Fornasini M, Cohen H, Salvador I, Cargua O, Baldeón ME. Effect of Saccharomyces boulardii CNCM I-745 as complementary treatment of Helicobacter pylori infection on gut microbiome. Eur J Clin Microbiol Infect Dis 2020;39:1365-72. [PMID: 32125555 DOI: 10.1007/s10096-020-03854-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
490 Li J. Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis. Gastroenterol Res Pract 2020;2020:9512707. [PMID: 32190044 DOI: 10.1155/2020/9512707] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
491 Caguazango JC. Ecological models of gastric microbiota dysbiosis: Helicobacter pylori and gastric carcinogenesis. Medicine in Microecology 2020;3:100010. [DOI: 10.1016/j.medmic.2020.100010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
492 Rahimi F, Talebi Bezmin Abadi A. Tracking the Virulent Helicobacter pylori Strains Instead of Its Pan-Screening to Prevent Gastric Cancer. BioNanoSci 2020;10:315-317. [DOI: 10.1007/s12668-019-00678-0] [Reference Citation Analysis]
493 Lin T, Wu D, Tsay F, Tsai K, Tsai T, Peng N, Kao S, Chen W, Chen Y, Hsu P. Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection. Journal of the Chinese Medical Association 2020;83:233-7. [DOI: 10.1097/jcma.0000000000000256] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
494 Meyer C, Bowers A, Tritz D, Fuller K, Wayant C, Cook C, Torgerson T, Som M, Vassar M. The fragility of randomized trial outcomes underlying management of dyspepsia and Helicobacter pylori infections. International Journal of Evidence-Based Healthcare 2020;18:125-37. [DOI: 10.1097/xeb.0000000000000203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
495 Saranathan R, Levi MH, Wattam AR, Malek A, Asare E, Behin DS, Pan DH, Jacobs WR Jr, Szymczak WA. Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing. J Clin Microbiol 2020;58:e01591-19. [PMID: 31801839 DOI: 10.1128/JCM.01591-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
496 Papastergiou J, Donnelly M, Yuen T, Li W, van den Bemt B. Community pharmacy-based H. pylori screening for patients with uninvestigated dyspepsia. Can Pharm J (Ott) 2020;153:101-7. [PMID: 32206155 DOI: 10.1177/1715163520903065] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
497 Kim BJ, Lee H, Lee YC, Jeon SW, Kim GH, Kim HS, Sung JK, Lee DH, Kim HU, Park MI, Choi IJ, Yoon SM, Kim SW, Baik GH, Lee JY, Kim JI, Kim SG, Kim J, Lee J, Kim JG, Kim JJ;  Korean College of Helicobacter Upper Gastrointestinal Research. Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for Helicobacter pylori Infection: A Nationwide Randomized Trial in Korea. Gut Liver. 2019;13:531-540. [PMID: 31505907 DOI: 10.5009/gnl19136] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 10.0] [Reference Citation Analysis]
498 Kim TH, Park JM, Cheung DY, Oh JH. Comparison of 7- and 14-Day Eradication Therapy for Helicobacter pylori with First- and Second-Line Regimen: Randomized Clinical Trial. J Korean Med Sci 2020;35:e33. [PMID: 32030921 DOI: 10.3346/jkms.2020.35.e33] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
499 Zhang Q, Wu W, Zhang J, Xia X. Eradication of Helicobacter pylori: the power of nanosized formulations. Nanomedicine (Lond) 2020;15:527-42. [PMID: 32028847 DOI: 10.2217/nnm-2019-0329] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
500 Ji J, Yang H. Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy.Int J Mol Sci. 2020;21. [PMID: 32046317 DOI: 10.3390/ijms21031136] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 14.0] [Reference Citation Analysis]
501 Alzahrani AM, Al Zaidi AA, Alzahrani SM, Binmahfouz SA, Farahat FM. Association between type 2 diabetes mellitus and Helicobacter pylori infection among Saudi patients attending National Guard Primary Health Care Centers in the Western Region, 2018. J Family Community Med 2020;27:8-14. [PMID: 32030073 DOI: 10.4103/jfcm.JFCM_142_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
502 Howden CW. One Step Forward But Room for Improvement in Reducing Risk of Gastric Cancer by Curing Helicobacter pylori Infection. Gastroenterology 2020;158:466-7. [PMID: 31730770 DOI: 10.1053/j.gastro.2019.11.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
503 Iuchi K, Tasaki Y, Shirai S, Hisatomi H. Upregulation of nuclear factor (erythroid-derived 2)-like 2 protein level in the human colorectal adenocarcinoma cell line DLD-1 by a heterocyclic organobismuth(III) compound: Effect of organobismuth(III) compound on NRF2 signaling. Biomed Pharmacother 2020;125:109928. [PMID: 32004978 DOI: 10.1016/j.biopha.2020.109928] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
504 Bi Q, Song X, Chen Y, Zheng Y, Yin P, Lei T. Zn-HA/Bi-HA biphasic coatings on Titanium: Fabrication, characterization, antibacterial and biological activity. Colloids Surf B Biointerfaces 2020;189:110813. [PMID: 32018139 DOI: 10.1016/j.colsurfb.2020.110813] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
505 Tariq H, Patel H, Kamal MU, Abbas N, Ameen M, Azam S, Kumar K, Ravi M, Vootla V, Shaikh D, Amanchi V, Hussain AN, Makker J. Reevaluation of the Efficacy of First Line Regimen for Helicobacter pylori. Clin Exp Gastroenterol 2020;13:25-33. [PMID: 32158248 DOI: 10.2147/CEG.S239343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
506 Nemchenko OO, Danylo Halytsky Lviv National Medical University, 69, Pekarskaya St., Lviv 79010, Ukraine, Shykula RG, Panas MI, Tymchuk IV, Panas MA, Danylo Halytsky Lviv National Medical University, 69, Pekarskaya St., Lviv 79010, Ukraine, KNP ENT Lviv Regional Clinical Diagnostic Center, 69 – b, Pekarska St., Lviv 79010, Ukraine, Danylo Halytsky Lviv National Medical University, 69, Pekarskaya St., Lviv 79010, Ukraine, Danylo Halytsky Lviv National Medical University, 69, Pekarskaya St., Lviv 79010, Ukraine. Antimicrobial Therapy in Conditions of Helicobacter Pylori–Infection. Ukr ž med bìol sportu 2020;5:167-171. [DOI: 10.26693/jmbs05.01.167] [Reference Citation Analysis]
507 Saracino IM, Fiorini G, Zullo A, Pavoni M, Saccomanno L, Vaira D. Trends in Primary Antibiotic Resistance in H. pylori Strains Isolated in Italy between 2009 and 2019. Antibiotics (Basel) 2020;9:E26. [PMID: 31941121 DOI: 10.3390/antibiotics9010026] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
508 Valenzano M, Bisio A, Grassi G. Helicobacter pylori and diabetes mellitus: a controversial relationship. Minerva Endocrinol 2019;44:301-9. [PMID: 31304727 DOI: 10.23736/S0391-1977.19.03021-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
509 Valencia ME, Montejano R, Moreno V, Martín Carbonero L, Bernardino JI, Serrano L. [Helicobacter pylori infection in the HIV + population: a comorbidity to think about]. Rev Esp Quimioter 2020;33:68-72. [PMID: 31933346 DOI: 10.37201/req/033.2019] [Reference Citation Analysis]
510 Peng C, Hu Y, Ge ZM, Zou QM, Lyu NH. Diagnosis and treatment of Helicobacter pylori infections in children and elderly populations. Chronic Dis Transl Med 2019;5:243-51. [PMID: 32055783 DOI: 10.1016/j.cdtm.2019.12.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
511 Ahmed M. Peptic Ulcer Disease. Digestive System - Recent Advances 2020. [DOI: 10.5772/intechopen.86652] [Reference Citation Analysis]
512 Georgopoulos SD, Michopoulos S, Rokkas T, Apostolopoulos P, Giamarellos E, Kamberoglou D, Mentis A, Triantafyllou K. Hellenic consensus on Helicobacter pylori infection. Ann Gastroenterol 2020;33:105-24. [PMID: 32127732 DOI: 10.20524/aog.2020.0446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
513 Lee S, Sneed GT, Brown JN. Treatment of Helicobacter pylori with nitazoxanide-containing regimens: a systematic review. Infect Dis (Lond) 2020;52:381-90. [PMID: 31900002 DOI: 10.1080/23744235.2019.1708454] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
514 Patel P, Sengupta N. PPIs and Beyond: A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19. Dig Dis Sci 2020;65:2181-6. [PMID: 32537704 DOI: 10.1007/s10620-020-06408-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
515 Fong IW. Helicobacter pylori Infection: When Should It Be Treated? Current Trends and Concerns in Infectious Diseases 2020. [DOI: 10.1007/978-3-030-36966-8_4] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
516 Gabriel V, Aggarwal S, Smith BR. Severe Epigastric Abdominal Pain. Surgery 2020. [DOI: 10.1007/978-3-030-05387-1_50] [Reference Citation Analysis]
517 Wilcox CM. Peptic and Marginal Ulcer Disease. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65692-1] [Reference Citation Analysis]
518 Prashar A, Lozano-ruf A, Jones NL. Helicobacter pylori Infection. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.65907-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
519 Wang R, Li H, Ip TK, Sun H. Bismuth drugs as antimicrobial agents. Medicinal Chemistry 2020. [DOI: 10.1016/bs.adioch.2019.10.011] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
520 Leja M, Chapelle N, Kikuste I, Fedorov E, Sivins A, Carneiro F, Matysiak-budnik T. Gastric Cancer; Prevention and Treatment. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11317-0] [Reference Citation Analysis]
521 Alter DN. Clinical chemistry of the gastrointestinal disorders. Contemporary Practice in Clinical Chemistry 2020. [DOI: 10.1016/b978-0-12-815499-1.00032-6] [Reference Citation Analysis]
522 Brown B, Ramaiya AK, Cronkright P. Chronic Disease Management. Refugee Health Care 2020. [DOI: 10.1007/978-3-030-47668-7_10] [Reference Citation Analysis]
523 Leja M, Dumpis U. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? Dig Dis Sci 2020;65:1632-42. [PMID: 31659615 DOI: 10.1007/s10620-019-05893-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
524 Mangat R, Armstrong D. Duodenal Ulcer. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11328-5] [Reference Citation Analysis]
525 Costable NJ, Greenwald DA. Upper Gastrointestinal Bleeding. Geriatric Gastroenterology 2020. [DOI: 10.1007/978-3-319-90761-1_47-1] [Reference Citation Analysis]
526 Herardi R, Syam AF, Simadibrata M, Setiati S, Darnindro N, Abdullah M, Makmun D. Comparison of 10-Day Course of Triple Therapy Versus 14-Day Course for Eradication of Helicobacter pylori Infection in an Indonesian Population: Double-Blinded Randomized Clinical Trial. Asian Pac J Cancer Prev 2020;21:19-24. [PMID: 31983158 DOI: 10.31557/APJCP.2020.21.1.19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
527 Arenas A, Serrano C, Quiñones L, Harris P, Sandoval M, Lavanderos M, Sepúlveda R, Maquilón S, Echeverría A, Ríos C, Fuentes-López E, Rojas L, Jorquera A, Pizarro M, Camargo MC, Riquelme A. High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Sci Rep 2019;9:20070. [PMID: 31882676 DOI: 10.1038/s41598-019-56399-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
528 Kumar S, Sangitha R, Nachamkin I, Metz DC. Resistance patterns of refractory H. pylori infection in a referral center in the Delaware Valley. GastroHep 2020;2:6-12. [PMID: 32377173 DOI: 10.1002/ygh2.382] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
529 Asenov Angelov T, Dimitrova Kovacheva-slavova M, Ilianov Iliev H, Yankov Valkov H, Georgiev Vladimirov B. Helicobacter pyloriInfection. Gastritis - New Approaches and Treatments 2019. [DOI: 10.5772/intechopen.86963] [Reference Citation Analysis]
530 Clines N, Beckman E. Development of a high throughput human stool specimen processing method for a molecular Helicobacter pylori clarithromycin resistance assay. PLoS One 2019;14:e0224356. [PMID: 31841502 DOI: 10.1371/journal.pone.0224356] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
531 Kim Y, Chung WC. Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin Resistance. Korean J Helicobacter Up Gastrointest Res 2019;19:225-30. [DOI: 10.7704/kjhugr.2019.0019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
532 Lee JY, Kim N, Nam RH, In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter 2019;24:e12660. [PMID: 31507036 DOI: 10.1111/hel.12660] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
533 Perfilova K, Shutova I, Neumoina N, Neumoina M, Troshina T, Butina T, Kuznetsova I. The prevalence of different variants of Helicobacter pylori genotypes in families of patients with helicobacter-associated diseases. PH&LE 2019. [DOI: 10.35627/2219-5238/2019-321-12-66-70] [Reference Citation Analysis]
534 Chey WD. Helicobacter pylori: When We Should Treat…. Am J Gastroenterol 2019;114:1829-32. [PMID: 31658124 DOI: 10.14309/ajg.0000000000000425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
535 Hanafy AS, Seleem WM. Refractory Helicobacter pylori gastritis: The hidden predictors of resistance. Journal of Global Antimicrobial Resistance 2019;19:194-200. [DOI: 10.1016/j.jgar.2019.05.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
536 Azadi M, Ebrahimi A, Khaledi A, Esmaeili D. Study of inhibitory effects of the mixture of cinnamon and ginger extracts on cagA gene expression of Helicobacter pylori by Real-Time RT-PCR technique. Gene Reports 2019;17:100493. [DOI: 10.1016/j.genrep.2019.100493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
537 Deguchi H, Yamazaki H, Yamamoto Y, Fukuhara S. Association between parental history of Helicobacter pylori treatment failure and treatment failure in the offspring. J Gastroenterol Hepatol 2019;34:2112-7. [PMID: 31264254 DOI: 10.1111/jgh.14774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
538 Walker MJ, Crews NR, El-Halabi M, Fayad NF. Educational Intervention Improves Proton Pump Inhibitor Stewardship in Outpatient Gastroenterology Clinics. Gastroenterology Res 2019;12:305-11. [PMID: 31803310 DOI: 10.14740/gr1238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
539 Burgos‐santamaría D, Mcnicholl AG, Gisbert JP. Empirical Helicobacter pylori rescue therapy: an 18‐year single‐centre study of 1200 patients. GastroHep 2019;1:311-24. [DOI: 10.1002/ygh2.372] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
540 Miller JM, Binnicker MJ, Campbell S, Carroll KC, Chapin KC, Gilligan PH, Gonzalez MD, Jerris RC, Kehl SC, Patel R, Pritt BS, Richter SS, Robinson-Dunn B, Schwartzman JD, Snyder JW, Telford S 3rd, Theel ES, Thomson RB Jr, Weinstein MP, Yao JD. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67:e1-e94. [PMID: 29955859 DOI: 10.1093/cid/ciy381] [Cited by in Crossref: 200] [Cited by in F6Publishing: 219] [Article Influence: 50.0] [Reference Citation Analysis]
541 Berlamont H, Smet A, De Bruykere S, Boyen F, Ducatelle R, Haesebrouck F, De Witte C. Antimicrobial susceptibility pattern of Helicobacter suis isolates from pigs and macaques. Vet Microbiol 2019;239:108459. [PMID: 31767067 DOI: 10.1016/j.vetmic.2019.108459] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
542 Khani S, Talebi Bezmin Abadi A, Mohabati Mobarez A. Clarithromycin-Susceptible But Virulent Helicobacter pylori Strains Infecting Iranian Patients' Stomachs. Infect Drug Resist 2019;12:3415-20. [PMID: 31802920 DOI: 10.2147/IDR.S223602] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
543 Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Chen YH, Tsai TJ, Wu DC, Tsai KW. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol 2019;34:1968-76. [PMID: 31115933 DOI: 10.1111/jgh.14736] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 7.0] [Reference Citation Analysis]
544 Muresan IAP, Pop LL, Dumitrascu DL. Lactobacillus reuteri versus triple therapy for the eradication of Helicobacter pylori in functional dyspepsia. Med Pharm Rep 2019;92:352-5. [PMID: 31750434 DOI: 10.15386/mpr-1375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
545 Sgouras D, Tegtmeyer N, Wessler S. Activity and Functional Importance of Helicobacter pylori Virulence Factors. Adv Exp Med Biol 2019;1149:35-56. [PMID: 31016624 DOI: 10.1007/5584_2019_358] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
546 Liang CM, Yang SC, Wu CK, Li YC, Yeh WS, Tai WC, Lee CH, Yang YH, Tsai TH, Hsu CN, Chuah SK. Risk of Recurrent Peptic Ulcer Disease in Patients Receiving Cumulative Defined Daily Dose of Nonsteroidal Anti-Inflammatory Drugs. J Clin Med 2019;8:E1722. [PMID: 31635253 DOI: 10.3390/jcm8101722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
547 Safarov T, Kiran B, Bagirova M, Allahverdiyev AM, Abamor ES. An overview of nanotechnology-based treatment approaches against Helicobacter Pylori. Expert Review of Anti-infective Therapy 2019;17:829-40. [DOI: 10.1080/14787210.2019.1677464] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
548 Bonelli P, Borrelli A, Tuccillo FM, Silvestro L, Palaia R, Buonaguro FM. Precision medicine in gastric cancer. World J Gastrointest Oncol 2019; 11(10): 804-829 [PMID: 31662821 DOI: 10.4251/wjgo.v11.i10.804] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 44] [Article Influence: 9.5] [Reference Citation Analysis]
549 Nashed K, Lai K, Stevens T, Morris-Stiff G. An unusual presentation of gastric mucosa-associated lymphoid tissue (MALT) lymphoma following blunt abdominal trauma. BMJ Case Rep 2019;12:e230878. [PMID: 31604718 DOI: 10.1136/bcr-2019-230878] [Reference Citation Analysis]
550 Sandhika W. DETECTION OF HELICOBACTER PYLORI INFECTION IN CHRONIC GASTRITIS BIOPSY SPECIMEN USING WARTHIN-STARRY AND MODIFIED GIEMSA STAIN IN DR SOETOMO HOSPITAL SURABAYA. IJTID 2019;7:150. [DOI: 10.20473/ijtid.v7i6.8404] [Reference Citation Analysis]
551 de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019; 25(37): 5578-5589 [PMID: 31602159 DOI: 10.3748/wjg.v25.i37.5578] [Cited by in CrossRef: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
552 Kapizioni C, Koutoufaris G, Ntouli V, Makris K, Milioni K, Kourkoulis P, Giannelis P, Mellos A, Michalopoulos G, Vrakas S, Xourgias V. Optimal duration of concomitant nonbismuth quadruple therapy as first-line therapy for Helicobacter pylori: a prospective, open-label, comparative study. Eur J Gastroenterol Hepatol 2019;31:1206-10. [PMID: 31441794 DOI: 10.1097/MEG.0000000000001517] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
553 Ciccaglione AF, Cellini L, Marzio L. Pylera® plus ranitidine vs Pylera® plus esomeprazole in first-line treatment of Helicobacter pylori infection: Two pilot studies. Helicobacter 2019;24:e12606. [PMID: 31168941 DOI: 10.1111/hel.12606] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
554 Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter 2019;24:e12651. [PMID: 31414551 DOI: 10.1111/hel.12651] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
555 Howden CW. Emerging Regimens for H. pylori Infection Should Enhance Efficacy and Circumvent Resistance. Dig Dis Sci 2019;64:2691-2. [PMID: 31346952 DOI: 10.1007/s10620-019-05747-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
556 Alsamman MA, Vecchio EC, Shawwa K, Acosta-Gonzales G, Resnick MB, Moss SF. Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA. Dig Dis Sci 2019;64:2893-8. [PMID: 31187323 DOI: 10.1007/s10620-019-05694-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
557 Alboraie M, Elhossary W, Aly OA, Abbas B, Abdelsalam L, Ghaith D, Shady Z, Gaber Y, Adel E, Peura D, Armstrong D, Esmat G; special interest group., Egyptian Association for Study of Gastrointestinal Diseases and Liver (E A S G L D). Egyptian recommendations for management of Helicobacter pylori infection: 2018 report. Arab J Gastroenterol 2019;20:175-9. [PMID: 31564518 DOI: 10.1016/j.ajg.2019.09.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
558 Kandil M, Alhashmi H, Alzahrani M, Alhejazi A, Motabi I, Dada R, Al-Mansour M, Sagheir A. Marginal Zone Lymphoma: Saudi Lymphoma Group's Clinical Practice Guidelines for Diagnosis, Management and Follow-up. Saudi J Med Med Sci 2019;7:202-8. [PMID: 31543745 DOI: 10.4103/sjmms.sjmms_97_19] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
559 Jiang X, Duan Y, Zhou B, Guo Q, Wang H, Hang X, Zeng L, Jia J, Bi H. The Cyclopropane Fatty Acid Synthase Mediates Antibiotic Resistance and Gastric Colonization of Helicobacter pylori. J Bacteriol 2019;201:e00374-19. [PMID: 31358615 DOI: 10.1128/JB.00374-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
560 Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med 2019;8:E1498. [PMID: 31546909 DOI: 10.3390/jcm8091498] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
561 Jun JS, Seo JH, Park JS, Rhee KH, Youn HS. Changes in the Treatment Strategies for Helicobacter pylori Infection in Children and Adolescents in Korea. Pediatr Gastroenterol Hepatol Nutr 2019;22:417-30. [PMID: 31555566 DOI: 10.5223/pghn.2019.22.5.417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
562 Nguyen CT, Davis KA, Nisly SA, Li J. Treatment of Helicobacter pylori in Special Patient Populations. Pharmacotherapy 2019;39:1012-22. [DOI: 10.1002/phar.2318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
563 Lin KD, Chiu GF, Waljee AK, Owyang SY, El-Zaatari M, Bishu S, Grasberger H, Zhang M, Wu DC, Kao JY. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2019;17:1991-9. [PMID: 30580094 DOI: 10.1016/j.cgh.2018.12.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
564 Wiens E, Kovaltchouk U, Koomson A, Targownik LE. The Clinician's Guide to Proton-Pump Inhibitor Discontinuation. J Clin Gastroenterol 2019;53:553-9. [PMID: 31356559 DOI: 10.1097/MCG.0000000000001243] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
565 Poonyam P, Chotivitayatarakorn P, Vilaichone RK. High Effective of 14-Day High-Dose PPI- Bismuth-Containing Quadruple Therapy with Probiotics Supplement for Helicobacter Pylori Eradication: A Double Blinded-Randomized Placebo-Controlled Study. Asian Pac J Cancer Prev 2019;20:2859-64. [PMID: 31554388 DOI: 10.31557/APJCP.2019.20.9.2859] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
566 Justo JA, Kufel WD, Avery L, Bookstaver PB. Penicillin Allergy Skin Testing in the Inpatient Setting. Pharmacy (Basel) 2019;7:E120. [PMID: 31461837 DOI: 10.3390/pharmacy7030120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
567 Veliev AM, Maev IV, Andreev DN, Dicheva DT, Zaborovskii AV, Lobanova EG, Bektemirova LG. [The efficacy and safety of quadruple therapy without bismuth (concomitant therapy) in the treatment of patients with Helicobacter pylori - associated gastric and duodenal peptic ulcer disease]. Ter Arkh 2019;91:28-33. [PMID: 32598751 DOI: 10.26442/00403660.2019.08.000382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
568 Livzan MA. [Underwater rocks of anti - helicobacter therapy]. Ter Arkh 2019;91:141-7. [PMID: 32598766 DOI: 10.26442/00403660.2019.08.000386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
569 Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and Its Antibiotic Heteroresistance: A Neglected Issue in Published Guidelines. Front Microbiol 2019;10:1796. [PMID: 31456763 DOI: 10.3389/fmicb.2019.01796] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
570 Ivashkin VT, Kasoev SG, Stepanov EV. Analysis of the Isotopic Composition of Exhaled Air by the Diode Laser Spectroscopy Method in the 2-μm Region for Diagnosis of Helicobacter pylori-Associated Diseases. Opt Spectrosc 2019;126:710-20. [DOI: 10.1134/s0030400x19060109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
571 Attia TZ, Yamashita T, Tsujino H, Derayea SM, Tsutsumi Y, Uno T. Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy. Chem Pharm Bull (Tokyo) 2019;67:810-5. [PMID: 31366830 DOI: 10.1248/cpb.c19-00084] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
572 Lee JH, Ahn JY, Choi KD, Jung HY, Kim JM, Baik GH, Kim BW, Park JC, Jung HK, Cho SJ, Shin CM, Choi YJ, Lee SH, Kim JH, Lee WS, Sung JK, Chung JW, Cheung DY, Lee H, Min YW, Kim JJ, Kim SY; Korean College of Helicobacter, Upper Gastrointestinal Research. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter 2019;24:e12592. [PMID: 31111572 DOI: 10.1111/hel.12592] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 13.0] [Reference Citation Analysis]
573 Koletzko L, Macke L, Schulz C, Malfertheiner P. Helicobacter pylori eradication in dyspepsia: New evidence for symptomatic benefit. Best Pract Res Clin Gastroenterol 2019;40-41:101637. [PMID: 31594649 DOI: 10.1016/j.bpg.2019.101637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
574 Ng JC, Yeomans ND. Helicobacter pylori infection and the risk of upper gastrointestinal bleeding in low dose aspirin users: systematic review and meta-analysis.Med J Aust. 2018;209:306-311. [PMID: 30257623 DOI: 10.5694/mja17.01274] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
575 Choi YI, Jeong SH, Chung JW, Park DK, Kim KO, Kwon KA, Kim YJ, So S, Lee JH, Jeong JY, Lee SM. Rifabutin and Furazolidone Could Be the Candidates of the Rescue Regimen for Antibiotic-Resistant H. pylori in Korea. Can J Infect Dis Med Microbiol. 2019;2019:9351801. [PMID: 31360270 DOI: 10.1155/2019/9351801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
576 Bruce MG, Bruden D, Newbrough D, Hurlburt DA, Hennessy TW, Morris JM, Reasonover AL, Sacco F, Mcmahon BJ. The relationship between previous antimicrobial use, antimicrobial resistance and treatment outcome among Alaskans treated forHelicobacter pyloriinfection. GastroHep 2019. [DOI: 10.1002/ygh2.352] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
577 Song H, Zhou L, Liu D, Ge L, Li Y. Probiotic effect on Helicobacter pylori attachment and inhibition of inflammation in human gastric epithelial cells. Exp Ther Med 2019;18:1551-62. [PMID: 31410109 DOI: 10.3892/etm.2019.7742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
578 Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology 2019;157:44-53. [PMID: 30998990 DOI: 10.1053/j.gastro.2019.04.011] [Cited by in Crossref: 144] [Cited by in F6Publishing: 141] [Article Influence: 36.0] [Reference Citation Analysis]
579 Baihaqi AI, Rahayu DUC, Budianto E. Effect of Drug Loading Method on Drug Dissolution Mechanism of Amoxicillin Trihydrate Encapsulated in Chitosan-Poly(N-Vinylpyrrolidone) Full-IPN Hydrogel as a Floating Drug Delivery System Matrix. MSF 2019;964:251-256. [DOI: 10.4028/www.scientific.net/msf.964.251] [Reference Citation Analysis]
580 Jansson L, Agardh D. Prevalence of clarithromycin-resistant Helicobacter pylori in children living in South of Sweden: a 12-year follow-up. Scand J Gastroenterol 2019;54:838-42. [PMID: 31305189 DOI: 10.1080/00365521.2019.1637452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
581 Marinoni C, Ribaldone DG, Rosso C, Astegiano M, Caviglia GP. Diagnosis of Helicobacter pylori infection: a look into molecular aspects of urea breath test. Minerva Biotecnol 2019;31. [DOI: 10.23736/s1120-4826.19.02555-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
582 Jaka H, Rüttgerodt N, Bohne W, Mueller A, Gross U, Kasang C, Mshana SE. Helicobacter pylori Mutations Conferring Resistance to Fluoroquinolones and Clarithromycin among Dyspeptic Patients Attending a Tertiary Hospital, Tanzania. Can J Gastroenterol Hepatol 2019;2019:8481375. [PMID: 31355162 DOI: 10.1155/2019/8481375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
583 Singh A, Narayan J, Singh S. Helicobacter pylori Infection: Challenges in India. J Pure Appl Microbiol 2019;13:715-723. [DOI: 10.22207/jpam.13.2.07] [Reference Citation Analysis]
584 Nezami BG, Jani M, Alouani D, Rhoads DD, Sadri N. Helicobacter pylori Mutations Detected by Next-Generation Sequencing in Formalin-Fixed, Paraffin-Embedded Gastric Biopsy Specimens Are Associated with Treatment Failure. J Clin Microbiol. 2019;57:pii: e01834-18. [PMID: 31068413 DOI: 10.1128/jcm.01834-18] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
585 Kim YJ, Lee SY, Yang H, Kim JH, Sung IK, Park HS. [Nodular Gastritis as a Precursor Lesion of Atrophic and Metaplastic Gastritis]. Korean J Gastroenterol 2019;73:332-40. [PMID: 31234623 DOI: 10.4166/kjg.2019.73.6.332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
586 Li H, Yang T, Tang H, Tang X, Shen Y, Benghezal M, Tay A, Marshall B. Helicobacter pylori infection is an infectious disease and the empiric therapy paradigm should be changed. Precision Clinical Medicine 2019;2:77-80. [DOI: 10.1093/pcmedi/pbz009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
587 Bluemel B, Goelz H, Goldmann B, Grüger J, Hamel H, Loley K, Ludolph T, Meyer J, Miehlke S, Mohr A, Tüffers K, Usadel H, Wagner S, Wenzel H, Wiemer L, Vorreiter J, Eisele B, Hofreuter D, Glocker EO. Antimicrobial resistance of Helicobacter pylori in Germany, 2015 to 2018. Clin Microbiol Infect 2020;26:235-9. [PMID: 31212078 DOI: 10.1016/j.cmi.2019.06.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
588 Mari A, Mahroum N, Bragazzi NL, Shalaata M, Khoury T, Watad A, Mahamid M. Demographics and Clinical and Endoscopic Characteristics of Patients with Helicobacter pylori Infection and Gastroesophageal Reflux Disease: A Case-Control Study. Gastroenterol Res Pract 2019;2019:3819893. [PMID: 31198421 DOI: 10.1155/2019/3819893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
589 Bordin DS, Embutnieks YV, Vologzhanina LG, Il'chishina TA, Voinovan IN, Sarsenbaeva AS, Alekseenko SA, Zaitsev OV, Abdulkhakov RA, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Dekhnich NN, Tarasova LV, Plotnikova EY, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovskii AY, Abdulkhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia. Ter Arkh 2018;90:35-42. [PMID: 30701770 DOI: 10.26442/terarkh201890235-42] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
590 Choi IJ. [Helicobacter pylori Eradication Therapy and Gastric Cancer Prevention]. Korean J Gastroenterol 2018;72:245-51. [PMID: 30642140 DOI: 10.4166/kjg.2018.72.5.245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
591 Boltin D, Levi Z, Gingold-Belfer R, Gabay H, Shochat T, Niv Y, Dickman R, Dotan I, Birkenfeld S. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol 2019;114:900-6. [PMID: 31095531 DOI: 10.14309/ajg.0000000000000223] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
592 Baylina M, Muñoz N, Sánchez-Delgado J, López-Góngora S, Calvet X, Puig I. Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced? Helicobacter 2019;24:e12584. [PMID: 30990575 DOI: 10.1111/hel.12584] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
593 Laredo V, Sostres C, Alfaro E, Arroyo MT, Lanas Á. Management of Helicobacter pylori infection at the primary care level. The implementation of specific counseling improves eradication rates. Helicobacter 2019;24:e12586. [PMID: 30950147 DOI: 10.1111/hel.12586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
594 Chen X, Li P, Shen Y, Zou Y, Yuan G, Hu H. Rhamnolipid-involved antibiotics combinations improve the eradication of Helicobacter pylori biofilm in vitro: A comparison with conventional triple therapy. Microbial Pathogenesis 2019;131:112-9. [DOI: 10.1016/j.micpath.2019.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
595 Kwon YJ, Kim N, Baek SM, Lee HS, Lee J, Hwang YJ, Yoon H, Shin CM, Park YS, Kim JW, Lee DH. The prevalence of histologic atrophy and intestinal metaplasia in the corpus has decreased over 15 years in females in the Korean population. Helicobacter 2019;24:e12579. [PMID: 30920087 DOI: 10.1111/hel.12579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
596 Arévalo Galvis A, Trespalacios Rangel AA, Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. Helicobacter 2019;24:e12574. [PMID: 30859680 DOI: 10.1111/hel.12574] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
597 Huang Y, Hang X, Jiang X, Zeng L, Jia J, Xie Y, Li F, Bi H. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori. Antimicrob Agents Chemother. 2019;63. [PMID: 30936098 DOI: 10.1128/aac.00004-19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
598 Liou JM, Lee YC, El-Omar EM, Wu MS. Efficacy and Long-Term Safety of H. pylori Eradication for Gastric Cancer Prevention. Cancers (Basel) 2019;11:E593. [PMID: 31035365 DOI: 10.3390/cancers11050593] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
599 Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 [PMID: 31086459 DOI: 10.3748/wjg.v25.i16.1907] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
600 Shi X, Zhang J, Mo L, Shi J, Qin M, Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis. Medicine (Baltimore). 2019;98:e15180. [PMID: 30985706 DOI: 10.1097/md.0000000000015180] [Cited by in Crossref: 48] [Cited by in F6Publishing: 55] [Article Influence: 12.0] [Reference Citation Analysis]
601 Korolenko RN, City hospital No. 4 1, Admiral Makarov St., Mykolaiv 54000, Ukraine, Avramenko АА, Petro Mohyla Black Sea National University 10, 68 Desantnykiv St., Mikolayiv 54003, Ukraine. Frequency of Determining the Active Forms of Helicobacter Infection in Patients with Chronic Non-Throphic Gastritis with Various Forms of Biliary Dyskinesia. Ukr ž med bìol sportu 2019;4:136-141. [DOI: 10.26693/jmbs04.02.136] [Reference Citation Analysis]
602 Nam JH, Ryu KH, Park BJ, Lee CW, Park EC. Rate and predictive factors of Helicobacter pylori recurrence: Analysis of a screening cohort. Saudi J Gastroenterol 2019;25:251-6. [PMID: 30950407 DOI: 10.4103/sjg.SJG_456_18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
603 Hsieh MS, Liu CJ, Hsu WH, Li CJ, Tsai PY, Hu HM, Shih HY, Lu CY, Yu FJ, Kuo FC, Wu DC, Kuo CH. Gastric juice-based PCR assay: An alternative testing method to aid in the management of previously treated Helicobacter pylori infection. Helicobacter 2019;24:e12568. [PMID: 30821043 DOI: 10.1111/hel.12568] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
604 Kavitt RT, Lipowska AM, Anyane-yeboa A, Gralnek IM. Diagnosis and Treatment of Peptic Ulcer Disease. The American Journal of Medicine 2019;132:447-56. [DOI: 10.1016/j.amjmed.2018.12.009] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 18.8] [Reference Citation Analysis]
605 Dua A, Venu M. Associated risks of proton pump inhibitors and their influence on prescribing habits: is change truly warranted? Dis Esophagus 2019;32:doy103. [PMID: 30496546 DOI: 10.1093/dote/doy103] [Reference Citation Analysis]
606 Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter 2019;24:e12565. [PMID: 30698318 DOI: 10.1111/hel.12565] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
607 Lee JW, Kim N, Nam RH, Lee SM, Soo In C, Kim JM, Lee DH. Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:666-72. [PMID: 30726563 DOI: 10.1111/jgh.14625] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
608 Tran VH. EFFICACY OF MODIFIED BISMUTH QUADRUPLE THERAPY (RBMA) AS FIRST-LINE THERAPY FOR ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH CHRONIC GASTRITIS. JMP 2019. [DOI: 10.34071/jmp.2019.2.5] [Reference Citation Analysis]
609 Lu B, Wang J, Li J, Liu L, Chen Y. Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial. Helicobacter 2019;24:e12566. [PMID: 30780194 DOI: 10.1111/hel.12566] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
610 Dore MP, Bibbò S, Pes GM, Francavilla R, Graham DY. Role of Probiotics in Helicobacter pylori Eradication: Lessons from a Study of Lactobacillus reuteri Strains DSM 17938 and ATCC PTA 6475 (Gastrus®) and a Proton-Pump Inhibitor. Can J Infect Dis Med Microbiol 2019;2019:3409820. [PMID: 31065301 DOI: 10.1155/2019/3409820] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
611 Lee JW, Kim N, Nam RH, Lee SM, Kwon YH, Sohn SD, Kim JM, Lee DH, Jung HC. Favorable outcomes of culture-based Helicobacter pylori eradication therapy in a region with high antimicrobial resistance. Helicobacter 2019;24:e12561. [PMID: 30632237 DOI: 10.1111/hel.12561] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
612 Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: A systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14396. [PMID: 30762742 DOI: 10.1097/md.0000000000014396] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
613 Seo SI, Kang JG, Kim HS, Shin WG, Jang MK, Lee JH, Kim HY. Risk of Peptic Ulcer Bleeding Associated with Helicobacter pylori Infection, Nonsteroidal Anti-inflammatory Drugs, and Low-dose Aspirin Therapy in Peptic Ulcer Disease: A Case-control Study. Korean J Helicobacter Up Gastrointest Res 2019;19:42-7. [DOI: 10.7704/kjhugr.2019.19.1.42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
614 Gweon TG, Kim JS, Kim BW. An Economic Modeling Study of Helicobacter pylori Eradication: Comparison of Dual Priming Oligonucleotide-Based Multiplex Polymerase Chain Reaction and Empirical Treatment. Gut Liver 2018;12:648-54. [PMID: 30037167 DOI: 10.5009/gnl18079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
615 Hou B, Zhang M, Liu M, Dai W, Lin Y, Li Y, Gong M, Wang G. Association of active Helicobacter pylori infection and anemia in elderly males. BMC Infect Dis 2019;19:228. [PMID: 30836932 DOI: 10.1186/s12879-019-3849-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
616 Hallowell BD, Endeshaw M, Senkomago V, Razzaghi H, McKenna MT, Saraiya M. Gastric cancer mortality rates among US and foreign-born persons: United States 2005-2014. Gastric Cancer 2019;22:1081-5. [PMID: 30830640 DOI: 10.1007/s10120-019-00944-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
617 Sarri GL, Grigg SE, Yeomans ND. Helicobacter pylori and low-dose aspirin ulcer risk: A meta-analysis. J Gastroenterol Hepatol 2019;34:517-25. [PMID: 30408229 DOI: 10.1111/jgh.14539] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
618 Slomiany BL, Slomiany A. Syk: a new target for attenuation of Helicobacter pylori-induced gastric mucosal inflammatory responses. Inflammopharmacology. 2019;27:203-211. [PMID: 30820719 DOI: 10.1007/s10787-019-00577-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
619 Mendes JJ, Silva MJ, Miguel LS, Gonçalves MA, Oliveira MJ, Oliveira CDL, Gouveia J. Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit. Rev Bras Ter Intensiva 2019;31:5-14. [PMID: 30843949 DOI: 10.5935/0103-507X.20190002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
620 Chiba N. Ulcer Disease andHelicobacter PyloriInfection: Current Treatment. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
621 Makunts T, Cohen IV, Awdishu L, Abagyan R. Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Sci Rep 2019;9:2282. [PMID: 30783195 DOI: 10.1038/s41598-019-39335-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 8.3] [Reference Citation Analysis]
622 Wang G, Pang J, Hu X, Nie T, Lu X, Li X, Wang X, Lu Y, Yang X, Jiang J, Li C, Xiong YQ, You X. Daphnetin: A Novel Anti-Helicobacter pylori Agent. Int J Mol Sci 2019;20:E850. [PMID: 30781382 DOI: 10.3390/ijms20040850] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
623 Bordin DS, Embutnieks YV, Vologzhanina LG, Ilchishina TA, Voynovan IN, Sarsenbaeva AS, Zaitsev OV, Alekseenko SA, Abdulkhakov RA, Dehnich NN, Osipenko MF, Livzan MA, Tsukanov VV, Burkov SG, Bakulina NV, Plotnikova EY, Tarasova LV, Maev IV, Kucheryavyi YA, Baryshnikova NV, Butov MA, Kolbasnikov SV, Pakhomova AL, Zhestkova TV, Baranovsky AY, Abdulhakov SR, Ageeva EA, Lyalyukova EA, Vasyutin AV, Golubev NN, Savilova IV, Morkovkina LV, Kononova AG, Megraud F, O'Morain C, Ramas M, Nyssen OP, McNicholl AG, Gisbert JP. [European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years]. Ter Arkh 2019;91:16-24. [PMID: 32598623 DOI: 10.26442/00403660.2019.02.000156] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
624 Kuna L, Jakab J, Smolic R, Raguz-Lucic N, Vcev A, Smolic M. Peptic Ulcer Disease: A Brief Review of Conventional Therapy and Herbal Treatment Options. J Clin Med 2019;8:E179. [PMID: 30717467 DOI: 10.3390/jcm8020179] [Cited by in Crossref: 82] [Cited by in F6Publishing: 86] [Article Influence: 20.5] [Reference Citation Analysis]
625 Cholankeril G, Hu M, Cholankeril R, Khan MA, Gadiparthi C, Yoo ER, Perumpail RB, Nair S, Howden CW. Inpatient Outcomes for Gastrointestinal Bleeding Associated With Percutaneous Coronary Intervention. J Clin Gastroenterol 2019;53:120-6. [PMID: 29351155 DOI: 10.1097/MCG.0000000000000971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
626 Graham DY, Lu H, Dore MP. Relative potency of proton-pump inhibitors, Helicobacter pylori therapy cure rates, and meaning of double-dose PPI. Helicobacter 2019;24:e12554. [PMID: 30440097 DOI: 10.1111/hel.12554] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
627 Seddik H, Boutallaka H, Elkoti I, Nejjari F, Berraida R, Berrag S, Loubaris K, Sentissi S, Benkirane A. Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. Eur J Clin Pharmacol 2019;75:639-45. [DOI: 10.1007/s00228-019-02625-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
628 Yang Y, Chen L, Sun HW, Guo H, Song Z, You Y, Yang LY, Tong YN, Gao JN, Zeng H, Yang WC, Zou QM. Epitope-loaded nanoemulsion delivery system with ability of extending antigen release elicits potent Th1 response for intranasal vaccine against Helicobacter pylori. J Nanobiotechnology 2019;17:6. [PMID: 30660182 DOI: 10.1186/s12951-019-0441-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
629 Boltin D, Dotan I, Birkenfeld S. Improvement in the implementation of Helicobacter pylori management guidelines among primary care physicians following a targeted educational intervention. Ann Gastroenterol 2019;32:52-9. [PMID: 30598592 DOI: 10.20524/aog.2018.0329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
630 Smith SM, O'Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol 2019;35:6-13. [PMID: 30489412 DOI: 10.1097/MOG.0000000000000497] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
631 Torbenson M. Common Types of Gastritis. Surgical Pathology of Non-neoplastic Gastrointestinal Diseases 2019. [DOI: 10.1007/978-3-030-15573-5_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
632 Talley NJ, Cook DR. Functional Dyspepsia. Essential Medical Disorders of the Stomach and Small Intestine 2019. [DOI: 10.1007/978-3-030-01117-8_8] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
633 Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication. J Gastroenterol Hepatol 2019;34:59-67. [PMID: 30169908 DOI: 10.1111/jgh.14462] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
634 Mandal AK, Kafle P, Puri P, Chaulagai B, Sidhu JS, Hassan M, Paudel MS, Kanth R, Gayam V. An association of Helicobacter pylori infection with endoscopic and histological findings in the Nepalese population. J Family Med Prim Care 2019;8:1227-31. [PMID: 31041278 DOI: 10.4103/jfmpc.jfmpc_82_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
635 Khan MA, Howden CW. Helicobacter pylori and Related Diseases. Essential Medical Disorders of the Stomach and Small Intestine 2019. [DOI: 10.1007/978-3-030-01117-8_7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
636 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Medicina Clínica (English Edition) 2019;152:65-71. [DOI: 10.1016/j.medcle.2018.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
637 Matsumoto H, Shiotani A, Graham DY. Current and Future Treatment of Helicobacter pylori Infections. Adv Exp Med Biol 2019;1149:211-25. [PMID: 31016626 DOI: 10.1007/5584_2019_367] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 7.8] [Reference Citation Analysis]
638 Wellehan JF, Divers SJ. Bacteriology. Mader's Reptile and Amphibian Medicine and Surgery. Elsevier; 2019. pp. 235-246.e4. [DOI: 10.1016/b978-0-323-48253-0.00029-5] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
639 Baiu I, Azagury DE. Risk Factor Modification in Patients with Peptic Ulcer Disease. The SAGES Manual of Foregut Surgery 2019. [DOI: 10.1007/978-3-319-96122-4_54] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
640 Chen Q, Zhou X, Tan W, Zhang M. Association between Helicobacter pylori infection and Sjögren syndrome: A meta-analysis. Medicine (Baltimore) 2018;97:e13528. [PMID: 30544455 DOI: 10.1097/MD.0000000000013528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
641 Ren WK, Xu YF, Wei WH, Huang P, Lian DW, Fu LJ, Yang XF, Chen FJ, Wang J, Cao HY, Deng YH. Effect of patchouli alcohol on Helicobacter pylori-induced neutrophil recruitment and activation. Int Immunopharmacol. 2019;68:7-16. [PMID: 30599446 DOI: 10.1016/j.intimp.2018.12.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
642 Blum FC, Singh J, Merrell DS. In vitro activity of neem (Azadirachta indica) oil extract against Helicobacter pylori. J Ethnopharmacol 2019;232:236-43. [PMID: 30578933 DOI: 10.1016/j.jep.2018.12.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
643 Tirado-Hurtado I, Carlos C, Lancho L, Alfaro A, Ponce R, Schwarz LJ, Torres L, Ayudant M, Pinto JA, Fajardo W. Helicobacter pylori: History and facts in Peru. Crit Rev Oncol Hematol 2019;134:22-30. [PMID: 30771870 DOI: 10.1016/j.critrevonc.2018.12.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
644 Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or Sequential Therapy as the First-line Therapy for Eradication of Helicobacter pylori Infection in Korea: A Systematic Review and Meta-analysis. Korean J Gastroenterol. 2018;71:31-37. [PMID: 29361811 DOI: 10.4166/kjg.2018.71.1.31] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
645 Violeta Filip P, Cuciureanu D, Sorina Diaconu L, Maria Vladareanu A, Silvia Pop C. MALT lymphoma: epidemiology, clinical diagnosis and treatment. J Med Life. 2018;11:187-193. [PMID: 30364585 DOI: 10.25122/jml-2018-0035] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 8.4] [Reference Citation Analysis]
646 Nusrat S, Syed T, Nusrat S, Chen S, Chen WJ, Bielefeldt K. Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels. JAMA Netw Open 2018;1:e186343. [PMID: 30646328 DOI: 10.1001/jamanetworkopen.2018.6343] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
647 Feder R, Posner S, Qin Y, Zheng J, Chow SC, Garman KS. Helicobacter pylori-associated peptic ulcer disease: A retrospective analysis of post-treatment testing practices. Helicobacter 2018;23:e12540. [PMID: 30246287 DOI: 10.1111/hel.12540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
648 Muñoz N, Sánchez-delgado J, Baylina M, López-góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterología y Hepatología (English Edition) 2018;41:654-662. [DOI: 10.1016/j.gastre.2018.11.021] [Reference Citation Analysis]
649 Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elhelaly R, Elzehery R, Abdelsalam M, Elgamal A, Nassar MR, Abu El-Soud A, Seif AS, Tawfik AM, El-Wakeel N, Eldars W. Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma? Helicobacter 2018;23:e12537. [PMID: 30246507 DOI: 10.1111/hel.12537] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
650 Park JY, Kim JG. [New Helicobacter pylori Eradication Therapies]. Korean J Gastroenterol 2018;72:237-44. [PMID: 30642139 DOI: 10.4166/kjg.2018.72.5.237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
651 Boltin D, Levi Z, Perets TT, Schmilovitz-Weiss H, Gingold-Belfer R, Dickman R, Dotan I. Correlation between Quantitative 13C-Urea Breath Test and Helicobacter pylori Treatment Success in a Population-Based Cohort. Gastroenterol Res Pract 2018;2018:5439539. [PMID: 30538739 DOI: 10.1155/2018/5439539] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
652 Malfertheiner P, Venerito M, Schulz C. Helicobacter pylori Infection: New Facts in Clinical Management. Curr Treat Options Gastroenterol. 2018;16:605-615. [PMID: 30415359 DOI: 10.1007/s11938-018-0209-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
653 Salar A. Gastric MALT lymphoma and Helicobacter pylori. Med Clin (Barc). 2019;152:65-71. [PMID: 30424932 DOI: 10.1016/j.medcli.2018.09.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
654 Dubinsky V, Reshef L, Bar N, Rabinowitz K, Godny L, Tulchinsky H, Gophna U, Dotan I. Prolonged Antibiotic Treatment Generates a Fluoroquinolone Resistant Gut Microbiome and Collateral Multi-Drug Resistance.. [DOI: 10.1101/467001] [Reference Citation Analysis]
655 Louise Møller Nordestgaard R, Roed Spiegelhauer M, Havnhøj Frandsen T, Gren C, Tving Stauning A, Percival Andersen L. Clinical Manifestations of the Epsilonproteobacteria (Helicobacter pylori). Helicobacter pylori [Working Title] 2018. [DOI: 10.5772/intechopen.80331] [Reference Citation Analysis]
656 Lin TF, Hsu PI. Second-line rescue treatment of Helicobacter pylori infection: Where are we now? World J Gastroenterol 2018; 24(40): 4548-4553 [PMID: 30386104 DOI: 10.3748/wjg.v24.i40.4548] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
657 Song HY, Zhou L, Liu DY, Yao XJ, Li Y. What Roles Do Probiotics Play in the Eradication of Helicobacter pylori? Current Knowledge and Ongoing Research. Gastroenterol Res Pract 2018;2018:9379480. [PMID: 30410538 DOI: 10.1155/2018/9379480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
658 Seo JH, Park JS, Rhee KH, Youn HS. Diagnosis of Helicobacter pylori Infection in Children and Adolescents in Korea. Pediatr Gastroenterol Hepatol Nutr 2018;21:219-33. [PMID: 30345235 DOI: 10.5223/pghn.2018.21.4.219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
659 Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Toward population specific and personalized treatment of Helicobacter pylori infection. J Biomed Sci 2018;25:70. [PMID: 30285834 DOI: 10.1186/s12929-018-0471-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
660 . UEG Week 2018 Poster Presentations. United European Gastroenterol j 2018;6. [DOI: 10.1177/2050640618792819] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
661 Chen MJ, Chen CC, Chen YN, Chen CC, Fang YJ, Lin JT, Wu MS, Liou JM; Taiwan Gastrointestinal Disease Helicobacter Consortium. Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2018;113:1444-57. [PMID: 30171216 DOI: 10.1038/s41395-018-0217-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
662 Sostres C, Lanas A. Low dose aspirin, H. pylori infection, and the risk of upper gastrointestinal bleeding. Medical Journal of Australia 2018;209:297-298. [DOI: 10.5694/mja18.00742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
663 Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection. Gastroenterology 2018;155:1109-19. [PMID: 29964036 DOI: 10.1053/j.gastro.2018.06.047] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 9.8] [Reference Citation Analysis]
664 Shah SC, Itzkowitz SH, Jandorf L. Knowledge Gaps among Physicians Caring for Multiethnic Populations at Increased Gastric Cancer Risk. Gut Liver 2018;12:38-45. [PMID: 28873510 DOI: 10.5009/gnl17091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
665 Bruno G, Rocco G, Zaccari P, Porowska B, Mascellino MT, Severi C. Helicobacter pylori Infection and Gastric Dysbiosis: Can Probiotics Administration Be Useful to Treat This Condition? Can J Infect Dis Med Microbiol. 2018;2018:6237239. [PMID: 30275917 DOI: 10.1155/2018/6237239] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
666 Li H, Tang H, Debowski AW, Stubbs KA, Marshall BJ, Benghezal M. Lipopolysaccharide Structural Differences between Western and Asian Helicobacter pylori Strains. Toxins (Basel) 2018;10:E364. [PMID: 30205541 DOI: 10.3390/toxins10090364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
667 Bhakta D, Graham DY, Chan J, El-Serag HB. Lessons From Using Culture-Guided Treatment After Referral for Multiple Treatment Failures for Helicobacter pylori Infection. Clin Gastroenterol Hepatol 2018;16:1531-2. [PMID: 29306045 DOI: 10.1016/j.cgh.2017.12.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
668 Muñoz N, Sánchez-Delgado J, Baylina M, López-Góngora S, Calvet X. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterol Hepatol 2018;41:654-62. [PMID: 30180998 DOI: 10.1016/j.gastrohep.2018.06.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
669 O'Morain NR, Dore MP, O'Connor AJP, Gisbert JP, O'Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23 Suppl 1:e12519. [PMID: 30203585 DOI: 10.1111/hel.12519] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
670 Kabakambira JD, Hategeka C, Page C, Ntirenganya C, Dusabejambo V, Ndoli J, Ngabonziza F, Hale D, Bayingana C, Walker T. Efficacy of Helicobacter pylori eradication regimens in Rwanda: A randomized controlled trial. BMC Gastroenterol. 2018;18:134. [PMID: 30165823 DOI: 10.1186/s12876-018-0863-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
671 Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018;16:679-687. [PMID: 30102559 DOI: 10.1080/14787210.2018.1511427] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
672 Andreev DN, Maev IV, Dicheva DT, Samsonov AA, Partzvania-vinogradova EV. Efficacy and safety of the use of rebamipide in the scheme of triple eradication therapy of Helicobacter pylori infection: a prospective randomized comparative study. Terapevticheskii arkhiv 2018;90:27-32. [DOI: 10.26442/terarkh201890827-32] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
673 Lopetuso LR, Napoli M, Rizzatti G, Scaldaferri F, Franceschi F, Gasbarrini A. Considering gut microbiota disturbance in the management of Helicobacter pylori infection. Expert Rev Gastroenterol Hepatol 2018;12:899-906. [PMID: 30040500 DOI: 10.1080/17474124.2018.1503946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
674 Howden CW. H. pylori and Barrett's Esophagus: Implications for Populations and Practice. Am J Gastroenterol 2018;113:1119-20. [PMID: 29915403 DOI: 10.1038/s41395-018-0135-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
675 Blümel B, Goelz H, Kist M, Glocker EO. Retrospective study on outcome of salvage Helicobacter pylori eradication therapies based on molecular genetic susceptibility testing. Helicobacter 2018;23:e12494. [PMID: 29873430 DOI: 10.1111/hel.12494] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
676 Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW; Taiwan Acid-related Disease (TARD) Study Group. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter 2018;23:e12498. [PMID: 29897654 DOI: 10.1111/hel.12498] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 9.6] [Reference Citation Analysis]
677 Li M, Oshima T, Horikawa T, Tozawa K, Tomita T, Fukui H, Watari J, Miwa H. Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori. Helicobacter 2018;23:e12495. [PMID: 29873436 DOI: 10.1111/hel.12495] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 12.2] [Reference Citation Analysis]
678 Zagari RM, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. Helicobacter 2018;23:e12502. [PMID: 29924430 DOI: 10.1111/hel.12502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
679 Iannone A, Giorgio F, Russo F, Riezzo G, Girardi B, Pricci M, Palmer SC, Barone M, Principi M, Strippoli GF, Di Leo A, Ierardi E. New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study. World J Gastroenterol 2018; 24(27): 3021-3029 [PMID: 30038469 DOI: 10.3748/wjg.v24.i27.3021] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
680 Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, Maldonado-Garza HJ, Garza-González E. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol 2018;12:819-27. [PMID: 29976092 DOI: 10.1080/17474124.2018.1496017] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
681 El-Serag HB, Kao JY, Kanwal F, Gilger M, LoVecchio F, Moss SF, Crowe SE, Elfant A, Haas T, Hapke RJ, Graham DY. Houston Consensus Conference on Testing for Helicobacter pylori Infection in the United States. Clin Gastroenterol Hepatol 2018;16:992-1002.e6. [PMID: 29559361 DOI: 10.1016/j.cgh.2018.03.013] [Cited by in Crossref: 118] [Cited by in F6Publishing: 96] [Article Influence: 23.6] [Reference Citation Analysis]
682 Bosques-padilla F, Remes-troche J, González-huezo M, Pérez-pérez G, Torres-lópez J, Abdo-francis J, Bielsa-fernandez M, Constanza-camargo M, Esquivel-ayanegui F, Garza-gonzález E, Hernández-guerrero A, Herrera-goepfert R, Huerta-iga F, Leal-herrera Y, Lopéz-colombo A, Ortiz-olvera N, Riquelme-pérez A, Sampieri C, Uscanga-domínguez L, Velarde-ruiz Velasco J. The fourth Mexican consensus on Helicobacter pylori. Revista de Gastroenterología de México (English Edition) 2018;83:325-341. [DOI: 10.1016/j.rgmxen.2018.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
683 Siddique O, Moss SF. Editorial: Helicobacter pylori resistance and sequential therapy. Aliment Pharmacol Ther 2018;48:95-6. [PMID: 29882987 DOI: 10.1111/apt.14643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
684 Mosites E, Bruden D, Morris J, Reasonover A, Rudolph K, Hurlburt D, Hennessy T, McMahon B, Bruce M. Antimicrobial resistance among Helicobacter pylori isolates in Alaska, 2000-2016. J Glob Antimicrob Resist 2018;15:148-53. [PMID: 29969753 DOI: 10.1016/j.jgar.2018.06.016] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
685 Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS, Pérez-Pérez G, Torres-López J, Abdo-Francis JM, Bielsa-Fernandez MV, Camargo MC, Esquivel-Ayanegui F, Garza-González E, Hernández-Guerrero AI, Herrera-Goepfert R, Huerta-Iga FM, Leal-Herrera Y, Lopéz-Colombo A, Ortiz-Olvera NX, Riquelme-Pérez A, Sampieri CL, Uscanga-Domínguez LF, Velarde-Ruiz Velasco JA. The fourth Mexican consensus on Helicobacter pylori. Rev Gastroenterol Mex (Engl Ed) 2018;83:325-41. [PMID: 29941237 DOI: 10.1016/j.rgmx.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
686 Lahner E, Carabotti M, Annibale B. Treatment of Helicobacter pylori infection in atrophic gastritis. World J Gastroenterol 2018; 24(22): 2373-2380 [PMID: 29904244 DOI: 10.3748/wjg.v24.i22.2373] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
687 Ansari S, Yamaoka Y. Current understanding and management of Helicobacter pylori infection: an updated appraisal. F1000Res. 2018;7. [PMID: 29946428 DOI: 10.12688/f1000research.14149.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
688 Chen L, He J, Wang L, Ge Q, Chu H, Chen Y, Chen X, Long Y, Deng Y, He H, Li A, Chen S. Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med 2018;18:569-76. [DOI: 10.1007/s10238-018-0510-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
689 Yeomans ND, Graham DY, Husni ME, Solomon DH, Stevens T, Vargo J, Wang Q, Wisniewski LM, Wolski KE, Borer JS, Libby P, Lincoff AM, Lüscher TF, Bao W, Walker C, Nissen SE; PRECISION investigators. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther 2018;47:1453-63. [PMID: 29667211 DOI: 10.1111/apt.14610] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
690 Muñoz N, Sánchez-Delgado J, Baylina M, Puig I, López-Góngora S, Suarez D, Calvet X. Systematic review, meta-analysis, and meta-regression: Successful second-line treatment for Helicobacter pylori. Helicobacter 2018;23:e12488. [PMID: 29663581 DOI: 10.1111/hel.12488] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
691 Liou J, Chen C, Fang Y, Chen P, Chang C, Chou C, Chen M, Tseng C, Lee J, Yang T, Chiu M, Yu J, Kuo C, Luo J, Hsu W, Hu W, Tsai M, Lin J, Shun C, Twu G, Lee Y, Bair M, Wu M, Liou J, Lee Y, Lin J, Wu C, Wu J, Chen C, Lin C, Fang Y, Bair M, Luo J, Wu M, Cheng T, Tseng P, Chiu H, Chang C, Yu C, Chiu M, Chen Y, Hu W, Chou C, Tai C, Lee C, Wang W, Chang W; Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium. 14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trial. Journal of Antimicrobial Chemotherapy 2018;73:2510-8. [DOI: 10.1093/jac/dky183] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
692 Yuan LT, Chuah SK, Yang SC, Liang CM, Wu CK, Tai WC, Hung TH, Nguang SH, Wang JW, Tseng KL, Ku MK, Hsu PI, Wu DC, Hsu CN. Multiple bacterial infections increase the risk of hepatic encephalopathy in patients with cirrhosis. PLoS One. 2018;13:e0197127. [PMID: 29746564 DOI: 10.1371/journal.pone.0197127] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
693 Hathroubi S, Servetas SL, Windham I, Merrell DS, Ottemann KM. Helicobacter pylori Biofilm Formation and Its Potential Role in Pathogenesis. Microbiol Mol Biol Rev 2018;82:e00001-18. [PMID: 29743338 DOI: 10.1128/MMBR.00001-18] [Cited by in Crossref: 77] [Cited by in F6Publishing: 79] [Article Influence: 15.4] [Reference Citation Analysis]
694 Gatta L, Scarpignato C, Fiorini G, Belsey J, Saracino IM, Ricci C, Vaira D. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-9. [PMID: 29536561 DOI: 10.1111/apt.14597] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
695 Shaheen NJ, Fennerty MB, Bergman JJ. Less Is More: A Minimalist Approach to Endoscopy. Gastroenterology 2018;154:1993-2003. [PMID: 29454789 DOI: 10.1053/j.gastro.2017.12.044] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
696 Tsipotis E, Leontiadis GI. Editorial: the prevalence of Helicobacter pylori infection worldwide-knowns and unknowns. Aliment Pharmacol Ther 2018;47:1330-1. [PMID: 29644744 DOI: 10.1111/apt.14609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
697 Siddique O, Ovalle A, Siddique AS, Moss SF. Helicobacter pylori Infection: An Update for the Internist in the Age of Increasing Global Antibiotic Resistance. The American Journal of Medicine 2018;131:473-9. [DOI: 10.1016/j.amjmed.2017.12.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
698 Kwon S, Lee DH, Kang JB, Kim N, Park YS, Shin CM, Yoon H, Choi YJ. [The Efficacy of Bismuth-containing Quadruple Therapy after Moxifloxacin-based Sequential Therapy Failure in Helicobacter pylori Eradication]. Korean J Gastroenterol 2018;71:196-203. [PMID: 29684968 DOI: 10.4166/kjg.2018.71.4.196] [Reference Citation Analysis]
699 Nagpal S, Oberoi A, Singh N. SEROPOSITIVITY OF H. PYLORI AMONG DYSPEPTIC PATIENTS. jemds 2018;7:2048-2050. [DOI: 10.14260/jemds/2018/460] [Reference Citation Analysis]
700 Chaudhry A. Pharmacist guidelines and considerations for treating H. pylori. JAPLR 2018;7. [DOI: 10.15406/japlr.2018.07.00222] [Reference Citation Analysis]
701 Yoon BK, Jackman JA, Valle-González ER, Cho NJ. Antibacterial Free Fatty Acids and Monoglycerides: Biological Activities, Experimental Testing, and Therapeutic Applications. Int J Mol Sci 2018;19:E1114. [PMID: 29642500 DOI: 10.3390/ijms19041114] [Cited by in Crossref: 195] [Cited by in F6Publishing: 198] [Article Influence: 39.0] [Reference Citation Analysis]
702 Li J, Perez-Perez GI. Helicobacter pylori the Latent Human Pathogen or an Ancestral Commensal Organism. Front Microbiol. 2018;9:609. [PMID: 29666614 DOI: 10.3389/fmicb.2018.00609] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
703 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Update on the management of Helicobacter pylori infection. Position paper from the Catalan Society of Digestology. Gastroenterología y Hepatología (English Edition) 2018;41:272-280. [DOI: 10.1016/j.gastre.2018.04.018] [Reference Citation Analysis]
704 Sugizaki K, Tari A, Kitadai Y, Oda I, Nakamura S, Yoshino T, Sugiyama T. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan. Helicobacter 2018;23:e12474. [PMID: 29504247 DOI: 10.1111/hel.12474] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
705 Sánchez Delgado J, García-iglesias P, Titó L, Puig I, Planella M, Gené E, Saló J, Martínez-cerezo F, Molina-infante J, Gisbert JP, Calvet X. Actualización en el manejo de la infección por Helicobacter pylori. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2018;41:272-80. [DOI: 10.1016/j.gastrohep.2017.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
706 Ohishi T, Masuda T, Abe H, Hayashi C, Adachi H, Ohba SI, Igarashi M, Watanabe T, Mimuro H, Amalia E, Inaoka DK, Mochizuki K, Kita K, Shibasaki M, Kawada M. Monotherapy with a novel intervenolin derivative, AS-1934, is an effective treatment for Helicobacter pylori infection. Helicobacter 2018;23:e12470. [PMID: 29488678 DOI: 10.1111/hel.12470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
707 Lewis PO, Covert KL. Appropriate Use of Proton Pump Inhibitors: A Double-Edged Sword. Am J Med 2018;131:218-9. [PMID: 29157650 DOI: 10.1016/j.amjmed.2017.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
708 Calvet X. Dealing with uncertainty in the treatment of Helicobacter pylori. Ther Adv Chronic Dis 2018;9:93-102. [PMID: 29623181 DOI: 10.1177/2040622318758240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
709 Tan B, Yang JC, Young CL, Bishu S, Owyang SY, El-Zaatari M, Zhang M, Grasberger H, Qian JM, Kao JY. Helicobacter pylori Antimicrobial Susceptibility Testing-Guided Salvage Therapy in the USA: A Real Life Experience. Dig Dis Sci 2018;63:437-45. [PMID: 29264696 DOI: 10.1007/s10620-017-4880-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
710 Graham DY, Dore MP. Update on the Use of Vonoprazan: A Competitive Acid Blocker. Gastroenterology 2018;154:462-6. [PMID: 29337157 DOI: 10.1053/j.gastro.2018.01.018] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
711 Hwang YJ, Kim N, Lee HS, Lee JB, Choi YJ, Yoon H, Shin CM, Park YS, Lee DH. Reversibility of atrophic gastritis and intestinal metaplasia after Helicobacter pylori eradication - a prospective study for up to 10 years. Aliment Pharmacol Ther 2018;47:380-90. [PMID: 29193217 DOI: 10.1111/apt.14424] [Cited by in Crossref: 104] [Cited by in F6Publishing: 90] [Article Influence: 20.8] [Reference Citation Analysis]
712 Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol 2018;3:252-62. [PMID: 29396034 DOI: 10.1016/S2468-1253(18)30003-7] [Cited by in Crossref: 135] [Cited by in F6Publishing: 138] [Article Influence: 27.0] [Reference Citation Analysis]
713 Muñoz-Gómez P, Jordán-Castro JA, Abanades-Tercero M, Blanco-González JJ, Andrés Esteban EM, Valle-Muñoz J. Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter 2018;23. [PMID: 29178562 DOI: 10.1111/hel.12452] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
714 González-Pons M, Soto-Salgado M, Sevilla J, Márquez-Lespier JM, Morgan D, Pérez CM, Cruz-Correa M. Seroprevalence of Helicobacter pylori in Hispanics living in Puerto Rico: A population-based study. Helicobacter 2018;23. [PMID: 29210527 DOI: 10.1111/hel.12453] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
715 Nayar DS. Current eradication rate of Helicobacter pylori with clarithromycin-based triple therapy in a gastroenterology practice in the New York metropolitan area. Infect Drug Resist 2018;11:205-11. [PMID: 29430191 DOI: 10.2147/IDR.S153617] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
716 Wang R, Lai TP, Gao P, Zhang H, Ho PL, Woo PC, Ma G, Kao RY, Li H, Sun H. Bismuth antimicrobial drugs serve as broad-spectrum metallo-β-lactamase inhibitors. Nat Commun 2018;9:439. [PMID: 29382822 DOI: 10.1038/s41467-018-02828-6] [Cited by in Crossref: 118] [Cited by in F6Publishing: 120] [Article Influence: 23.6] [Reference Citation Analysis]
717 Alba C, Blanco A, Alarcón T. Antibiotic resistance in Helicobacter pylori. Curr Opin Infect Dis 2017;30:489-97. [PMID: 28704226 DOI: 10.1097/QCO.0000000000000396] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 19.2] [Reference Citation Analysis]
718 Chey WD, Leontiadis GI, Howden CW, Moss SF. Response to Hsu et al. Am J Gastroenterol 2018;113:143. [PMID: 29311737 DOI: 10.1038/ajg.2017.401] [Reference Citation Analysis]
719 Yoon K, Kim N. Reversibility of Atrophic Gastritis and Intestinal Metaplasia by Eradication of Helicobacter pylori. Korean J Gastroenterol 2018;72:104. [DOI: 10.4166/kjg.2018.72.3.104] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
720 Koh JS, Joo MK. The Role of Helicobacter pylori Infection in Drug-induced Peptic Ulcer. Korean J Helicobacter Up Gastrointest Res 2018;18:89. [DOI: 10.7704/kjhugr.2018.18.2.89] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
721 Hwang Y, Kim N, Kim SE, Baik GH, Lee JY, Park KS, Joo Y, Myung D, Kim HJ, Song HJ, Kim HU, Nam K, Shin JE, Kim HJ, Kim GH, Lee J, Lim SH, Seo GS, Choi SC. Change in the Prevalences and Risk Factors of Atrophic Gastritis and Intestinal Metaplasia in Korea: Multicenter Clinical Trials. Korean J Helicobacter Up Gastrointest Res 2018;18:247. [DOI: 10.7704/kjhugr.2018.18.4.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
722 Bakulin IG, Pirogov SS, Bakulina NV, Stadnik EA, Golubev NN. Prophylaxis and early diagnosis of stomach cancer. Dok gastroenterol 2018;7:44. [DOI: 10.17116/dokgastro201872244] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
723 Shah E, Chey WD. Editorial: recurrence of Helicobacter pylori infection-still the same after all these years…. Aliment Pharmacol Ther 2018;47:131-2. [PMID: 29226398 DOI: 10.1111/apt.14372] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
724 Hsu PI, Tsai FW, Kao SS, Kao JY. Time to Make a Change in the Cutoff Value of Clarithromycin Resistance in the Treatment of Helicobacter pylori Infection. Am J Gastroenterol 2018;113:142-3. [PMID: 29311734 DOI: 10.1038/ajg.2017.283] [Reference Citation Analysis]
725 Zagari RM, Rabitti S, Eusebi LH, Bazzoli F. Treatment of Helicobacter pylori infection: A clinical practice update. Eur J Clin Invest. 2018;48. [PMID: 29144559 DOI: 10.1111/eci.12857] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 6.8] [Reference Citation Analysis]
726 Yuan L, Xu B, Yuan P, Zhou J, Qin P, Han L, Chen G, Wang Z, Run Z, Zhao P. Tumor-infiltrating CD4+ T cells in patients with gastric cancer. Cancer Cell Int. 2017;17:114. [PMID: 29213216 DOI: 10.1186/s12935-017-0489-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
727 Graham DY. Illusions regarding Helicobacter pylori clinical trials and treatment guidelines. Gut 2017;66:2043-6. [PMID: 28935677 DOI: 10.1136/gutjnl-2017-314744] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
728 Papastergiou V, Mathou N, Licousi S, Evgenidi A, Paraskeva KD, Giannakopoulos A, Stavrou PZ, Platsouka E, Karagiannis JA. Seven-day genotypic resistance-guided triple Helicobacter pylori eradication therapy can be highly effective. Ann Gastroenterol 2018;31:198-204. [PMID: 29507466 DOI: 10.20524/aog.2017.0219] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
729 Islami F, Goding Sauer A, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, McCullough ML, Patel AV, Ma J, Soerjomataram I, Flanders WD, Brawley OW, Gapstur SM, Jemal A. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018;68:31-54. [PMID: 29160902 DOI: 10.3322/caac.21440] [Cited by in Crossref: 570] [Cited by in F6Publishing: 622] [Article Influence: 95.0] [Reference Citation Analysis]
730 Liatsos C, Georgopoulos SD. Helicobacter pylori best treatment approach: should a national consensus be the best consensus? Ann Gastroenterol 2017;30:704-6. [PMID: 29118570 DOI: 10.20524/aog.2017.0183] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
731 Kahramanoğlu Aksoy E, Pirinçci Sapmaz F, Göktaş Z, Uzman M, Nazlıgül Y. Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen. Med Princ Pract 2017;26:523-9. [PMID: 29131124 DOI: 10.1159/000484930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
732 Tanabe H, Ando K, Sato K, Ito T, Goto M, Sato T, Fujinaga A, Kawamoto T, Utsumi T, Yanagawa N, Ichiishi E, Otake T, Kohgo Y, Nomura Y, Ueno N, Sugano H, Kashima S, Moriichi K, Fujiya M, Okumura T. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. Dig Dis Sci 2017;62:3069-76. [PMID: 28664410 DOI: 10.1007/s10620-017-4664-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
733 George CM. Chapter 25: Gastrointestinal Diseases. The APhA Complete Review for Pharmacy, 12th edition 2017. [DOI: 10.21019/9781582122816.ch25] [Reference Citation Analysis]
734 Oikawa R, Watanabe Y, Miyamoto S, Sato Y, Ono S, Mabe K, Yamamoto H, Kato M, Itoh F. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. Tumour Biol 2017;39:1010428317734865. [PMID: 28990461 DOI: 10.1177/1010428317734865] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
735 Kellerman R, Kintanar T. Gastroesophageal Reflux Disease. Prim Care. 2017;44:561-573. [PMID: 29132520 DOI: 10.1016/j.pop.2017.07.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
736 Shehata MA, Talaat R, Soliman S, Elmesseri H, Soliman S, Abd-Elsalam S. Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection. Helicobacter 2017;22. [PMID: 28524341 DOI: 10.1111/hel.12395] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
737 Rodríguez de Santiago E, Martín de Argila de Prados C, Marcos Prieto HM, Jorge Turrión MÃ, Barreiro Alonso E, Flores de Miguel A, de la Coba Ortiz C, Rodríguez Escaja C, Pérez Álvarez G, Ferre Aracil C, Aguilera Castro L, García García de Paredes A, Rodríguez Pérez A, Albillos Martínez A. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera(®) ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter 2017;22. [PMID: 28771880 DOI: 10.1111/hel.12423] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
738 Bjorkman DJ, Steenblik M. Best Practice Recommendations for Diagnosis and Management of Helicobacter pylori-Synthesizing the Guidelines. Curr Treat Options Gastroenterol 2017;15:648-59. [PMID: 28932965 DOI: 10.1007/s11938-017-0157-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
739 Pandit S, Boktor M, Alexander JS, Becker F, Morris J. Gastroesophageal reflux disease: A clinical overview for primary care physicians. Pathophysiology. 2018;25:1-11. [PMID: 28943113 DOI: 10.1016/j.pathophys.2017.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
740 Tanzi MG. PPIs recommended for dyspepsia and H. pylori , but long-term use has risks, benefits. Pharmacy Today 2017;23:26-27. [DOI: 10.1016/j.ptdy.2017.07.013] [Reference Citation Analysis]
741 Georgopoulos SD, Xirouchakis E. Which Regimens Should Be Used and Which Rejected for the Treatment of Helicobacter pylori? Am J Gastroenterol 2017;112:1168-9. [PMID: 28725073 DOI: 10.1038/ajg.2017.90] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
742 Dang BN, Graham DY. Helicobacter pylori infection and antibiotic resistance: a WHO high priority? Nat Rev Gastroenterol Hepatol 2017;14:383-4. [PMID: 28465548 DOI: 10.1038/nrgastro.2017.57] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
743 Chey WD, Leontiadis GI, Howden CW, Moss SF. Response to Georgopoulos et al. Am J Gastroenterol 2017;112:1169-70. [PMID: 28725080 DOI: 10.1038/ajg.2017.127] [Reference Citation Analysis]
744 Rodrigues JP, Pinho R, Silva J, Ponte A, Sousa M, Silva JC, Carvalho J. Appropriateness of the study of iron deficiency anemia prior to referral for small bowel evaluation at a tertiary center. World J Gastroenterol 2017; 23(24): 4444-4453 [PMID: 28706428 DOI: 10.3748/wjg.v23.i24.4444] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
745 Driscoll LJ, Brown HE, Harris RB, Oren E. Population Knowledge, Attitude, and Practice Regarding Helicobacter pylori Transmission and Outcomes: A Literature Review. Front Public Health 2017;5:144. [PMID: 28691004 DOI: 10.3389/fpubh.2017.00144] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
746 De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol. 2017;30:373-379. [PMID: 28655973 DOI: 10.20524/aog.2017.0166] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
747 Beckman E, Saracino I, Fiorini G, Clark C, Slepnev V, Patel D, Gomez C, Ponaka R, Elagin V, Vaira D. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. J Clin Microbiol. 2017;55:2400-2405. [PMID: 28515219 DOI: 10.1128/jcm.00506-17] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
748 Fong J. Peptic Ulcer Disease. PharmacotherapyFirst: A Multimedia Learning Resource 2017. [DOI: 10.21019/pharmacotherapyfirst.pud_overview] [Reference Citation Analysis]
749 Murakami TT, Scranton RA, Brown HE, Harris RB, Chen Z, Musuku S, Oren E. Management of Helicobacter Pylori in the United States: Results from a national survey of gastroenterology physicians. Prev Med 2017;100:216-22. [PMID: 28457713 DOI: 10.1016/j.ypmed.2017.04.021] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 3.5] [Reference Citation Analysis]
750 Chen D, Cunningham SA, Cole NC, Kohner PC, Mandrekar JN, Patel R. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. Antimicrob Agents Chemother 2017;61:e02530-16. [PMID: 28167563 DOI: 10.1128/AAC.02530-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
751 El-kady RAE, Department of Medical Microbiology and Immunology, Mansoura Faculty of Medicine, Mansoura, Egypt, Thaalab MM. Relevance between Helicobacter pylori Infection and Immune Thrombocytopenia. IJHT 2017;3:1-6. [DOI: 10.15436/2381-1404.17.018] [Reference Citation Analysis]
752 Mosińska P, Wasilewski A. Patient’s Guide: Diet and Lifestyle in Peptic Ulcer Disease. Introduction to Gastrointestinal Diseases Vol. 2 2017. [DOI: 10.1007/978-3-319-59885-7_7] [Reference Citation Analysis]
753 Jabini R, Eghbali SA, Ayatollahi H, Sheikhi M, Farzanehfar M. Analysis of KRAS gene mutation associated with Helicobacter pylori infection in patients with gastric cancer. Iran J Basic Med Sci 2019;22:529-33. [PMID: 31217933 DOI: 10.22038/ijbms.2019.32047.7707] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
754 Mehrabani S. Helicobacter pylori Infection in Children: a Comprehensive Review. Maedica (Bucur) 2019;14:292-7. [PMID: 31798748 DOI: 10.26574/maedica.2019.14.3.292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]